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1.1 | Breast cancer
The breast is located on the upper ventral region of the torso and overlies the pectoralis 
major muscle (Figure 1.1). The breast is composed of several tissues, predominantly 
adipose, or fatty, tissue, and glandular tissue, which enables the lactation function of 
the breast. The glandular tissue consists of 15 to 20 lobes that radiate from the nipple 
and divide into multiple lobules. Each lobule is subdivided into multiple alveoli or milk 
producing bulbs. Ducts are small tubes that connect the lobes, lobules, and bulbs with 
the nipple1. 
 
Figure 1.1 | Anatomy of the breast.
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer 
death in women worldwide2. In 2018, almost 2.1 million women worldwide were diagnosed 
with breast cancer, and more than 600 thousand died because of this disease2. In Europe, 
breast cancer risk has increased over the years and at least one in eight women who lives to 
be 80 years old will develop invasive breast cancer in her lifetime3,4. In the Netherlands this 
number is even higher, with 1 in 6.6 women receiving a breast cancer diagnosis (including 
ductal carcinoma in situ (DCIS)), during their lifetime3.
Breast cancers can be divided into two main groups; carcinomas and sarcomas. The 
majority of all breast cancers are carcinomas, which develop from the epithelial cells. 
Under normal conditions, the inner epithelial cells are responsible for milk production5. 
Sarcomas are cancers that arise from the stromal components of the breast, but account 
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for less than 1% of primary breast cancers6. Within the large group of carcinomas, there are 
many different types of breast cancer5-7. The three most common histopathological types 
are:
–  Invasive carcinoma of no special type (NST), previously denoted as invasive ductal 
carcinoma (IDC), is an invasive or infiltrating cancer originating from the milk ducts. 
It is the most common form of breast cancer, accounting for approximately 80% of all 
diagnosed invasive breast carcinomas5. Invasive carcinoma NST is most often present 
as a palpable mass and/or mammographic abnormality, with a firm consistency. 
Nevertheless there is great variation in its appearance5,7. 
–  Invasive lobular carcinoma (ILC) originates from the milk producing glands (lobules). 
ILC is the second most common type of breast carcinoma (approximately 10%)5. ILC 
frequently does not form a lump like invasive carcinoma NST does, but it spreads out 
into the surrounding connective tissue in a line formation, having multiple origins 
or branches7. Therefore, ILC has a diffuse growth pattern, making it hard to detect on 
mammography. Usually for this reason, ILC is more challenging to treat5. 
–  Ductal carcinoma in situ (DCIS) is described as a possible precursor to invasive cancer 
that originates from the milk ducts, but has not yet spread beyond the milk duct. It 
is commonly detected in mammography screening, as it tends to be asymptomatic, 
and identifiable only as calcifications in approximately 25% of cases. DCIS is not a life-
threatening condition, with a 10-year survival rate of 97%8. However, the diagnosis 
can be alarming and complete excision of the DCIS is still currently recommended. 
Treatment of DCIS aims to minimize the chance of local recurrence, an important goal, 
since half of the recurrences will be an invasive carcinoma9. 
1.2 | Early detection and diagnosis of breast cancer 
Early detection of breast cancer is important as it allows for a more effective and less 
aggressive treatment10. Methods for early breast cancer detection include screening 
and self-examination. Self-examination can help women know what is normal and they 
can seek medical advice or report any changes. Multiple randomized controlled trials 
showed a reduction in breast cancer mortality due to mammographic screening11,12, which 
prompted the promotion of breast cancer screening into guidelines13. Screening aims to 
detect tumors before these can be felt or are otherwise symptomatic, and is the key for 
early detection. 
1.2.1 | Screening
Many countries have implemented screening programs for the early detection of breast 
cancer. Due to population-based breast cancer screening with mammography, overall 
breast cancer mortality has been reduced by approximately 20% in women invited to 




Furthermore, thanks to screening, breast cancers are found at an earlier stage, making 
less aggressive treatment options feasible18,19. In the Netherlands, women between 50 and 
75 years of age are invited to participate in the national screening program with biennial 
mammography. Clear reductions in breast cancer mortality were observed in the screening 
target population over time18,19. 
Women in high-risk populations, like breast cancer-gene (BRCA) mutation carriers or with 
a high familial risk, are screened starting at a younger age. These younger women have 
a relatively large amount of fibroglandular tissue, denoted having dense breasts, which 
may mask breast cancers at mammography, decreasing the sensitivity of breast cancer 
screening20. Furthermore, younger women and BRCA mutation carriers are more sensitive 
to radiation. Therefore, women in high-risk populations receive alternate or additional 
imaging, such as magnetic resonance imaging (MRI). MRI screening has been shown 
to be superior in the early detection of breast cancer in comparison to mammographic 
screening21,22. In recent studies, the sensitivity and specificity ranges between 75% - 100% 
and 83% - 98%, respectively, compared to 39% and 95% for mammography, respectively, 
for high-risk women23,24. MRI is more sensitive in detecting aggressive high-grade invasive 
tumors, while it has a lower sensitivity for DCIS25.
1.2.2 | Diagnosis
As opposed to screening, diagnostic breast imaging is a tailored exam for evaluation of a 
specific clinical finding or an abnormality detected at screening. A more detailed overview 
of the different imaging modalities used for diagnosis can be found in paragraph 1.3. The 
mainstay of establishing pathological diagnosis of suspicious lesions is image-guided 
biopsy. There are numerous different types of breast biopsies. A more detailed overview of 
the different biopsy techniques will be presented in Chapter 2. 
1.2.3 | Staging and classification
Breast cancer can be staged according to its TNM classification, and classified by 
histopathological grades and receptor status. These three classifications together are 
important to determine patient prognosis and treatment decisions. 
The TNM classification is used for staging, describing the size of the primary tumor and 
the spread of cancer to regional lymph nodes or other body parts. Tumor (T) describes 
the size and local extent of the primary tumor. Lymph node (N) describes regional lymph 
nodes that are or are not involved. Metastasis (M) describes the presence or absence of 
distant metastasis26. The scoring of these categories can be assigned by clinical (cTNM) 
and pathological (pTNM) examination. If patients receive neoadjuvant therapy ycTNM/
ypTNM is used after it. cTNM is mostly based on imaging and image-guided biopsy results. 
In cases where a patient received neoadjuvant therapy, the ypT is based on the largest 
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focus of residual tumor, if any present. In cases where there is pathological complete 
response to neoadjuvant therapy, the tumor is scored as ypT026. Table 1.1 and Table 1.2 show 
an overview of the different TNM classifications and stages.
Table 1.1 | Summary of TNM classifications.
T - Tumor N - Lymph node M - Metastasis
T0 No evidence of 
primary tumor
cN0 No regional lymph node 
metastasis
M0 No clinical or 
radiographic evidence of 
distant metastases
Tis Cancer in situ cN1 Metastasis in movable 
ipsilateral level I, II axillary 
lymph node(s)
cM1 Distant metastases 
detected by clinical and 
radiographic means
T1mi Tumor size ≤ 1 mm, 
microinvasion
cN2 Metastasis in ipsilateral 
level I, II axillary lymph 
node(s) that are clinically 
fixed or matted
pM1 Distant metastasis 
microscopically 
confirmed
T1a Tumor size > 1 mm 
but ≤ 5 mm
cN3 Metastasis in ipsilateral 
infraclavicular (level III 
axillary) lymph node(s) with 
or without level I, II axillary 
lymph node involvement
T1b Tumor size > 5 mm 
but ≤ 10 mm
T1c Tumor size > 10 mm 
but ≤ 20 mm
pN0(i-) No axillary node metastasis 
or isolated tumor cells in 
regional lymph nodes
T2 Tumor size > 20 mm 
but ≤ 50 mm
pN0(i+) Isolated tumor cells in 
regional lymph nodes
T3 Tumor size > 50 mm pN1mi Micrometastases
T4a Extension to the 
chest wall
pN1 1-3 axillary nodes with 
metastasis
T4b Extension to the skin pN2 4-9 axillary nodes with 
metastases
T4c Extension to the 
chest wall and skin







Table 1.2 | Summary of TNM stage groups.
Stage T N M
0 Tis N0 M0
IA T1 (incl. T1mi) N0 M0



















IIIB T4 N0-2 M0
IIIC T0-4 N3 M0
IV T0-4 N0-3 M1
For breast cancer, the modified Bloom-Richardson grading system is used to determine 
differentiation grade as a proxy for more or less aggressive behavior of the tumor. This 
system combines scores for tubule formation, nuclear pleomorphism and mitotic count27. 
These three cancer cell features are assessed and each is assigned a score. The scores are 
then combined into a final histopathological grade. This grade depends on the similarity 
of breast cancer cells to normal breast tissue under the microscope. The cancer can be 
classified as well differentiated (grade 1), moderately differentiated (grade 2), and poorly 
differentiated (grade 3). A grade 3 tumor means a faster-growing cancer, which will divide 
more rapidly and tend to spread more easily. Patients with these higher-grade tumors have 
a worse survival rate and, if needed, systemic treatment can be more aggressive compared 
to patients with low-grade tumors. 
The status of three specific receptors is important for the treatment decision and prognosis 
in breast cancer. Receptor status is usually identified by immunohistochemistry, in which 
cells stain differently based on the presence of estrogen receptors (ER), progesterone 
receptors (PR), and overexpression of the human epidermal growth factor receptor 2 
(HER2). Hormone receptor-positive breast cancers need hormones to grow. ER+ cancers 
can be treated with a myriad or endocrine therapies, which slows or even stops the 
growth of the breast cancer, generally having a good prognosis. HER2+ (overexpressing) 
tumors used to have a worse prognosis, however, the introduction of anti-HER2 therapy 
(e.g., trastuzumab) improved prognosis significantly, with a lower risk of relapse, patient 
death, and if used as neo-adjuvant treatment, a higher rate of pathological complete 
response28. Triple negative breast cancers (ER-, PR-, and HER2-) have no receptor expression, 
and therefore do not respond to currently available targeted therapies. Triple-negative 
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breast cancers are more aggressive, have a higher grade, and have a poorer prognosis in 
comparison to other types of breast cancer29. 
1.3 | Imaging breast cancer
To improve the detection of breast cancer, different imaging modalities are used, all with 
their own characteristics. These different modalities can be used for screening, diagnosis, 
and/or adjunctive evaluation.
1.3.1 | Mammography
Mammography is the first line and oldest imaging modality for breast cancer detection 
and diagnosis, which can be used in screening or in the clinical diagnostic setting. During 
mammographic acquisition, the breast is positioned on the support table of an x-ray unit 
and compressed with a compression paddle. Compression is necessary to decrease the 
radiation dose and to increase the visibility of breast lesions. In a standard screening or 
clinical setting, the breast is imaged in two different directions, the mediolateral oblique 
(MLO) and craniocaudal (CC) views. The most common signs for malignant lesions are: 
masses, calcifications (often associated with DCIS), architectural distortions, asymmetries 
and densities30.
Contrast-enhanced mammography (CEM) is an emerging modality that combines digital 
mammography with the administration of contrast material. The basis of CEM is comparable 
to that of contrast-enhanced MRI: growth of tumors induces the development of new vessels, 
which can be leaky, allowing an intravenously injected contrast agent to accumulate in the 
tumor12,31. CEM has a high sensitivity, which is comparable to breast MRI, but the specificity 
is low32. There are only limited but promising results for the use of CEM as a screening 
modality32. More research is needed before its inclusion in breast cancer guidelines. 
1.3.2 |  Digital breast tomosynthesis (DBT) and dedicated breast 
computed tomography (CT)
The main limitation of mammography is the superimposition of fibroglandular tissue, 
which can be misinterpreted as a lesion or can obscure a lesion. DBT was developed to 
overcome this limitation, resulting in a significantly higher diagnostic accuracy and 
detection rate compared to conventional mammography33. Different prospective 
screening trials reported an increased detection rate ranging from 27% to 51%33-36. 
Positioning of the breast is the same in both modalities, but during DBT acquisition several 
2D projections of the breast are taken from different angles and combined into a pseudo-
3D image. However, the use of DBT increases the radiation dose and the reading time per 




A further extension of DBT is dedicated breast CT, in which the x-ray tube can fully rotate 
around the breast without compression, while this is limited in DBT. With this technique, 
superimposition and tissue compression are eliminated. Admittedly, although it has a 
high potential to detect breast cancer at an early stage, breast CT research is still at its 
infancy, and therefore further studies are needed to demonstrate its role in screening, 
diagnosis, and/or staging39.
1.3.3 | Ultrasound imaging (US)
The use of US is not common as a screening modality. However, it has the potential to find 
mammographically occult lesions in high-risk women or women with dense breasts40. 
There are many indications to use US as a first approach41. The major advantages of US 
are that it does not use ionizing radiation or contrast agent, making it patient friendly. In 
hand-held US, images are acquired and evaluated in real time by a radiologist or specially 
trained radiographers. 
Automated 3D breast ultrasound (ABUS) is a relatively new extension of hand-held US. 
ABUS does not have the limitations of hand-held US, such as operator dependency and 
lack of standardization and reproducibility. Especially in the screening setting of women 
with dense breast, this device may have an added value due to different reasons. It permits 
the acquisition by a non-physician in an automated setting, which facilitates workflow. 
Furthermore, it allows uncoupling of acquisition and interpretation, which supports 
the possibility of double-reading and/or comparison with previous screening rounds. 
Especially in women with dense breasts, this technique leads to an increased sensitivity 
compared to mammography42. However, ABUS increases recall rates and the number of 
biopsies, with a decrease in the positive predictive value, which makes it not yet feasible 
to be implemented in screening programs42.
1.3.4 | Magnetic resonance imaging (MRI)
MRI has a high sensitivity compared to mammography and ultrasound, without using 
ionizing radiation21. However, MRI is a modality with relatively high costs and limited 
availability, requires the use of a contrast agent, and is also very sensitive for benign 
lesions, which leads to additional recalls and biopsies. Therefore, use of breast MRI is 
limited, and is only used as a screening modality for women at a high-risk of breast cancer 
development, mostly those with germline genetic abnormalities (e.g., BRCA mutations) 
or a positive family history, albeit indications are widening. In the diagnostic setting, MRI 
is considered the most accurate technique, commonly used for assessing tumor location 
and estimating the lesion size of known breast cancers43-45.
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Acquisition of a breast MR protocol takes around 15 to 25 minutes, during which the 
patient lies in prone position. A complete protocol consists of multiple sequences that 
help the radiologist come to a diagnosis. 
The basis for the protocol is a T1-weighted contrast-enhanced sequence, using gadolinium-
chelates as contrast agent. When tissue uptakes gadolinium, it shortens the T1 relaxation 
time and tissue appears brighter in the T1-weighted volumes. Malignant lesions have an 
increased uptake of contrast agent, caused by increased vascularization of these lesions, 
which makes these lesions distinguishable from healthy breast tissue23. However, the use 
of contrast agent is time-consuming, costly, and has a potential for complications46. MRI 
sequences that do not rely on contrast agents are therefore promising.
Diffusion-weighted imaging (DWI)
Diffusion-weighted MRI is nowadays routinely added to the breast MRI protocol, 
improving specificity and avoiding unnecessary biopsies in benign enhancing breast 
lesions, due to its ability to distinguish benign and malignant lesions47. DWI explores 
the micromovement of water molecules, denoted Brownian motion. This movement is 
influenced by the size, the temperature, and in particular the microscopic environment 
of the examined molecules. Due to these ‘obstacles’, the mean diffusion distance of water 
molecules in tissue is reduced compared to that of free water, and a decreased effective 
diffusion coefficient, called the apparent diffusion coefficient (ADC), is found in tissue. 
For instance, high cellularity in malignant lesions limits the diffusion of water molecules, 
causing a low ADC signal intensity. In fact, diffusion properties can be used to distinguish 
different types of tissue without the use of any contrast agent. Thus, DWI might be a 
suitable technique for non-contrast breast MRI screening. However, DWI is known for the 
common presence of imaging artifacts and deficient image quality. 
The DWI sequence is based on a T2-weighted acquisition. Consequently, DWI not only 
consists of diffusion but also has an associated T2-weighted component. The ADC map 
can be calculated by acquiring two or more images with different gradient duration and 
amplitude (b-values). The contrast in the ADC map depends on the diffusion coefficient 
and does no longer contain any T2 value. The higher the b-value, the stronger the positive 
correlation between the signal and the diffusion. The “optimal” choice of b-value is not 
clearly defined and depends upon field strength, number of averaged signals, anatomical 
features, and expected pathology. A b-value near zero (or 50 s/mm2 to reduce signal from 
vessels) and a b-value around 800-850 s/mm2 is sufficient for clinical imaging48. However, 





1.4 | Current treatment options
Management of breast cancer depends on various factors; for instance, characteristics of 
the disease, stage of the cancer, patient age, and personal preferences. In general, non-
metastasized breast cancer is treated by surgical intervention in combination with other 
treatments such as radiation therapy, chemotherapy, hormone therapy and/or other 
targeted therapy. These treatment modalities can be applied before (neo-adjuvant) or 
after (adjuvant) surgical treatment. 
1.4.1 | Surgical treatment
Surgical treatment can involve mastectomy or breast conserving surgery (BCS). 
Mastectomy consists of removal of the entire breast. With BCS (also known as 
lumpectomy) only a lump of breast tissue, involving the cancer tissue and a rim of 
normal tissue, is removed. Over the past decades there has been an important shift from 
mastectomy toward breast conserving therapy (BCT) which consists of BCS and radiation 
therapy. Based on clinical trials and real-world data, partial removal of the breast, or 
lumpectomy, was found to be as effective as mastectomy for the treatment of invasive 
breast cancer50. Compared to mastectomy, BCS has fewer postoperative complications, 
better cosmetic results, and significantly improved quality of life50,51. Furthermore, overall 
survival after BCT is at least comparable, if not better, than that of mastectomy without 
radiation therapy in early breast cancer52. 
Lymph node assessment is routinely performed during surgery to estimate the risk 
of axillary nodal involvement. Sentinel lymph node biopsy (SLNB) has become the 
standard method and has largely replaced axillary lymph node dissection (ALND). SLNB 
is associated with lower morbidity and complications in comparison with ALND53. The 
sentinel lymph nodes are the first to receive lymphatic drainage from the compromised 
breast cancer region. These lymph nodes can be identified by injection of isosulfan blue 
dye into the breast cancer region, resulting in sentinel lymph nodes becoming blue in 
color. Furthermore, injection of radiolabeled colloid before surgery can also be used to 
find the sentinel lymph nodes. During surgery the radioactive lymph nodes can be found 
with the use of a hand-held gamma detector. The lymph nodes that are radioactive and/or 
blue are considered sentinel lymph nodes. When lymph node metastases are found with 
SLNB, additional treatment of the axilla (surgery and/or radiotherapy) may be advisable 
depending on the number of positive lymph nodes, primary tumor characteristics, or the 
use of (neo)adjuvant systemic therapy or not13. 
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1.4.2 | Radiation therapy
Radiation therapy involves exposure of the cancer to high-energy ionizing radiation, 
which causes cellular damage, with breaks in DNA in the targeted cancer cells. Dividing 
cells are unable to repair the damage and undergo apoptosis. However, radiation does not 
only affect cancer cells, but also normal cells, leading to many deleterious side effects 
associated with radiation therapy54.
BCS is almost always followed by radiation encompassing the whole breast to reduce the 
risk of cancer recurrence. An additional radiation boost on the tumor area may decrease 
local recurrence further in selected higher risk situations55,56. Nevertheless, it should be 
noted that an additional boost has a negative influence on the cosmetic result57.
1.5 | Minimally invasive treatment
As described above, breast surgery has evolved over the past few decades towards a more 
conservative approach. The principle of a minimally invasive approach is to achieve the 
same result as standard treatment but with less morbidity, thus leading to a better quality 
of life. Alongside this paradigm shift in BCS, there have been improvements in non- and 
minimally invasive techniques. Conventional percutaneous biopsies like fine-needle 
aspiration and core needle biopsy provide cells and tissue samples for diagnosis, but are 
not therapeutic. Surgical excision is considered the gold standard for both diagnostic 
and therapeutic purposes, but its role is being challenged by new non- and minimally 
invasive techniques that are able to remove a lesion completely without surgical incision 
or using only a small puncture incision. Another option that is showing promising results 
is single dose pre-operative radiation to the tumor58. Up to today, most minimally invasive 
protocols for the treatment of early-stage breast cancer have been conducted in a treat and 
resect research setting, with promising results. Nevertheless, an important disadvantage 
is the futility to evaluate tumor margins with most minimally invasive treatment options. 
Additional and solid evidence about the reliability and safety of minimally invasive 
treatment techniques is necessary. A more detailed elaboration of the currently available 
diagnostic and therapeutic minimally invasive techniques will be presented in Chapter 2.
1.5.1 | Requirements of screening to enable minimally invasive treatment
The evolution towards minimally invasive treatment is possible due to the implementation 
of breast cancer screening programs, with which breast tumors are detected earlier and, 
therefore, tend to be smaller. They can therefore be treated more easily with minimally 
invasive approaches. The current screening methods use ionizing radiation and/or 
contrast agents that may be harmful. In addition, screening with a complete MRI protocol 




Therefore, a new fast screening method without ionizing radiation and/or contrast agent 
would be an improvement. This improved screening method needs to achieve the same 
specificity as mammography and MRI, and the same sensitivity as MRI screening, to 
detect breast tumors in an early and small stage. 
1.6 | Thesis outline
The outline of this thesis is divided into three parts. Part 1 describes and explores different 
minimally invasive treatment options for small breast cancers. Chapter 2 introduces the 
current available diagnostic and therapeutic minimally invasive techniques. Chapter 3 
describes the current status of, and provides insight into possible future research on the 
breast lesion excision system (BLES) as a diagnostic and therapeutic device. For minimally 
invasive treatment, and especially for use with the BLES, it is essential to know in advance 
that the lesion is smaller than the excision needle. Therefore, in Chapter 4 we determine 
the reliability of MRI-based tumor size measurements to select patients for minimally 
invasive therapy. In Chapter 5 we investigate the feasibility of complete excision of small 
breast cancers using the BLES under ultrasound guidance. Finally, we describe in Chapter 6 
a new study proposal to evaluate under what conditions vacuum-assisted excision under 
ultrasound guidance could be useful as a minimally invasive treatment method. 
Detection at an early stage, which will be described in Part 2, is essential for small breast 
cancers. In Chapter 7 and Chapter 8 two prototype DWI sequences are evaluated to 
determine if these sequences can improve lesion detection in unenhanced DW images. 
Part 3 provides a general discussion and summaries in both English and Dutch regarding 
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In the past four decades, a variety of methods for minimal- or non-invasive diagnosis 
and treatment of breast cancer have been introduced. Although breast imaging has 
become more and more specific for diagnosis, specimen biopsy with histopathological 
confirmation is still necessary. Core-needle biopsy under ultrasound guidance is the 
appropriate first choice for the diagnosis of most lesions. Fine-needle aspiration is of 
interest for identification of the presence of metastatic disease in abnormal lymph 
nodes. For microcalcifications, vacuum-assisted biopsy is recommended, especially 
with stereotactic guidance. In recent years different therapeutic techniques have been 
developed for the treatment of solid lesions, including breast cancer. Certainly, with 
the improvement of technology and medical scientific progress, it is becoming more 
common to use minimal- or non-invasive therapies. The proposed minimally invasive 
techniques may offer complete treatment of breast cancer, with better cosmetic results, 
less psychological stress, and shorter hospital stays. In this chapter, the strengths and 
weaknesses of the different diagnostic and therapeutic techniques are presented, and 
promising techniques for the future are discussed.




Large-core breast biopsy was introduced in 1993. It is nowadays hard to believe that open 
surgical biopsy and complete surgical resection were the traditional approaches for 
diagnosis and management of breast abnormalities for many years. Naturally, to diagnose 
new-found breast lesions, an amount of tissue is necessary for the histopathologist. Open 
surgical biopsy is highly accurate for this purpose, because it obtains (almost) all of the 
suspicious lesion and underestimation of the significance of disease is uncommon. This 
technique is especially applicable for palpable masses. For non-palpable lesions, additional 
preoperative localization is necessary, and an extensive area of normal breast tissue may 
be removed. Although open biopsy has high accuracy, there are major disadvantages. 
Open surgical biopsy is relatively expensive, incurs physical and psychological stress for 
the patient, and is unnecessary for benign lesions. In addition, patients who undergo open 
surgical biopsy often have extensive scarring, which may hinder imaging in the future. 
Consequently, open surgical biopsy is now virtually obsolete for most indications. 
Over the past 40 years there has been a shift towards minimally invasive (needle) biopsy 
techniques as standard for the diagnosis of breast lesions, which is also fueled by the 
increased awareness of breast abnormalities and implementation of mammography for 
breast cancer screening, which has led to a strong increase in the number of small breast 
abnormalities requiring diagnosis. Different percutaneous image-guided breast biopsy 
devices were developed in recent years to reduce the impact of tissue diagnosis while 
maintaining high accuracy. 
In addition, for complete surgical resection of breast lesions, there is a deviation towards 
less invasive methods, but this process is much more complicated, and depends on 
the nature of the lesion. Until the 1970s, radical mastectomy with axillary lymph node 
dissection (ALND) was the standard surgical treatment for breast cancer patients. Radical 
mastectomy is disfiguring and ALND results in substantial complications including 
lymphoedema, neuropathic pain, and decreased arm motion. Since the late 90s, ALND 
has been replaced by sentinel lymph node biopsy (SLNB) in patients with a clinically node 
negative status which led to significantly less complications, without loss of optimal 
care for the patient1. When SLNB is positive, however, an ALND is still regularly performed. 
Minimally invasive proof of the presence of positive lymph nodes in the axilla thus allows 
SLNB to be avoided, which implies that biopsy techniques for axillary lymph nodes have 
also evolved. The field of evaluation of the axilla is rapidly shifting, and it might well be 
that in the near future a negative ultrasound (US) alone obviates all surgical procedures in 
this area, whereas only vastly abnormal nodes will be biopsied and treated.
In the last 40 years there was a substantial shift toward breast-conserving therapy 
(BCT; lumpectomy in combination with radiotherapy) to treat the index cancer2. BCT 
is nowadays generally accepted because of the similar overall survival to women who 
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undergo mastectomy or lumpectomy. Furthermore, it is less invasive and stressful for the 
patient with a faster recovery and better cosmetic results2. Still, a large fraction of women 
with breast cancer are treated with a mastectomy due to the presence of multifocal or 
multicentric breast cancer, which is regarded as a contraindication for BCT. Nonetheless, 
due to the development of oncoplastic techniques and the apparent safety of multiple 
lumpectomies, this will likely change substantially in the near future. Following the 
ongoing reduction of the aggressiveness of local therapy for breast cancer, methods are 
under development for treating breast cancer without a knife, using minimally invasive or 
even completely non-invasive techniques. 
Many different techniques for diagnostic biopsies and therapeutic approaches are 
available nowadays. This chapter will discuss the strengths and weaknesses of the 
different diagnostic and therapeutic minimally invasive techniques and discuss their 
potential future role. 
2.2 | Guidance techniques
For palpable lesions, it is possible to fix the lesion manually and biopsy without any image-
guidance technique; however, this is mostly regarded as obsolete and is not common 
nowadays. Many different imaging techniques are available for the guidance of biopsy 
devices. In general, US is preferred because it is well accepted, quick, patient friendly, and 
inexpensive. It is also the only imaging technique that allows real-time monitoring of the 
position of a needle within the lesion. Furthermore, it does not use ionizing radiation. 
A disadvantage of US guidance is the limited visibility of some breast abnormalities, 
especially microcalcifications.
Stereotactic guidance or, nowadays, digital breast tomosynthesis (DBT) guidance, can be 
used for suspicious lesions on mammography/DBT, which are not visible with US guidance, 
for example, microcalcifications or architectural distortions visible on mammography. A 
biopsy procedure with stereotactic guidance is more time-consuming, and less patient 
friendly than US. As it does not allow real-time monitoring of the needle position, it is also 
more prone to unsuccessful sampling due to motion.
The use of magnetic resonance imaging (MRI) for screening and preoperative breast 
cancer staging is more and more common. As its sensitivity is higher than that of either 
mammography or US, this yields a number of suspicious lesions that are only visible on 
MRI; however, MRI-guided biopsies are time-consuming, relatively expensive and contrast 
medium is necessary to visualize the lesion. Therefore, MRI guidance is only recommended 
if the lesion is not (properly) visible with US or mammography. This also implies that it 
is good practice to do a so-called “second-look” examination when lesions are initially 
MRI detected to find the lesion with the knowledge of the MRI examination and enable 
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the use of another technique for biopsy guidance (usually US, but also possible with 
mammography/DBT). In practice, approximately 57.5% of lesions can be found by second-
look US, and in these cases MRI-guided biopsy is not needed3.
2.3 | Diagnostic biopsies 
2.3.1 | Fine-needle aspiration
In 1930 Martin and Ellis introduced fine-needle aspiration (FNA) biopsy; however, the 
technique was not widely used in the early years. Since the 1950s, FNA was revived and 
became more common for the diagnosis of palpable breast lesions that were biopsied 
manually4,5. Nowadays FNA is mostly performed by radiologists under image guidance. 
During this procedure a thin needle (18-22 G; Figure 2.1) attached to a syringe is inserted 
to aspirate a small amount of tissue from a suspicious area. Due to the small size of the 
needle, the architecture of the lesion is lost, and evaluation is based mainly on cytology. 
Consequently, distinction between invasive and in situ cancer is, for example, not 
possible. For breast lesions, US is the most common guidance technique, but stereotactic 
guidance can also be used. FNA is a safe, effective and accurate technique without critical 
complications, although pain during or after the biopsy procedure may be present, which 
is more common when a larger needle is used6. The speed of evaluating a FNA biopsy is 
the most important advantage. With this technique, it is possible to receive a provisional 
diagnosis within a few hours.
FNA has a variable rate of insufficient samples ranging from 26.6% for masses to 46.1% 
for lesions with only calcifications7. Furthermore, the small amount of tissue that can 
be obtained makes it impossible to define biomarker status8. A recent systematic review 
by Wang et al. (2017) showed that the pooled sensitivity for FNA is 74% (95% confidence 
interval (CI): 72-77%) and pooled specificity is 96% (95% CI: 94-98%)9. The average 
success is higher for palpable lesions (75-90%) compared to non-palpable lesions (34-
58%). Furthermore the success rate decreases when lesions are small (<10 mm), large 
(>4 cm), or when only calcifications are seen on imaging9,10. Overall, FNA is generally not 
the first choice for diagnostic biopsy because the sensitivity and specificity are lower in 
comparison with core needle biopsy (CNB)10. 
Nevertheless, FNA may have an added value in specific cases, especially for patients with 
lesions close to the skin, chest wall, implants or other vital structures. This is caused by 
the fact that FNA is highly maneuverable and allows excellent targeting. 
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Figure 2.1 | Comparison in size between 15 mm BLES needle, 9 G vacuum biopsy needle, 14 G core 
biopsy needle, and 21 G needle for FNA
 
Also in the axilla FNA is commonly performed as lymph nodes may lie in close proximity 
to vessels and nerves. It has a good diagnostic value for lymph node staging. Based on 
a systematic review of Yu et al. (2016) FNA in combination with US guidance has a high 
specificity for lymph node staging with a mean of 99% (95% CI: 99-99%) but a lower 
sensitivity with a mean of 63% (95% CI: 61-65%)11. 
2.3.2 | Core needle biopsy
Around the early 1990s, CNB came into common use. Image-guided CNB of the breast 
received more attention after the publication by Parker et al. in 199312. With CNB, small 
cores of tissue can be obtained during a percutaneous procedure with a slightly larger, 
hollow needle (Figure 2.1). This yields a small tissue specimen with intact architecture. 
In daily practice, 14-G needles are generally used, providing a core with a thickness of 
approximately 1 mm, and a length ranging from 12 to 25 mm, depending on the needle 
used. Slightly smaller 16 and 18-G needles can be more practical in dense tissue where 
positioning of the needle may be difficult due to the stiffness of the tissue. Although 
one core biopsy through a solid lesion will, in general, provide a diagnosis, correct 
targeting of lesions may be difficult, and results are better when multiple cores 
are obtained. For US-visible lesions, a minimum of three cores is advised to obtain a 
reliable diagnosis of the breast lesion. For stereotactic-guided biopsies, the accuracy is 
optimal with six or more cores. For microcalcifications even more cores are needed in 
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comparison with solid lesions, which implies that CNB is usually insufficient for biopsy 
of microcalcifications12-17. 
In comparison with FNA, CNB has some advantages. With CNB significantly more tissue is 
obtained, and tissue architecture is to some extent evaluable, as opposed to the few cells 
and tissue fragments that are obtained with FNA. As a result of this increased amount 
of tissue the pathologist is able to provide a more accurate diagnosis and distinguish 
between invasive cancer and carcinoma in situ. CNB has comparable complications as 
FNA, with pain as the main complication. The occurrence of infection and hematoma are 
rare (0-2%). 
Westenend et al. (2001) found that the positive predictive value of lesions diagnosed 
as malignant on either FNA or CNB was comparable, 100% and 99%, respectively, but 
for lesions where the results were not certainly malignant (i.e., suspicious) this value 
decreased for FNA to 78%, and even only 18% in case of atypia. In comparison with CNB 
this was 100% and 80%, respectively17.
A recent systematic review by Wang et al. (2017) showed that the pooled sensitivity for CNB 
is 87% (95% CI: 84-88%) and pooled specificity is 98% (95% CI: 96-99%)9. The sensitivity 
is significantly higher for palpable lesions compared to non-palpable lesions. Based on 
the same systematic review, there is no significant difference in sensitivity and specificity 
when US or stereotactic guidance is used9. Nevertheless, US guidance is recommended 
because real-time feedback is achieved, which is not available during a stereotactic or 
MRI-guided procedure. In a study conducted by Houssami et al. (2007), it was shown that 
CNB still underestimates the overall severity of disease in 27.7% of cases (95% CI: 24.5-
30.9%)18. The upgrade rate of atypical ductal hyperplasia (ADH) to ductal carcinoma in 
situ (DCIS) or invasive carcinoma was 44.2% (95% CI: 36.0-52.5%) and for DCIS to invasive 
carcinoma was 22.8% (95% CI: 19.0-26.5%). The underestimation rates are especially high 
in lesions with microcalcifications18.
Britton et al. (2009) examined the sensitivity of US-guided core biopsy of axillary lymph 
nodes in patients with proven invasive breast cancer, which was 53.4% (95% CI: 41-65%)19. 
The sensitivity varied between macro- and micrometastatic lymph nodes with figures of 
60.3% (95% CI: 47-73%) and 26.7% (95% CI: 8-55%), respectively19, therefore, the results 
are similar to those obtained with FNA. 
2.3.3 | Vacuum-assisted biopsy
Vacuum-assisted biopsy (VAB) was introduced in 1995 by Fred Burbank and Mark Retchard 
as an answer to the limitations of FNA and CNB. First, stereotactic-guided VAB was 
introduced and a few years later the US-guided procedure. In the late 1990s, VAB became 
generally accepted and came into common use20. A double-lumen probe is placed into the 
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suspicious lesion. Using the vacuum, the tissue is sucked into the biopsy chamber and 
the internal rotating trocar cuts the sample (Figure 2.1). Multiple larger samples can be 
obtained under vacuum suction. In contrast to CNB, for the current VAB systems only a 
single insertion of the probe is necessary. As VAB is mainly aimed at the biopsy of either 
very small or very diffuse lesions, including those presenting with microcalcifications, it 
aims to remove substantially more tissue than CNB. For this reason, needles have become 
thicker over the years, and currently systems from 12 G to 7 G are available.
Complications for VAB may include bleeding (1-3.9%), infection (0-0.1%) or pain during 
and after the procedure21,22. The removal of more tissue results in larger hematomas, and 
some scarring may occur after extensive sampling.
The technique is more accurate than FNA and CNB, especially in the evaluation of 
microcalcifications, due to the larger amount of tissue sampled in these general diffuse 
lesions. VAB is also preferred over CNB in architectural distortions and MRI-only lesions, 
due to the larger amount of tissue sampled. In a systematic review, Yu et al. (2010) found 
that sensitivity ranged from 85% to 100% with a mean of 98.1% (95% CI: 97.2-98.7%)23. 
The specificity ranged from 96% to 100% with a mean of 99.9% (95% CI: 99.7-99.9%). 
Underestimation rates, however, remain substantial: they found a pooled ADH and 
DCIS underestimation of 20.9% (95% CI: 17.7–24.5%) and 11.2% (95% CI: 9.8–12.8%), 
respectively23. 
2.3.4 | Breast lesion excision system
In 2001, the breast lesion excision system (BLES) was approved by the Food and Drug 
Administration (FDA; Figure 2.1). This is an automated, image-guided, single-pass biopsy 
system using radiofrequency (RF). It is a percutaneous biopsy system, comparable with 
VAB. Different from most devices for histological breast biopsy (including VAB), the aim 
of the BLES is to excise and retrieve an intact breast tissue specimen, instead of obtaining 
fragmented samples24-26. Theoretically this should lead to an easier evaluation of the 
lesion architecture, and thus a reduced underestimation rate of ADH and DCIS; however, 
the needle can only be used once, and there is thus only one specimen available. BLES is 
the only biopsy device that cannot be used in combination with MRI guidance, due to the 
use of the diathermic wire system.
Several studies have indicated that complications that may occur during and after the 
BLES procedure are similar in type and frequency to those observed using VAB, for example 
hematoma, infection, and bleeding. Specific BLES-related complications occur too; in 
particular in fatty breasts, the biopsy basket may be empty after the procedure, due to 
melting of the fat and concurrent fragmentation of the biopsied lesion. Furthermore, 
thermal artefacts on the specimen may arise caused by the use of RF, although mostly 
these artefacts are superficial and small varying between 0.1 and 1 mm in thickness24,27,28, 
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and are similar in nature to the cauterization artefacts caused by diathermic knives in 
surgery. The BLES is not suitable for ALNB or biopsy of lesions located close to the surface, 
nipple or pectoral muscle. Reported underestimation rates of ADH and DCIS still range 
from 0% to 9.4% and from 0% to 21.4%, respectively24,26,27,29-33.
2.4 | Therapeutic approaches
Although the use of needles for diagnostic evaluation of breast lesions is, based on 
the above, established as current state-of-art, the introduction of minimally invasive 
techniques for treatment of breast cancer is somewhat lagging behind. Ablative therapies 
can be subdivided into those using hyperthermia, such as radiofrequency ablation (RFA), 
microwave ablation, laser ablation (LA), and high-intensity focused ultrasound (HIFU); 
those using hypothermia, basically cryoablation using either argon or liquid nitrogen; and 
those destroying the cell membrane (i.e., irreversible electroporation (IRE)). In addition, 
minimally invasive excision techniques exist using the tools that are also in the diagnostic 
spectrum, i.e., vacuum-assisted excision (VAE) and BLES. For all these techniques, it is 
important that the needle is positioned centrally in the lesion and cells are destroyed 
evenly in all directions.
Despite the many different techniques for non- or minimally invasive ablation that are 
available, and discussed in more detail below, none have so far made it into the standard 
practice of treatment of patients with breast cancer, albeit there are some techniques that 
are regularly used in the treatment of benign disease, such as cryoablation and VAE for the 
treatment of fibroadenomas. Furthermore, ablation with local anesthesia can be used for 
patients who are not fit enough for a general anesthetic excision; however, most of these 
unfit patients may respond well to adjuvant hormone therapy and excision is not needed. 
In the treatment of known cancer, several key aspects need to be addressed that are 
important for patient care, but difficult to achieve without actually excising a cancer. 
First of all, it is essential to know the receptor status of a cancer for determination of 
adequate (neo)adjuvant systemic treatment. With local tissue destruction by ablation 
this information is not available and therefore needs to be obtained from biopsy samples 
prior to the therapy. In addition, determination of margin status is no longer possible by 
histopathological assessment. Consequently, image guidance needs to be highly reliable 
in the determination of actual tumor extent, and an ablation margin of sufficient size 
needs to be created before any treatment can be considered complete. In addition, safety 
needs to be assessed in combination with subsequent radiotherapy if the technique is 




2.4.1 | Hyperthermic ablation techniques
Radiofrequency ablation
Jeffrey et al. (1999) were the first to report the use of RFA for breast cancer treatment34. It is 
currently the most applied minimally invasive technique, relying on hyperthermia for the 
treatment of solid breast lesions. The needle-like RFA probe is percutaneously placed within 
the lesion under stereotactic or US guidance. In larger lesions twines may be pushed out of 
the center needle to expand the treated area (Figure 2.2). Alternative systems use multiple 
needles to cover the required ablation volume. After correct positioning, a high-frequency 
alternating current is passed through the probe causing friction in the surrounding tissue, 
which results in local heating, cell death, and eventually in necrosis of the tumor. The aim 
is to affect only the target tissue with minimal destruction of surrounding healthy tissue; 
however, in malignancies, an ablation margin needs to be created to ensure that the entire 
tumor is destroyed. 
Ensuring adequate margins is not easy. Breast tissue is composed of stromal and fatty 
tissue, and these different tissues have different thermal features, which may lead 
to irregular and unpredictable heating processes. In addition, the heated blood flow 
has influence on the ablation volume, which may lead to over- or under-treatment35,36. 
The most common complication of RFA is skin burn or burn of the pectoralis muscle in 
approximately 4-5% of the patients37,38. To avoid this complication, the distance between 
the lesion and skin or chest wall should be at least 1 cm. Skin protection can further be 
enhanced by active (ice) cooling of the skin or by displacing the tumor away from the skin 
with hydro- or pneumo-dissection. The procedure is also relatively painful, which should 
be managed with abundant local anesthesia and sedation or even general anesthesia. 
Furthermore, after RFA a hard lump or palpable mass may remain in the breast. This mass 
is mostly larger than the original lesion, but may decrease between 2 and 6 months after 
treatment38. Several studies employed so-called treat and resect protocols, in which the 
lesion after ablation is still surgically removed to assess the fraction of cell death. In a 
meta-analysis, Chen et al. (2016) reported a complete ablation rate ranging from 76% to 
96.15%, with a pooled estimates of 89% (95% CI: 58-93%)37. Few studies have reported 
on curative treatment with RFA alone, or in combination with radiotherapy. In most of 
these studies, patient selection was limited to women unfit for surgical procedures. 
Nonetheless, initial results were highly promising. In seven studies, local recurrences were 
detected in only five of 125 patients after a follow-up period of between 15 and 50 months. 
Nevertheless, radiotherapy may still be needed for these patients to reduce recurrence38. 
In conclusion, RFA has serious potential for the treatment of early-stage breast cancers 
because it is less invasive and is associated with improved cosmetic outcome compared to 
surgical excision.
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Figure 2.2 | Comparison in size between RITA multi-tine electrode system for radiofrequency 
ablation and 17 G IceRod™ cryoablation needle
 
Microwave thermotherapy
In 2002, Gardner et al. published the first study of breast cancer patients treated with 
microwave thermotherapy39. As in RFA, a needle-like probe is placed under local anesthesia 
into the tumor under imaging guidance. A microwave generator emits electromagnetic 
microwaves that agitate and heat water molecules in the surrounding tissues, which 
produces heat and cell death by coagulation necrosis40. It can be used to treat cancers up 
to 2 cm when one probe is used, for larger lesions multiple needles can be used. The mean 
treatment time for ablation reported in different studies was 19±18.2 min41.
In a systematic review and meta-analysis, Peek et al. (2017) reported a complete ablation 
rate of 83.2% (89/107) in treat and resect studies. Based on the same meta-analysis 
microwave thermotherapy resulted in the most complications of the compared ablative 
techniques (14.6%, 21/144), which included skin burns, seroma, flap necrosis, and muscle 
burns41. Overall, microwave thermotherapy is not as popular as the other ablation 
techniques, and until now, only a small number of patients are treated with this technique 
in a treat and resect setting.
Laser ablation 
Breast cancer treatment with LA is rarely studied. In 1994, Harries et al. reported the first 
study of breast cancer patients treated with LA42. With this technique, light energy is 
guided through a very thin laser fiber and absorbed into the tissue, which causes tissue 
heating (60°C) and eventually cell death. Laser fibers can be inserted through a small 
needle and the therapy can be performed under stereotactic, US, and MRI guidance, with 
local anesthesia. When MRI guidance is used also a very accurate temperature map can be 
obtained during the procedure, which can be very useful for treatment accuracy. 
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The exposure time can vary greatly from 1 to several minutes depending on the lesion size. 
When lesions are larger or irregular in shape, it is also possible to insert multiple laser 
fibers at the same time. 
There are not many studies on the treatment accuracy and performance of LA. The 
complete ablation rates are reported to range between 13% and 70%, although tissue 
damage was seen in 90-100% of treated patients43. Furthermore, 6.3% developed 
complications, such as skin burns and necrosis41,43. Akimov et al. (1998) performed the 
only study, in which seven patients were treated without subsequent resection. Only 3/7 
patients had a disease-free survival after a follow-up of 19-60 months44. 
Figure 2.3 | (a) Pre-treatment and (b) post-treatment with HIFU gadolinium-enhanced T1-weighted 
images of 53-year-old woman with invasive ductal carcinoma. The treated region can be clearly 
identified as a region of absent contrast medium uptake (area between the arrows). Courtesy of Dr. 
F. Pediconi, Department of Radiology, Sapienza University, Rome, Italy
High-intensity focused ultrasound 
HIFU is a relatively new ablation technique and was first reported by Huber et al. (2001) for 
breast cancer treatment45. HIFU has the advantage over all other ablation techniques that 
it is completely non-invasive; it is unnecessary to place a probe inside the target lesion. 
Guiding can be performed using either US or MRI. HIFU uses US energy from a bowl-
shaped transducer that converges into the focal zone or a small volume of tissue. In this 
focal zone, the energy causes a temperature elevation up to 95°C in a very short time (1-2 
seconds). A good to excellent cosmetic outcome in 93% of the patients is reported46. In 
the nearfield, skin burns can occur as a side effect, but with cooling of the skin this can be 
prevented or minimized. Lesions close to the surface or pectoral muscle cannot be treated 
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with this technique due to the risk of damaging these tissues. Figure 2.3 shows the MRI 
images of pre- and posttreatment with HIFU. Although the temperature elevation is very 
rapid, a long treatment time is needed to destroy an entire tumor, as the focal spot is 
very small. In the systematic review of Peek et al. (2015), the mean treatment time ranged 
between 78 and 171 minutes46. HIFU has been used in only a few limited feasibility and 
safety studies. They reported a wide range of complete ablation rates varying between 
24% and 100%43. 
2.4.2 | Other ablation techniques
Cryoablation
Cryoablation generates tissue necrosis by freezing the target lesion. Cryoablation is 
mainly used for treatment of cancers in the prostate, liver, and kidney, but in 1997 Staren 
et al. presented the first breast cancer patient treated with cryoablation47. In contrast to 
RFA, the ice-ball created always has a symmetric shape and a symmetric temperature 
distribution within the ice ball, which allows simple image-guided monitoring of therapy. 
Figure 2.4 shows US-guided cryoablation. The boundary between frozen and unfrozen 
tissue is clearly visible under US due to sonographic reflection, and in MRI signal void 
indicates the frozen area. In other words, the frozen tissue is visible in real-time with 
US showing a hyper-echoic rim and MRI showing a cryohalo. Nevertheless, intracellular 
freezing and cell dead occurs in almost all cells only at -40°C, therefore it is important to 
bear in mind that the killing zone is smaller than the ice ball. Better results are obtained 
when at least two cycles of freezing and thawing are performed, causing intracellular ice 
formation and dehydration. In addition, during the freezing process the blood flow is 
interrupted which causes damage to the microcirculation of the target lesion48.
 
 
Figure 2.4 | (a) US image of a 10.2-mm infiltrating ductal carcinoma of the breast prior to 
cryoablation in an 81-year-old woman. (b) US image of the same patient obtained during 
cryoablation of small breast cancer. Courtesy of Prof. M.H. Fuchsjäger, Department of Radiology, 
Medical University of Graz, Austria
Currently, there are two different cryoablation systems available. Most studies so far have 
employed a technique based upon cooling with argon gas, which is advanced through a 
very thin needle towards an expansion room at the needle tip, which leads to a very sharp 
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decrease in temperature based upon the Joule-Thompson effect. Depending on the size 
of the expansion chamber, ice-balls of different sizes can be created. The other technique 
uses liquid nitrogen, and has the advantage of even more rapid cooling, and therefore, 
also has a steeper temperature decline within the ice-ball (and thus a thinner margin that 
is frozen but does not reach -40°C); however, the latter is technically more challenging and 
has therefore only recently become commercially available. Figure 2.2 shows a cryoablation 
needle. The treatment time is strongly affected by the lesion size but takes on average 30-
40 minutes. A large advantage of cryoablation over hyperthermic techniques is that the 
cooling also has an anesthetic effect, i.e., the procedure is relatively painless and can be 
performed under local anesthesia only; however, similar to the hyperthermic therapies, 
10.9% of the patients develop a complication during this procedure, which includes skin 
necrosis and hematoma41. In a systematic review, Zhao et al. (2010) reported a complete 
ablation rate varying from 36-83%; the success rate is higher in small tumors (<2 cm)43. 
Peek et al. (2017) and Fleming et al. (2017) reported comparable values for complete 
ablation41,49. Larger tumors and patients with extensive in situ components are poor 
candidates for treatment with this technique43,50. Treatment of patients with breast cancer 
without subsequent surgical therapy has been performed to limited extent. Littrup et al. 
(2009) reported no local recurrences in 11 patients after an average imaging follow-up of 18 
months. Radiation therapy and/or chemotherapy was recommended for these patients51. 
In addition, in a study by Cazzato et al. (2015), 23 patients were treated with cryoablation 
without subsequent surgical therapy. Five patients had a poor primary treatment, which 
resulted in recurrence during follow-up, and two patients were successfully retreated52.
Recently, cryoablation has also been tested extensively for the treatment of benign breast 
masses, particularly fibroadenomas. Patients may choose removal, because the mass is 
palpable, may grow, and can cause anxiety. Treatment with cryoablation appears safe, and 
has an excellent cosmetic outcome. Directly after therapy a palpable lump is present, but 
this tends to resolve in months and leaves less scarring than with RFA. Risks are similar as 
for the treatment of malignant lesions and therefore sufficient space between the lesion 
and the skin must be ensured53.
Irreversible electroporation
IRE is a non-thermal ablation method that uses an electroporation pulse. When electric 
voltage is passed across the cell membrane, it results in membrane permeabilization or 
in simpler terms it creates very small holes (nanopores) in the cell membrane. Depending 
on the voltage and duration of these pulses, the mechanism is reversible or irreversible. 
Reversible electroporation is used in gene therapy and electrochemotherapy to allow 
small drugs or macromolecules to be introduced in the target cells. The irreversibel variant 
can be used for percutaneous ablation54. 
Although the effects of IRE have been known for decades, the use of IRE for breast cancer 
treatment is relatively new and rarely examined. Most of the in vivo investigations involve 
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animal models on several organ systems. To the authors’ knowledge, there has been no in 
vivo evaluation of IRE in humans with breast cancer.
2.4.3 | Minimally invasive excision
Every radiologist performing stereotactic or MRI-guided biopsies with relatively large 
vacuum-assisted needles will encounter the incidental patient where the biopsy proved 
to be curative after subsequent surgical resection. In other words, the entire tumor 
was removed during the biopsy and at surgical resection only healthy normal tissue is 
obtained (with the marker to ensure representativeness of the surgical excision specimen). 
Obviously, this can also be done on purpose, using fairly large needles to rapidly extract 
complete lesions through a limited skin incision.
Vacuum-assisted excision
The procedure of the therapeutic vacuum-assisted excision (VAE) is comparable with the 
diagnostic biopsy procedure. In general, larger needles (up to 7G) are preferred to limit 
the number of samples required to extract an entire lesion. After administration of 
local anesthesia around the lesion, the probe is inserted through a small skin incision 
and positioned in the area under the lesion using stereotactic or US guidance. Multiple 
samples in different directions can be obtained until the whole lesion is visibly removed 
and no residual lesion can be detected on imaging. 
This procedure, which is known as the MIRABEL technique, is effective and useful for the 
removal of benign lesions, especially under US guidance. Wang et al. (2012) examined the 
complete excision rate of benign breast lesions with different VAB devices. They found an 
overall complete excision rate of 94.8% after follow-up with US examination55. In addition, 
research of Johnson et al. (2002) and Fine et al. (2003) concluded that VAE of benign breast 
lesions is effective and feasible56,57. Therefore, VAE is considered the standard-of-care for 
the removal of symptomatic fibroadenomas. In the guidelines, VAE is also recommended 
for lesions with a uncertain malignant potential (B3 lesions), because they are associated 
with an increased risk of developing cancer and they may correlate with coexisting 
adjacent malignancy58,59. For malignant breast lesions, the use of VAE is somewhat 
more difficult because VAE is only able to remove a lesion in fragments. Because of 
this, the pathologist is not able to examine the margins of the lesion or determine the 
completeness of excision. Although this could be remedied by introducing a new needle 
in the biopsy cavity after the initial excision, obtaining additional biopsy samples of the 
cavity wall, it remains impossible to ascertain completion of tumor extraction, which 
implies that for VAE in malignant lesions similar oncological safety trials are required as 
for the ablative techniques60, which are currently still lacking.
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Breast lesion excision system
In contrast to VAE, the BLES provides unique opportunities for histopathological 
examination, with particular attention to margin examination and complete removal 
determination, as eventual lesions are removed in total (Figure 2.5). Particularly the larger 
2 cm and the recently introduced 3 cm needle seem fit for the purpose of removing small 
breast cancers; however, few studies have investigated the ability to use the BLES as a 
therapeutic device. Although most studies did not aim to excise the entire lesion, they 
showed promising results for complete excision rates. A complete excision rate of DCIS 
was reported between 38.7% and 75%25,27,29,30,32,33. For complete excision rates of ADH and 
invasive carcinomas studies reported values, which range from 66% to 86% and 14% to 
63%, respectively24,29,30,32,33. Nonetheless, targeted studies, in which lesion selection and 
targeting technique are tailored to the therapeutic goal, are required in order to show its 
feasibility for breast cancer therapy. 
 
Figure 2.5 | (a) Right mediolateral oblique mammogram of a 51-year-old woman shows a well-
defined 4x6 mm nodule in the upper outer quadrant, BI-RADS 4b category. (b) US-guided image 
of BLES procedure. (c) The 15-mm wand from the breast lesion excision system with representative 
sample of intact breast lesion. Courtesy of Prof. N. Abdel Razek, Department of Radiology, Cairo 
University, Egypt
2.5 | Discussion
Minimally invasive percutaneous image-guided biopsy is the current cornerstone in 
the diagnosis of breast abnormalities. CNB, obtaining two to three cores (14-16 G) under 
US guidance is the appropriate first choice for the diagnosis of most lesions. FNA is of 
interest for identification of the presence of metastatic disease in abnormal lymph 
nodes, and can be of use in specific technically challenging situations, such as small 
lesions adjacent to implants. The advantages of US guidance in terms of speed, ease and 
costs are so large that, in general, second-look US is always recommended when lesions 
are detected at another imaging technique3. For lesions without a clear correlation at 
US VAB is recommended22. The lack of real-time feedback of the needle position and 
the often more diffuse nature of these lesions requires more tissue to be obtained. This 
includes the assessment of microcalcifications that can be excellently targeted under 
stereotactic (or DBT) guidance, and also holds true for virtually all procedures under MRI 
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guidance. In general, a diagnosis can be established with approximately six to eight 
samples (9-11 G)13. 
The use of surgical excision biopsy is for the primary diagnosis of a palpable or imaging 
detected finding in essence obsolete; however, for the diagnosis of high-risk lesions, 
standard sampling might yield not enough tissue, leading to, for example, relatively 
high rates of underestimation of DCIS and even invasive disease after the diagnosis of 
ADH. In such cases, more tissue can be obtained either by surgical excision biopsy, VAE, 
or BLES. The same holds true for patients in whom an initial cancer visually disappears 
after neoadjuvant treatment. Eventual residual disease may be dispersed throughout 
the initial tumor bed, and large scale sampling should be indicated to ensure that a true 
pathological complete response is obtained61. For this purpose, surgical exploration is still 
currently advised, although it is foreseen that this will change too in the coming years.
Despite the success of minimally invasive breast biopsy, it should be acknowledged that 
the current situation is still far from ideal. The positive predictive values of diagnostic 
breast biopsies range from ~10 to 40%, which implies that more than half of breast 
biopsies are performed for benign disease62,63. As in these cases biopsy was unnecessary, 
better lesion characterization, using either imaging or other non-invasive tests, might 
in the future prevent a substantial number of breast biopsies. While outside the scope 
of this review, several newer imaging techniques such as tomosynthesis, contrast-
enhanced mammography, (shear wave) elastography, opto-acoustic imaging, ultrafast- 
and multiparametric MRI have already shown to increase the differentiation between 
benign and malignant breast disease, thus possibly allowing a reduction in the number 
of biopsies performed for benign disease64-66. Although the negative effects of such 
additional non-invasive investigations to rule out malignancy (time, discomfort, costs) 
must always be balanced against the negative effects of biopsy (pain and associated risks 
of hematoma and infection), it is still foreseen that modern imaging techniques, possibly 
in combination with blood or breath tests may in the future replace a large fraction of the 
biopsies currently performed for benign disease.
In the therapeutic domain, the use of minimally invasive techniques lags behind the 
technical developments in this area. Certainly, with the improvement of technology 
and medical scientific progress, it is becoming more common to use minimal- or non-
invasive therapies. These treatment techniques may offer complete treatment for breast 
cancer, with better cosmetic results, less psychological stress, and shorter hospital stays 
than conventional surgical approaches. Current research mainly focuses on HIFU and 
cryoablation, whereas in the previous years, RFA was the most used technique. HIFU has 
the obvious added advantage of being completely non-invasive, but suffers from long 
treatment times. The main advantage of cryoablation over RFA is the fact that cooling 
produces local analgesia and hence the therapy is well tolerated under local anesthesia 
only41,43; however, while there are many different techniques for image-guided ablation 
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available, they all suffer from one huge limitation: the lack of a surgical specimen for the 
evaluation of therapy success41. Furthermore, the receptor status cannot be verified and 
must be examined in advance. To circumvent the absence of surgical specimen, further 
research must be undertaken in the following areas: accurate staging of the tumor, 
imaging of tumor response during and after the treatment, the effect of radiation therapy 
after ablation, and the value of long term follow-up imaging. 
Just as in the diagnostic setting, current imaging techniques are not good enough to 
accurately stage breast cancer. Even with modern MRI techniques, not all tumor foci are 
depicted and especially DCIS components of a tumor may remain invisible. Optimization 
of staging is still required to better document the true extent of a lesion and hence 
facilitate the choice for minimally invasive ablative techniques in patients suitable for 
such therapy. In general, these are women with relatively small mass-like breast cancers, 
without a large DCIS component. In addition, better staging techniques (currently 
mostly multiparametric MRI, but in the future possibly also multiparametric breast US or 
contrast enhanced breast CT, molecular imaging, and PET mammography) should allow 
clear pre-therapeutic assessment of the spatial heterogeneity of the tumor in order to 
facilitate biopsy of the most relevant (in general most aggressive) parts of the tumor prior 
to therapy in order to select the best-suited adjuvant therapies.
For all ablation techniques (except for HIFU), the needle must be placed in the geometric 
center of the lesion for optimal treatment results. This requires a high level of skill from 
the radiologist, especially for very small lesions. Consequently, it is necessary to monitor 
the success of the applied therapy, which in most studies is not performed adequately. 
Appropriate imaging techniques during the procedure, should allow the radiologist to 
assess real-time whether the entire area of interest is treated sufficiently38. The ease of US 
in breast cancer patients still makes this the most desirable technique for all relatively fast 
ablative needle techniques, whereas MRI might be preferred for the guidance of slower 
techniques performed under general anesthesia. All heating procedures unfortunately 
lead to gas formation in the tumor, which acutely distorts the US image. Cryoablation does 
still allow the visualization of the front of the ice-ball, but no signal is obtained from the 
dorsal part, so current assessment of therapy success is largely dependent on the accuracy 
of initial needle placement in the center of the lesion48. One option to assess treatment 
success directly after therapy is the use of contrast-enhanced US, as a well-ablated tumor 
should not have active vascularization; however, the technique is not widely used.
To bypass the difficulty of real-time evaluation of ablative therapy success, it is possible to 
document tumor necrosis a few days after treatment, which allows determining whether 
the entire lesion area is affected, but obviously requires a second procedure in case of 
incomplete initial ablation. 
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Long-term follow-up must also be further improved. Mammographic control in women 
treated with lumpectomy has a sensitivity for local recurrence of only approximately 
50%. After ablation, the tumor is, in principle, left in situ, and may therefore still be visible 
at the control mammogram (it has likely only increased in size due to scar formation). 
Especially, in the presence of a residual palpable lump (these tend to regress over time 
(more so after cryoablation than after RFA), but are directly after therapy larger than the 
initial cancer), this may lead to anxiety and psychological stress for the patient and the 
treating physician38. Follow-up therefore likely requires imaging with a technique that can 
show viability of tissue, which is most easily achieved by imaging perfusion. Therefore, 
candidate follow-up examinations after ablation exclude techniques that only image 
anatomy, and rely heavily on the administration of contrast medium. Currently, contrast-
enhanced MRI appears to be the most appropriate follow-up examination. 
As is clear from the overview of current ablative techniques, ablation is commonly not 
complete (i.e., 100%) according to subsequent histopathological analysis of the post-
ablative surgical specimen41,43. It might therefore easily be concluded that ablative 
therapies are not good enough to cure cancer patients and need to be reserved for 
palliative care in women unfit for surgery only; however, the current results must also be 
seen with respect to the findings in the initial lumpectomy trials, where residual cancer 
after lumpectomy was still present in over 40% of patients2. As it has become clear over 
the years that breast conserving therapy is as safe as mastectomy for women with smaller 
breast cancers, even when surgery is only debulking, subsequent cure can be expected 
from adjuvant radiotherapy and systemic therapies. So far, very few studies left the tumor 
in situ after application of an initial ablative therapy, and even fewer studies applied 
subsequent radiotherapy to the treated breast. Moreover, the few studies in which ablation 
was used instead of surgical therapy were mostly performed in women with a limited life 
expectancy. Consequently, it is currently completely unclear whether radiotherapy after 
initial ablation is capable of providing sufficient supplemental therapy, as it does after 
surgical excision. This, therefore still requires large randomized prospective trials with 
local recurrence or even breast cancer-related survival as endpoints. This implies that 
minimally invasive breast cancer ablation is not expected to gain widespread use in the 
coming years as follow-up of such trials needs to be long enough to determine oncological 
safety of these new procedures.
A huge advantage of minimally invasive excision over ablation, especially when the 
BLES device is used, is that it is theoretically possible to evaluate the tumor margin, 
and hence show success of therapy in a similar fashion as currently with surgery24,26. 
This would bypass the need for trials with oncological safety endpoints and therefore, 
facilitate rapid implementation of minimally invasive techniques in the therapy of breast 
cancer, assuming that it can be proven that margin evaluation is as accurate using these 




In conclusion, minimally invasive biopsy is indispensable for the diagnosis of breast 
lesions. Current research should focus on optimizing patient selection in order to reduce 
the frequency of biopsy of benign lesions. Use of minimally invasive therapy is only slowly 
progressing. Most studies employed treat and resect protocols and hence only document 
the ablation fraction in the treated cancers. To facilitate further implementation, there is a 
strong need for randomized trials supplementing the ablation with radiotherapy, and with 
oncological safety as outcome parameter.
Currently, minimally invasive techniques are mostly used for patients who are unsuitable 
for surgery. For these patients minimally invasive therapy is a good replacement for 
surgery and often the only possible treatment available.
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Purpose: To outline the current status of and provide insight into possible future research 
on the breast lesion excision system (BLES) as a diagnostic and therapeutic device.
Methods: A systematic search of the literature was performed using PubMed, Embase, and 
the Cochrane databases to identify relevant studies published between January 2002 and 
April 2018. Studies were considered eligible for inclusion if they evaluated the diagnostic 
or therapeutic accuracy or safety of BLES. 
Results: Ultimately, 17 articles were included. The reported underestimation rates of 
atypical ductal hyperplasia and ductal carcinoma in situ (DCIS) ranged from 0% to 14.3% 
and from 0% to 22.2%, respectively. Complete excision rates for invasive ductal carcinoma 
and DCIS ranged from 5.3% to 76.3%. Bleeding was the most frequently reported 
complication (0-11.8%). Device-related complications may arise, with an empty basket 
being the most common (0.6-3.6%). Thermal damage of the specimen, caused by the 
use of a radiofrequency cutting wire, was reported in eight of the included studies. Most 
thermal artifacts were reported as superficial and small (0.1-1.9 mm). 
Conclusion: The BLES, an automated, image-guided, single-pass biopsy system for breast 
lesions using radiofrequency is designed to excise and retrieve an intact tissue specimen. 
It is an efficient and safe breast biopsy method with acceptable complication rates, which 
may be used as an alternative to vacuum-assisted biopsies. The variable rate of complete 
excision raises questions about the possibility to use BLES as a therapeutic device for the 
excision of small lesions. Further research should focus on this aspect of BLES.




Breast cancer is the most frequently diagnosed cancer and one of the leading causes of 
cancer death in women worldwide1. The prevalence and incidence of breast cancer have 
increased over the last 25 years in most countries. Due to increased awareness and 
screening, up to 53% of cancers are smaller than 2 cm and asymptomatic at detection2,3. 
Therefore, technologies aimed at achieving minimally invasive complete resection are 
being investigated.
Recently, the breast lesion excision system (BLES) has been developed, which is an 
automated, image guided, single-pass biopsy system using radiofrequency (RF). This 
device is designed to extract entire breast lesions, keeping the tissue architecture intact. 
The device consists of a probe that can be inserted through a small skin incision of 6-8 
mm, with a sharp blade at the distal end to access the target lesion. Just behind the blade, 
capture wire electrodes are positioned that, once activated, are pushed forward by a motor 
in the device handle. In approximately 8 s the device deploys the RF cutting mechanism, 
enclosing the target lesion. To keep the biopsy cavity clear of fluid, which is essential for 
RF cutting, vacuum ports are located at the distal end of the probe. The capture snare 
enclosing the specimen can be retracted after the procedure, and a marker clip can be 
placed in the biopsy cavity through the biopsy canal. Figure 3.1 and Figure 3.2 show the 
BLES probe and an obtained specimen, respectively.
As opposed to other breast biopsy devices, the aim of BLES is to excise and retrieve an 
intact breast tissue specimen, rather than to obtain fragmented samples4-7, which may 
not only facilitate easier diagnosis but also might allow for minimally invasive resections.
In this systematic review, we aim to determine the current status of BLES as a potential 
diagnostic and therapeutic device in patients with small suspicious or proven (pre-)
malignant breast lesions, and its related complications.
  




3.2.1 | Search strategy
A search of the literature was performed in order to identify all articles that examined the 
diagnostic accuracy, therapeutic efficiency, related complications, and/or thermal damage 
of BLES in patients with suspicious breast lesions. We searched for articles in PubMed, 
Embase, and the Cochrane database to identify English language, peer-reviewed articles 
published between January 1, 2002 and April 24, 2018. The search terms included: breast, 
percutaneous, intact, specimen, sample, biopsy, breast lesion, excision and radiofrequency, 
in various combinations. A full list of all performed searches is given in Table 3.5 in the 
Appendix. Furthermore, the reference lists of all included articles were manually searched 
for relevant references.
3.2.2 | Study selection
The search in PubMed and Embase generated 531 and 261 articles, respectively. The 
Cochrane Library was manually searched, yielding no relevant articles. Duplicate articles 
were manually filtered using the bibliographic EndNote database, version X8 (Thomas 
Reuters, New York City, NY, USA), and 537 potentially relevant articles remained.
Titles and abstracts of the remaining articles were evaluated by two authors (WS and BL). 
Articles were included only if they met all of the following criteria: (I) BLES or a prototype 
was used as a diagnostic or therapeutic device; (II) a minimum sample size of 10 patients 
with suspicious lesions referred for breast biopsy was included; (III) stereotactic or 
ultrasound guidance was used; (IV) the BLES procedure was followed by open surgery in 
malignant cases, or clinical follow-up of at least 1 year if surgery was not indicated. 
3.2.3 | Data extraction, statistics, and quality assessment
The following characteristics were, if available, collected: first author, publication year, 
country, study design, study period, number of patients, mean age, number of lesions, 
type of lesions, lesion size, guidance modality, used needle size, procedural success rate, 
histological data, underestimation rates, complete excision rate, frequency and type 
of complications, thermal artifacts, and procedural problems. There was no agreement 
between the papers about the definition of complete excision. Therefore, these definitions 
were also collected. Results are presented as aggregated data from individual studies. 
Underestimation rates for invasive and in situ malignant disease associated with the 
detection of atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) in the 
biopsy specimens were used to determine the diagnostic accuracy of the BLES. “ADH 
A systematic review on the use of the BLES in breast disease
61
3
underestimation” was defined as the percentage of ADH lesions on BLES specimen 
upgraded to DCIS or invasive cancer at subsequent excision. “DCIS underestimation” was 
defined as the percentage of DCIS lesions on BLES biopsy upgraded to invasive cancer in 
the surgical specimen. Complete excision rate was defined as the fraction of BLES excisions 
with ADH, DCIS, or invasive cancer that were negative at subsequent surgical excision (i.e., 
no residual lesion was found). 
The quality of the included studies was evaluated by the same two independent observers 
using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) scoring 
system8. This checklist comprises four domains: patient selection, index test, reference 
standard, and flow and timing. Not all signaling questions were relevant to assess the 
study quality for the present review. Two signaling questions were added to the QUADAS-2 
scoring system: at the index test domain, the signaling question: “Physicians who 
performed the index test had appropriate training or the first patients were excluded to 
account for a learning curve” and at the reference standard domain: “Were patients who 
did not receive the reference standard specified?”. Table 3.6 in the Appendix shows how the 
QUADAS-2 score was adapted for this review. Inequalities in scoring by the observers were 
subsequently resolved by consensus. 
Meta-analysis was not performed due to heterogeneity across studies regarding patient 




Five hundred thirty-seven potential relevant articles remained after the search. Five 
hundred eighteen articles were excluded because they did not use the BLES device or a 
prototype. We identified 19 full-text versions of studies that used the BLES as a diagnostic 
or therapeutic device and that fulfilled all the inclusion criteria4-7,9-23. Figure 3.3 shows the 
results of the study search and identification of eligible studies. We did not retrieve any 
additional items after reference screening. The study by Fine et al.19 was excluded because 
although a comparable device was used, it was not a prototype of BLES. Citgez et al.18 
published their findings as an abstract only and was therefore excluded.
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Figure 3.3 | Flowchart of systematic review
The characteristics of the 17 included studies are shown in Table 3.1. All studies were 
observational: 10 studies enrolled participants prospectively while 7 studies were 
retrospective. In all of these studies, included patients had known mammographic 
abnormalities (masses or suspicious calcifications) with a mean lesion size on imaging 
ranging from 5.7 mm to 12.7 mm (reported range, 1 mm -76 mm). Mean age ranged from 50.5 
years to 61.8 years (reported range, 21 years - 93 years). The number of lesions ranged from 19 
to 1170. Ten studies used stereotactic guidance during the BLES procedure4,6,7,9,11,13,15,16,20,22. Six 
studies used stereotactic or ultrasound guidance5,10,12,14,21,23; only Graham et al.17 performed 
all BLES procedures with ultrasound guidance.
Overall 4373 BLES biopsies were performed in 17 studies. The procedure was technically 
successful in 4320 procedures, with success rates varying between 84% and 100%. Eight 
studies were performed for diagnostic purposes only4,6,7,9,11,13,15,17. In two studies, one or 
more biopsies were performed to remove benign lesions for which histology was already 
known21,23. One study aimed at a complete, tumor-free margin excision of small solid 
carcinomas22.
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3.3.2 | Quality assessment
The results of bias risk and applicability according to the QUADAS-2 evaluation are 
summarized in Figure 3.4. In five studies, the risk of bias in patient selection was considered 
uncertain due to unreported details5,11-14. The study of Scaperrotta et al.16 was considered 
to present a high risk of bias in patient selection since patients were not consecutively 
enrolled. The decision to use the BLES was entirely based on the radiologist’s assessment. 
Presence of bias risk of the index test was uncertain in 11 studies6,7,9,12,13,15-17,20-22 and high in 
two studies10,23. The risk of bias in the “reference standard” domain was generally scored 
low. Only the study by Al-Harethee et al.7 had an unclear bias risk because there was no 
information available about the used reference standard. Admittedly, this was beyond the 
scope of their study. The risk of bias in the flow and timing was generally scored as high, 
because not all patients with a high-risk lesion (HRL) or malignancy based on the BLES 
received surgical excision. Only five studies15,20-23 were scored with a low risk of this bias 
and one7 with an unclear risk of bias. All studies were deemed applicable to the research 
question. In short, no studies were excluded based on the quality assessment.  



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3.3 | Diagnostic accuracy
BLES was, in most studies, used as a diagnostic tool for breast abnormalities for which 
histopathology was not yet available. Diagnostic accuracy was usually reported as the 
underestimation rates of more aggressive disease in lesions diagnosed as ADH and/or 
DCIS by BLES. The ADH and DCIS underestimation rates ranged from 0% to 14.3% and from 
0% to 22.2%, respectively. In addition, the diagnosis was upgraded by subsequent BLES 
excision after ADH, DCIS, or intraductal papilloma was found on core needle biopsy (CNB) 
or fine needle aspiration (FNA) cytology in 2.7%, 0.9%, and 19.7% of cases, respectively21,23. 
Results of all individual studies are shown in Table 3.2.
Table 3.2 | Summary of underestimation rates of BLES in literature
First author ADH underestimation rate n/N (%) DCIS underestimation rate n/N (%)
Sie et al.4 3/32 (9.4) 6/115 (5.2)
Killebrew et al.9 NA 1/31 (3.2)
Allen et al.5 NA NA 
Seror et al.10 0/4 (0) 6/27 (22.2)
Diepstraten et al.11 NA 0/3 (0)
Whitworth et al.6 3/32 (9.4)a NA 
Razek et al.12 0/14 (0) 0/8 (0)
Medjhoul et al.13 0/4 (0)b 1/9 (11.1)
Al-Harethee et al.7 NA NA 
Allen et al.14 0/6 (0) 0/11 (0)
Al-Harethee et al.15 NA NA 
Scaperrotta et al.16 NA 5/32 (15.6)
Graham17 1/38 (2.6)b 0/8 (0)
Milos et al.20 2/14 (14.3)b 0/10 (0)
Sklair-Levy et al.21 NA NA
Papapanagiotou et al.22 NA 0/5 (0)
Niinikoski et al.23 NA NA
ADH, atypical ductal hyperplasia; DCIS, ductal carcinoma in situ; n, number of DCIS/invasive carcinoma 
reference (initially ADH) or number of invasive carcinoma reference (initially DCIS); N, total number of 
initially ADH or DCIS; NA, not available;
a 23/32 based on open surgical excision, 6/32 based on image follow-up 
b High-risk lesion underestimation
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3.3.4 | Therapeutic accuracy
Only two studies have investigated the ability to use BLES as a therapeutic device for 
removal of lesions for which histological results were already obtained by other means21,23. 
An additional three studies assessed the therapeutic value of the system without prior 
knowledge of histology16,20,22, and several studies reported the complete excision rate of 
biopsied lesions, even though they did not aim to excise the entire lesion4,5,9-14. See Table 3.3. 
The median of all reported DCIS complete excision rates was 50% (range, 0.9-80%)4,5,9-
12,14,16,20,22,23. For complete excision rates of ADH, studies reported a median of 60% (range, 
22.2-83.3%)4,10,12,13,20,23. For complete excision rates of invasive ductal carcinoma (IDC), the 
median was 43% (range, 0-62.5%)5,10,12-14,16,20,22,23.
3.3.5 | Complications and procedural problems
Studies reported various complications associated with the use of BLES (Table 3.4), 
although complications were infrequent and usually mild. The most common 
complications were bleeding (0-11.8%), hematoma (0-8.8%), infection (0-5.3%), wound 
leakage (5.3%), wound healing problems (0.9-5.2%), and skin burn (0-1.5%)4,5,7,9-14,17,20-23. In 
addition to patient-related complications, device and procedure-related problems were 
also reported: wire break (0.6-1%), basket failed to deploy (0.7-2%), incorrect guidance 
(0.9-1.2%), and an empty basket after the procedure (0.6-3.6%)7,9,10,15,16,21,22. In the case of 
device-related complications that lead to an unsuccessful procedure, the use of a second 
probe was necessary to complete the procedure. 
Thermal damage to the specimen is regularly present due to the use of the RF-based 
cutting wire and reported by several studies that evaluated the BLES. However, the 
reported thermal artifacts were mostly superficial and small. The affected tissue thickness 
ranged overall from 0.1 mm to 1.9 mm4,5,9-12,14,15 and was more extensive toward the pole of 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This systematic review reports on 17 studies on the diagnostic and therapeutic accuracy, 
and complications of BLES in patients with suspicious breast lesions. A (pooled) meta-
analysis was not performed because of heterogeneity in study design and included 
patient populations. Overall, the procedural success rates are high. Despite the fact that 
most studies did not aim to remove lesions entirely, complete excision occurs regularly, 
depending on the type of lesion. Finally, complications are infrequent and usually mild. 
Although technical failures might occur due to specific properties of the BLES, they are 
infrequent. Although the device is only approved for diagnostic purposes it certainly has 
the potential to be used as a therapeutic device. 
The overall study quality of all included studies is reasonably high according to the 
QUADAS-2 score. According to the instructions for use, the QUADAS-2 tool was tailored 
for this systematic review, which means that some signaling questions were added or 
omitted, as provided in Table 3.6 in the Appendix. The signaling question “Physicians 
who performed the index test had appropriate training or the first patients were excluded 
for the learning curve?” was added because the likely present learning curve may have 
an influence on other variables, such as success rate, complications, and technical 
failure. Also, the letter of Michalopoulos et al. describes that it has been estimated that 
for dedicated breast radiologists approximately four procedures and for those without 
previous VAB experience nine procedures are required to gain experience with the BLES 
technique24. The signaling question “Were patients who did not receive the reference 
standard specified?” was added because surgical excision is mandatory for patients 
with a malignant or HRL in the index test. Underestimation rates of biopsies containing 
ADH and DCIS are commonly used to determine the accuracy of percutaneous biopsy 
techniques25,26. Multiple studies focused on ADH or DCIS underestimation rates of VAB 
and of CNB with varying needle sizes. In a systematic review of VAB, Yu et al.27 reported 
a pooled ADH and DCIS underestimation of 20.9% (95% CI: 17.7-24.5%) and 11.2% (95% 
CI: 9.8-12.8%), respectively. Reported underestimation rates for CNB are generally higher: 
44.2% (95% CI: 36.0-52.5%) and 22.8% (95% CI: 19.0-26.5%), respectively28. In the current 
review of BLES, ADH and DCIS underestimation rates are therefore in the same order of 
magnitude as those reported for VAB. The en bloc resection obtained with BLES preserves 
lesion architecture, which may make subsequent histopathological classification easier, 
facilitating discrimination between atypical and (pre-)malignant lesions. Furthermore, 
the possibility to examine the margins of the lesion allows determination of the excision 
completeness, which is crucial for high-risk or (pre-)malignant lesions29. However, in 
normal clinical situations, the BLES will not be the first choice biopsy device, because it is 
more invasive, expensive, and requires adequate training.
The varying rates of complete excision suggest that future research should focus on the 
characteristics of lesions for which BLES can be used for therapeutic resection. It should 
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be noted that complete excision rates of clusters of suspicious microcalcifications under 
stereotactic guidance are low. The cluster size of microcalcifications on mammography 
is anyhow poorly correlated with pathological tumor size in both DCIS and invasive 
disease30. Therefore, it is highly recommended to focus future research on lesions that are 
clearly visible on mammography or US. It would be appropriate to modify the needles to 
make them appropriate for MRI-guided biopsy (ferromagnetic-material-free), so that the 
lesion size could be measured more precisely and needle size selection could be adjusted 
accordingly. It is important to realize that the basket should be large enough to capture 
the entire lesion when the intended use is therapeutic. An upgraded BLES needle with a 
diameter of 30 mm is under development. This may further reduce underestimation rates 
and expand therapeutic possibilities.
Although most studies recorded the presence of RF-coagulation artifacts, these artifacts 
are most prominent around the pole of the ellipsoid specimen. A possible explanation 
is that the precursor electrode is situated at the distal end of the probe and tissue is 
more exposed to this part. Some studies note that pathologists may have difficulties 
with interpretation and assessment of edges and margins of lesions obtained with BLES 
because of these RF artifacts. However, this problem seems to wane when the pathologist 
gains more experience with BLES samples9-11,13,14. In fact, most breast pathologists are used 
to coagulation artifacts at the edges of breast specimens as breast surgeons commonly 
work with a diathermic knife. Nevertheless, there are some options to minimize the 
effect of RF artifacts. First, placing local anesthetic fluid effectively around the entire 
lesion, because dry tissue burns easier. Second, aiming to get the lesion in the middle of 
the resection specimen, rather than at the distal pole, will reduce the effect of thermal 
damage to the lesion. Using a larger wand should increase the distance between the RF 
artifact and the lesion. 
The most frequently reported device-related failure was an empty basket. The cause of 
this failure is unknown, but thought to be associated with the presence of excessive 
(anesthetic) fluid which blocks the RF cutting mechanism or the presence of very fatty 
breast tissue which melts during the procedure9,15,31. Unfortunately, in case of an empty 
cage after biopsy, no salvage technique is available other than marker placement followed 
by surgical excision, or when the lesion is still visible, an attempt using VAB. In case of 
a basket deployment failure, a second disposable is necessary, with associated costs, 
because the system uses single-shot only needles. Adjusting the needles for re-use in the 
same patient could be a solution. 
In conclusion, BLES is a diagnostic device with a diagnostic accuracy at least as good as 
VAB, as expressed by ADH and DCIS underestimation rates. The technique is safe for use. 
Disadvantages of BLES are the reported device-specific problems and the fact that only one 
attempt of lesion removal per needle is possible. Advantages include preservation of lesion 
architecture, and the possibility to assess lesion margins. Although there is a small risk of 
A systematic review on the use of the BLES in breast disease
73
3
thermal damage to the biopsy specimen that might hinder pathological evaluation, this 
appears limited. BLES therefore offers a viable alternative to VAB. Based upon the balance 
between advantages and disadvantages, BLES seems most suited for the complete excision 
of small breast lesions for which a definitive diagnosis is required (e.g., papillomas). Because 
BLES is minimally invasive and permits margin evaluation, the value of this device may 
be mainly in the therapeutic field, future research should therefore focus on this. A “treat 
and resect” study design, in which a BLES excision is immediately followed by a surgical 
procedure of the biopsy cavity, seems to be most feasible for the evaluation of the potential 
of the technique for treatment of small cancers. This may depend on the availability of 
larger basket sizes. It is also important to assess whether it is possible to predict successful 
tumor extraction based upon patient and tumor characteristics, as adequate patient 
selection seems mandatory. If such studies are successful, then follow-up studies should 
be performed in large-scale multi-center settings to evaluate the resection of small invasive 
carcinomas under local anesthesia only with BLES, followed by additional surgery only if 
resection margins are positive. Afterward, these patients must be followed for a long 
period to analyze possible effects on local recurrence and disease-free survival. Also, the 
improvement, if any, in quality of life should be evaluated. Finally, a cost-effectiveness 
analysis from a healthcare perspective is necessary to assess the impact on healthcare costs. 
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3.6 | Appendix
Table 3.5 | Full list of performed searches
Set Search statement for Pubmed and Embasea
#1 Breast lesion excision[tiab]
#2 Breast [tiab] AND Percutaneous excision[tiab]
#3 Breast [tiab] AND Percutaneous biops*[tiab]
#4 Breast [tiab] AND Intact[tiab] AND (Sample*[tiab] OR Specimen*[tiab])
#5 Percutaneous[tiab] AND Biops*[tiab] AND Breast lesion*[tiab]
#6 Biops*[tiab] AND Breast lesion*[tiab] AND Radiofrequency[tiab]
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
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Introduction: Due to the shift towards minimal invasive treatment, accurate tumor 
size estimation is essential for small breast cancers. The purpose of this study was to 
determine the reliability of MRI-based tumor size measurements with respect to clinical, 
histological and radiomics characteristics in small invasive or in situ carcinomas of the 
breast to select patients for minimal invasive therapy.
Materials and methods: All consecutive cases of cT1 invasive breast carcinomas that 
underwent preoperative MRI, treated in two hospitals between 2005 and 2016, were 
identified retrospectively from the Dutch cancer registry and cross-correlated with local 
databases. Concordance between MRI-based measurements and final pathological size 
was analyzed. The influence of clinical, histological and radiomics characteristics on the 
accuracy of MRI size measurements were analyzed.
Results: Analysis included 343 cT1 breast carcinomas in 336 patients (mean age, 55 
years; range, 25-81 years). Overall correlation of MRI measurements with pathology was 
moderately strong (ρ=0.530, P < 0.001), in 42 cases (12.2%) MRI underestimated the size 
with more than 5 mm. Underestimation occurs more often in grade 2 and grade 3 disease 
than in low grade invasive cancers. In DCIS the frequency of underestimation is higher 
than in invasive breast cancer. Unfortunately, none of the patient, imaging or biopsy 
characteristics appeared predictive for underestimation.
Conclusion: Size measurements of small breast cancers on breast MRI are within 5 mm of 
pathological size in 88% of patients. Nevertheless, underestimation cannot be adequately 
predicted, particularly for grade 2 and grade 3 tumors, which may hinder patient selection 
for minimal invasive therapy.




Mostly as a result of screening, more than half of breast cancers are diagnosed when 
smaller than 2 cm1,2. This has helped make breast-conserving therapy (BCT), usually 
involving surgery and radiation therapy, the most common treatment for breast cancer3. 
However, cosmetic outcomes after BCT are suboptimal in 20%-30% of cases4-6. In addition, 
breast-conserving surgery (BCS) is performed under general anesthesia, which requires 
planning and brings considerable costs. Furthermore, postoperative complications, such 
as a bleeding, infections or pain, can occur. 
To overcome these issues, technologies for minimally invasive treatment are being 
investigated, including thermal ablation (cell destruction using either very high or very 
low temperatures), and minimally invasive resection (needle biopsy resection under local 
anesthesia). All such therapies are imaging-driven, both for assessment and localization 
of the target, and determination of therapy success. The relatively small cancers are often 
not palpable, and the treatment may actually create a bigger lump than was present before 
therapy. To determine if minimally invasive therapy is feasible as primary treatment, 
accurate determination of tumor size, presence of additional tumor foci, and extent of 
disease on imaging is of great importance. 
Magnetic resonance imaging (MRI) is widely regarded as the most accurate modality for 
evaluation of tumor size. Many studies have examined the accuracy of MRI in estimating 
the pathologic size of breast cancer7-11. However, while demonstrating that MRI is more 
accurate than both mammography or ultrasound, these studies also have found that 
at MRI the tumor size is underestimated in 7%-19% of the cases7-11. Likewise, although 
breast MRI has been found to be more accurate than ultrasound and mammography 
in estimating the extent of concurrent ductal carcinoma in situ (DCIS)12-16, a substantial 
portion of DCIS is still occult at MRI (range, 1.6%-16%)14,17. 
While none of these studies focused on size-measurement accuracy in small tumors 
(<2 cm) only, it has been shown that measurement errors on MRI increase with tumor size, 
partly because the radiology and histopathology correlation in tumor shape decreases for 
larger cancers, due to the work-up of the histopathological specimen. However, generally, 
since breast MRI is less frequently used for the assessment of small cancers, its accuracy 
for determining tumor size estimates in small cancers is unclear. Consequently, the 
primary aim of this study is to assess the clinical accuracy of breast MRI for size estimation 
in small breast cancers (≤2 cm; cT1).
Furthermore, it would be useful to identify if any a priori patient and cancer characteristics 
may be predictive of lesion size underestimation and, consequently, which patients may 
be less suitable for minimal invasive treatment due to uncertainty in the true tumor size. 
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Therefore, the second aim of this study is to examine which factors (clinical-, histological-, 
and radiomics-based), if any, are associated with underestimation of the tumor size 
preoperatively. 
4.2 | Material and methods
4.2.1 | Study population
This retrospective study was approved by our local institutional review board and 
the requirement for informed consent was waived. Patients were selected from the 
Netherlands Cancer Registry when they were female, clinically diagnosed with small 
invasive or in situ breast carcinoma staged as cT1, cN0-3, M0, between January 1, 2005, 
and December 31, 2016, and had primary BCS in the Radboudumc or Canisius Wilhelmina 
Hospital, both in Nijmegen, the Netherlands. We subsequently excluded patients who 
had no pre-surgical MRI or had undergone neoadjuvant treatment. Once selected, 
patient-, tumor-, and treatment-related characteristics were obtained from the Registry 
while lesion size at MRI was obtained from the corresponding hospital database. 
Patients for whom the lesion size on the preoperative MRI was not documented were 
excluded. 
The largest diameter, as determined by the pathologist, was considered the gold standard. 
Concordance between tumor diameter at MRI and histopathology was defined as there 
being a difference smaller or equal to 5 mm, with larger differences being labeled as under- 
or over-estimation at MRI.
4.2.2 | Breast MRI review
All selected examinations had undergone MRI acquisition on scanners having a field 
strength ≥1.5 T with a dedicated breast coil, and patients imaged in prone position. 
Although MRI systems and sequence protocols varied slightly between the two study 
centers and over time, they complied with the guidelines of the European Society of 
Breast Imaging18,19. The protocols consisted of a T2-weighted sequence with or without fat 
suppression, combined with a dynamic, contrast enhanced T1-weighted sequence series 
with an in-plane resolution below 1x1 mm and a slice thickness of 2.5 mm or lower. 
All data were obtained from the reports generated at the time of treatment to obtain 
clinically realistic MRI evaluations. Breast MRIs were reported by 13 different radiologists, 
with experience in breast MRI ranging from 0 to 23 years after training. In most reports 
the tumor size was reported in two or three imaging planes, and the largest diameter was 
used, hereafter denoted the ‘index lesion’ diameter. In some patients, in addition to that 
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of the index lesion, an additional measurement was included in the radiological report 
for surrounding enhancement, strongly suspected for DCIS, hereafter denoted ‘extent of 
disease’ diameter, which therefore includes both the invasive carcinoma and the potential 
DCIS components. 
4.2.3 | Pathology review
Information on histopathology was extracted from the clinical pathology reports. The 
reports were created by one of 15 breast pathologists, with post-training experience 
in breast pathology ranging from 0 to 25 years. The reports were reviewed for: tumor 
histologic subtype, tumor size (invasive and non-invasive), multifocality, histologic grade 
(based on the modified Bloom and Richardson grading system20), estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. 
Although specimen processing might have varied slightly between the two study centers 
and changed over years, it complied with the Dutch Breast Cancer Guidelines21. Size 
measurements were performed as stated in the Dutch guidelines21. For invasive tumors 
>1 cm, the maximum macroscopic dimension was used. For smaller lesions the size 
was also measured on the microscopic slide. Concerning DCIS, size was determined by 
assessing the proportion of the excisional specimen that contained DCIS on microscopy, 
as DCIS is seldom visible for the naked eye. In one of the hospitals, specimen radiography 
was used to assist in the above-mentioned procedures. In most reports the largest tumor 
diameter was reported, hereafter denoted the ‘index lesion’ diameter. However, in some 
patients, in addition to that of the index lesion, an additional measurement was included 
in the pathology report for surrounding DCIS, hereafter denoted the ‘extent of disease’ 
diameter, which therefore includes both the invasive carcinoma and the DCIS components.
Breast cancers were divided into four subtypes based on hormone receptor status (HR) 
that included ER, PR and HER222. The subtypes were defined as: HR+ (ER+ and/or PR+)/HER- 
(luminal type HER2 negative), HR+ (ER+ and/or PR+)/HER+ (luminal type HER2 positive), 
HR- (ER- and PR-)/HER2+ (HER2-enriched), and HR- (ER- and PR-)/HER2- (triple negative)20,22,23. 
Finally, invasive tumors were divided into three histologic groups: invasive carcinoma 
of no special type (NST), invasive lobular carcinoma (ILC) and ‘other’ (mixed carcinomas, 
tubular carcinoma, apocrine carcinoma, mucinous carcinoma and medullary carcinoma). 
4.2.4 | Radiomics assessment
To investigate whether quantitative imaging biomarkers could help predict the mismatch 
in MRI and pathology tumor size, a radiomic analysis was performed on the MRI tumor 
images. Radiomics aims at the extraction and quantification of mineable features 
contained in medical images24. These features, extracted via dedicated image analysis 
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algorithms, have been shown to help recognize different imaging phenotypes, and, in 
some cases, to correlate with specific clinical outcome (such as survival rate and cancer 
risk assessment)25. 
In this study, radiomic features were calculated only for selected patients who were 
treated at Radboudumc and underwent breast MRI between 2011 and 2016. This was done 
to keep the image characteristics and acquisition settings as consistent as possible for 
this analysis. The specific MR protocols were described by Dalmis et al.26 and van Zelst 
et al.27,28. Consequently, radiomic analysis of the MRI scans of 88 patients with invasive 
breast cancer was performed. To prevent correlation towards single outliers, tumors 
with an absolute size mismatch larger than 15 mm were excluded. The algorithm used 
for radiomic feature extraction captures several image characteristics quantified by five 
major radiomic descriptor types29-36. All descriptors aim at quantifying the image texture 
at different scales and orientations, and have been previously investigated to achieve 
computer-based prediction of a given outcome (typically, histological evaluation). In 
total, 141 radiomic descriptors were applied, using a previously developed pipeline29, and 
the extracted features were analyzed to search for potential correlation with the mismatch 
in MRI and pathology tumor size. 
Features were extracted from a square region of interest (ROI) around each tumor, 
with dimensions equal to the depicted tumor plus an additional margin of 10 mm. 
Subsequently, the impact of setting other margin sizes (15 mm, 20 mm, and 25 mm) was 
investigated.
The feature extraction was performed on a 2D-basis on ROIs collected from nine MRI 
image views for each tumor, corresponding to the planes of symmetry of an imaginary 
cube circumscribing the tumor37, and radiomic features were then averaged over these 
nine planes.
4.2.5 | Statistical analysis
Concordance of sizes measured at MRI and pathology were explored with Bland-Altman 
plots and Pearson correlation coefficient (ρ). Since the sample size is sufficiently large 
(n = 343), as specified by Lumley et al.38, differences were compared using a paired t-test. 
Statistical analyses of patient age was performed using one-way ANOVA. Concordance 
rates according to histologic subtype, receptor subtype, multiplicity, lymph node status, 
histological grade, DCIS grade (biopsy and surgery), ER, PR and HER2 status were compared 
using the Fisher exact test. After a positive Fisher exact test (P < 0.05), a Bonferroni post-
hoc analysis was conducted within the underestimated group, performing pairwise 
comparison of subgroups. Multivariate logistic regression analysis was performed to 
determine factors influencing the accuracy of MRI. 
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The extracted features from radiomics were correlated, one by one, with the tumor size 
mismatch using a univariate linear regression model. Statistical significance of the 
regression was investigated using the Chi-squared test, and correlation between feature 
values and the size mismatch was quantified through the Pearson correlation coefficient (ρ). 
All statistical analyses of patient and pathology characteristics were performed using SPSS 
software version 25 (SPSS Inc., Chicago, IL, USA). Statistical analyses of radiomic features 
were performed using Matlab statistical toolbox version 2018a (Mathworks, Natick, MA). 
P-values <0.05 were considered statistically significant.
4.3 | Results
A total of 2192 female patients diagnosed with 2251 small (≤2 cm) invasive (cT1) or ductal in 
situ breast lesions between January 2005 and December 2016 recorded in the Netherlands 
Cancer Registry were eligible. Of these, we excluded 1834 (81%) lesions which did not 
receive a preoperative MRI and 42 (2%) lesions which received neoadjuvant treatment. 
7 lesions (1 invasive carcinoma NST, 1 ILC, 5 DCIS) were completely excised during the 
diagnostic biopsy procedure; 3 of these lesions had no pathological enhancement on MRI 
after the diagnostic biopsy procedure, the other 4 lesions had a mean MRI size of 6.8 mm 
± SD 4.5 mm (range, 2.3-13 mm). 14 lesions (3 invasive carcinoma NST, 4 ILC, 7 DCIS) showed 
no pathological enhancement on MRI images (mean pathological size 18.2 mm ± 14.1 mm 
(range, 1.5-58 mm). For 11 lesions there was no size measurement available in the MRI and/
or pathology report. 
The final study population consisted of 336 (12%) patients (mean age, 55 years; range, 25-81 
years) with 343 breast lesions. The breakdown of histopathologic diagnosis and receptor 
subtype of the study sample is listed in Table 4.1. 
Tumor sizes were accurate within 5 mm, or overestimated by MRI in 301/343 lesions 
(87.8 %). MRI underestimated the size in 42/343 cases (12.2%) with a mean underestimation 
of 14.8 mm ± SD 14.3 mm (range, 5.5-78 mm). The mean size of the index lesion on MRI 
was 0.3 mm smaller than at pathology, with no significant difference (P = 0.493). The size 
of the extent of disease was significantly underestimated by MRI with a mean difference 
of 1.8 mm (P = 0.003). An overview of these results is shown in Table 4.2 and Figure 4.1. 
The overall correlation between pathology and MRI measurements for the index lesion 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.1 | Bland-Altman plots illustrating the differences between MRI and pathology diameters as 
a function of their average in (A) invasive carcinomas for the index lesion, (B) invasive carcinomas for 

















































































































































Average of MRI and pathology diameter (mm)
Ductal carcinoma in situ
Histological subtypes
C Pure DCIS
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Table 4.2 | Comparison of tumor size by MRI and pathology
4.3.1 |  Effect of clinical and histologic factors on the differences between 
MRI and pathology measurements
Table 4.1 shows the results of univariate analysis of clinical and histological factors 
between tumors with an accurate size estimation and those underestimated or 
overestimated by more than 5 mm. A difference between tumor size on MRI and pathology 
was associated with histological subtyping (invasive or in situ carcinoma), histological 
grade of invasive carcinomas and DCIS grade in surgical specimens (invasive carcinoma 
with DCIS component and pure DCIS). In a post-hoc analysis, DCIS was underestimated 
more often than invasive carcinoma, especially against invasive carcinoma NST. 
Moderately and poorly differentiated (grade 2 and 3) invasive tumors were more often 
underestimated than well differentiated (grade 1) invasive tumors. A grade 2 or 3 DCIS in 
the surgical specimen was more often underestimated than a grade 1 DCIS. However, it 
was only significant in the invasive carcinomas with a DCIS component (P = 0.003). For 
the group with pure DCIS, the DCIS grade had no influence on outcome (P = 0.337). For 
the other subgroups we did not find any difference in the probability of underestimating 
the tumor size at MRI. The presence of DCIS in the biopsy specimen had no influence 
on the difference in size measurements, albeit a trend was observed of more frequent 
underestimation when a grade 2 or 3 DCIS was present, which is consistent with the 
finding of the correlation with the grade of DCIS in the surgical specimen. 
In multivariate logistic regression analysis, there was no significant influence of a 
combination of histological subtype, histological grade of invasive carcinomas, and the 
DCIS grade in surgical specimen that predicted the size of the difference between MRI and 
pathological measurement. 
Size (mean ± SD)














Overall 343 (100.0) 14.13 ± 6.04 15.25 ± 7.51 14.43 ± 9.71 17.05 ± 12.61 0.493 0.003
Invasive carcinoma 297 (86.6) 13.38 ± 4.63 14.67 ± 6.78 13.30 ± 7.25 16.32 ± 11.52 0.829 0.008
Invasive  
carcinoma NST
216 (72.7) 13.66 ± 4.64 14.97 ± 6.89 13.09 ± 5.47 16.37 ± 10.67 0.085 0.032
ILC 54 (18.2) 12.61 ± 4.46 13.39 ± 5.97 14.50 ± 12.49 14.50 ± 12.49 0.237 0.487
Other 27 (9.01) 12.69 ± 4.80 14.84 ± 7.33 12.52 ± 5.41 19.56 ± 15.30 0.899 0.138
DCIS 46 (13.4) 19.15 ± 10.50 21.77 ± 17.54 0.227
‡ Paired t-test was used to assess differences between the MRI and pathology size measurements. Significant 
differences p < 0.05




4.3.2 | Predictive value of radiomic assessment 
Radiomic analysis was performed on 88 tumors (mean size mismatch, 2.1 mm ± SD 10.2 
mm, range,  18 mm − 78 mm). After outlier removal, 83 cases were used (56 invasive 
carcinoma NST, 17 ILC, 1 DCIS and 9 other) (mean size mismatch, 0.9 mm ± SD 4.8 mm, 
range, -9 mm − 14 mm) (Figure 4.2).
Figure 4.2 | Distribution of the mismatch in tumor size between MRI and pathology
Table 4.3 shows the radiomic features with an absolute correlation ρ > 0.15 for each of 
the four ROI sizes evaluated. Overall, 16 (9 with P < 0.05), 12 (6 with P < 0.05), 10 (2 with 
P < 0.05), and 6 (none with P < 0.05) radiomic features fulfilled the above-stated criterion, 
respectively, for all ROI sizes. As shown in Table 4.3, many of these features proved to be 
robust over the different ROI dimensions, although the best results were found for the 
smallest ROI. Features showing the best regression performance (maximum ρ = 0.3) all 
belong to the radiomic group of structural and pattern descriptors. Scatter plots and 
linear fitting of the 9 features extracted from the 10 mm-border ROIs, showing the best 
correlation with a P < 0.05, are shown in Figure 4.3. Due to the limited correlation observed 
we did not attempt to make a predictive model based upon radiomic features.
Difference between MRI and pathology diameter (mm)





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.3 | Scatter plots and linear fitting of the 9 featues extracted from the 10 mm-border ROI 
with the highest statistically significant correlation (P < 0.05). Of all features reported in Table 4.3, 
the ones with the highest absolute correlation coefficient were three local binary patterns.
4.4 | Discussion
In this study we showed that in clinical practice breast MRI underestimates the size of 
small breast cancers by 5 mm or more in 12% of cases. Underestimation occurs more often 
in grade 2 and 3 invasive disease than in low grade invasive cancers. In DCIS the frequency 
of underestimation is higher than in invasive breast cancer. Unfortunately, none of the 
patient, imaging, or biopsy characteristics, nor a combination appeared predictive for 
underestimation.
Recent studies have indicated that MRI offers the best correlation with histological tumor 
size39-42. So far, breast MRI has been mainly evaluated as a means to reduce the re-excision 
rate of BCS in primarily operable cancers. A problem is that breast MRI is generally reserved 
for cases where the tumor size is not well defined, while it is often bypassed for small 
cancers. While the main goal of every surgical procedure is to minimize tissue removal and 
local recurrence rates, taking an adequate margin in patients with small breast cancers is 
relatively easy. Consequently, there has been little attention for underestimation in small 
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these ratios are relevant. Onesti et al.9 found that MRI underestimated 12.5% of the small 
(≤2 cm) tumors, which is comparable with our data. On the other hand Grimsby et al.10 and 
Choi et al.8 described that the larger tumors were underestimated by MRI more often than 
the smaller tumors (28% in both studies vs. 6% and 5.2%, respectively).
In our study, only the histological subtype (invasive versus in situ), the grade of invasive 
carcinoma, and the grade of DCIS in the surgical specimen of invasive carcinomas with 
a DCIS component, predicted MRI underestimation in univariate analysis, which is 
consistent with Mennella et al.43, who reported that DCIS histology is the strongest 
independent predictor of under- and overestimation. DCIS is more likely to be detected 
at mammography whereas most invasive carcinomas are detected at MRI44. Nevertheless, 
MRI can help due to its ability to diagnose DCIS17. However, it is important to take into 
account that the sensitivity of MRI is higher for DCIS of higher nuclear grade, while 
mammography is more sensitive to low grade DCIS17. 
Despite the recommendation in the Dutch Breast Cancer Guidelines21, the DCIS grade 
in the biopsy specimen is not always described in pathological reports. We think this 
may have an important value for determining in advance whether a patient can opt for 
minimal invasive treatment or if BCS is more suitable, because a trend was observed of 
more frequent underestimation when grade 2 or 3 DCIS was present. Therefore, we would 
recommend that the DCIS grade at biopsy is recorded. 
The radiomic analysis suggests that some textural information contained in the images 
might be useful to help predict whether a mass is likely to be under- or overestimated by 
MRI. However, the observed correlations do not yet seem to be clinically useful. Further 
assessment with a larger dataset is required, to allow for the creation of multinomial 
regression models that could be used for clinically relevant predictions.
Our study has several limitations. First, we assessed the data retrospectively with a 
limited number of patients who underwent MRI, since many patients with clinically 
small tumors in current clinical practice are treated without a presurgical MRI. In fact, 
the Dutch breast cancer guidelines recommend to perform MRI only in patients where 
mammography and US are insufficient to accurately assess the size of the lesion, or when 
the findings are discrepant. A large-scale, prospective study with a presurgical MRI for 
every patient with small tumors would provide a more homogeneous study group with 
more robust findings. In such a prospective study it would also be possible to compare 
MRI tumor size measurements with mammography and US tumor size measurements. 
Second, the studied data was based on clinical reports and MRI BI-RADS descriptors for 
each lesion were not extracted45,46, which might have a predictive value for explaining the 
difference in size estimations. Especially the differentiation between masses and non-
mass enhancement seems relevant in this regard. However, we performed an extensive 
quantitative radiomic analysis to overcome the well-known intra- and inter-reader 
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variability of BI-RADS descriptors, which unfortunately did not yield strong correlations to 
adequately predict underestimation in this study. 
4.5 | Conclusion
In general, MRI provides an accurate estimation of small invasive and ductal in situ breast 
tumor size. However, MRI underestimates tumor sizes in approximately 12% of the lesions 
by more than 5 mm. For minimal invasive treatment planning, patients with a grade 2 or 
3 invasive tumor, or with a DCIS grade 2 or 3 in the tumor, should be selected with caution 
and be informed of the slightly higher potential for undertreatment. 
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Purpose: To assess the feasibility of completely excising small breast cancers using the 
automated, image-guided, single-pass radiofrequency-based breast lesion excision 
system (BLES) under ultrasound (US) guidance.
Methods: From February 2018 to July 2019, 22 patients diagnosed with invasive carcinomas 
≤15 mm at US and mammography were enrolled in this prospective, multi-center, ethics 
board approved study. Patients underwent breast MRI to verify lesion size. BLES-based 
excision and surgery were performed during the same procedure. Histopathology findings 
from the BLES procedure and surgery were compared, and total excision findings were 
assessed.
Results: Of the 22 patients, ten were excluded due to the lesion being >15 mm and/or being 
multifocal at MRI, and one due to scheduling issues. The remaining 11 patients underwent 
BLES excision. Mean diameter of excised lesions at MRI was 11.8 mm (range 8.0 – 13.9 mm). 
BLES revealed ten (90.9%) invasive carcinomas of no special type, and one (9.1%) invasive 
lobular carcinoma. Histopathological results were identical for the needle biopsy, BLES, 
and surgical specimens for all lesions. None of the BLES excisions were adequate. Margins 
were usually compromised on both sides of the specimen, indicating that the excised 
volume was too small. Margin assessment was good for all BLES specimens. One technical 
complication occurred (retrieval of an empty BLES basket, specimen retrieved during 
subsequent surgery).
Conclusion: BLES allows accurate diagnosis of small invasive breast carcinomas. However, 
BLES cannot be considered as a therapeutic device for small invasive breast carcinomas 
due to not achieving adequate excision.




Due to a substantial portion of breast cancers being detected at screening, the average 
size of newly detected breast cancers is decreasing, with 53% of them being below 2 cm1. 
For small cancers, breast conserving therapy (BCT), including wide local excision and 
radiation therapy, has largely replaced mastectomy2. The trend towards BCT has been set 
despite clear evidence that local surgical excision alone frequently leaves residual cancer 
deposits in the breast3,4. However, since the addition of radiation therapy decreases the 
local recurrence risk, BCT is as safe as mastectomy5,6. Nonetheless, residual cancer in the 
resection margin is predictive for recurrence, which results in poorer overall survival6. 
Consequently, assessment of tumor involvement of the surgical resection margin has 
become standard of care7. 
Recently the breast lesion excision system (BLESTM, Medtronic Inc., Dublin, Ireland) has been 
introduced for breast cancer diagnosis8. Briefly, the device, designed for diagnostic breast 
biopsy, excises a lump of tissue through a very small skin incision under mammographic 
or ultrasound (US) guidance. The size of the extracted lump is dependent on the biopsy 
needle chosen, which is available in diameters of 12 mm, 15 mm, and 20 mm9. 
There are a few reports suggesting that, in a diagnostic setting, up to 66% of invasive 
cancers are completely excised using the BLES, albeit these studies did not aim to excise 
the entire lesion, and where mainly performed under mammographic guidance9-16. 
Very little literature exists on the use of BLES under US guidance17,18, with only Niinikoski et 
al.18 reporting a complete excision rate under US guidance of 46.6%. US guidance allows 
for real-time feedback of the needle position during biopsy, and has been shown to be 
beneficial for surgical tumor excision19,20. Therefore, US seems to be a logical choice as the 
guidance technique when BLES is used as a therapeutic device. 
Therefore, the aim of this study was to evaluate whether it is feasible to excise small breast 
cancers completely using the BLES under US guidance.
5.2 | Materials and methods
5.2.1 | Study design and patient population
This prospective multi-center study was approved by the local ethical review board, and 
all study participants provided written informed consent. Two different hospitals situated 
in Nijmegen, the Netherlands, were participating (Radboud University Medical Center, 
an academical hospital and Canisius-Wilhelmina Hospital, a district hospital). Patients 
with histologically proven invasive breast cancer based upon a diagnostic 14G core needle 
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biopsy, and with a maximum diameter of 15 mm as assessed at US and mammography 
were included in our study. The tumor had to be clearly visible with US according to the 
radiologist who performed the primary evaluation. Patients with an indication of more 
extensive disease on imaging (e.g., an area of calcifications adjacent to the mass) were 
excluded. Pregnant patients, patients with breast implants, and patients with implanted 
electronics, such as a cardiac pacemaker, were not suitable to undergo the BLES biopsy 
and therefore also excluded. Furthermore, patients were excluded when the breast lesion 
was situated closer than 6 mm to the dermis, nipple, or pectoral muscle. 
5.2.2 | Imaging
In all subjects the lesion diameter and the absence of a multifocal tumor was verified with 
magnetic resonance imaging (MRI). For this, all patients were scanned on a 3T system with 
a 16 channel breast coil (Skyra, Siemens, Erlangen, Germany), using a state-of-the-art full 
diagnostic protocol as previously described by Dalmis et al.21, including high resolution 
T1-weighted pre- and post-contrast acquisitions. Tumor diameter was assessed in three 
orthogonal directions, on both the original images obtained two minutes after contrast 
administration and on the subtracted images generated from pre- and post-contrast 
acquisitions by one of two breast radiologists with 12 and 16 years of experience. When 
the maximum lesion diameter was confirmed as being ≤15 mm at MRI, the subjects could 
continue in the study.
5.2.3 | BLES and surgical procedure
The BLES procedure was scheduled directly preceding the regularly planned surgery, to 
take place when the patient was already under general anesthesia, to minimize the burden 
of the study on the patient.
Although the patient positioning was optimized for surgery, when required the table 
could be tilted to improve the accessibility of lesions for the BLES procedure. All BLES 
procedures were performed by one of two radiologists using a 20 mm disposable BLES 
needle under US guidance using an US system equipped with a 34 mm 4 - 12MHz linear 
probe (L12-4 Broadband linear array transducer, Philips, Eindhoven, the Netherlands). The 
20 mm probe used during this study enables an excision of a spheroid specimen with a 
maximum thickness of 20 mm.
Following the BLES procedure, the BLES excision cavity and at least 1 cm of surrounding 
tissue was excised by one of two dedicated breast surgeons with 22 and 26 years of 
experience. Both specimens (BLES and surgical) were marked with sutures by the surgeon 
to document the orientation according to standard protocols and sent to histopathology. 
Minimally invasive breast cancer excision using the BLES under US guidance
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5.2.4 | Histopathology analysis
The specimens were processed as per standard procedures at the pathology department, 
including X-ray imaging of both specimens (intact and sliced). The specimens were inked 
on the external surfaces and sliced perpendicular to the longest axis of the specimens. 
These slices were serially embedded and examined using standard pathological analysis 
(hematoxylin and eosin staining) as well as advanced pathological evaluation such as 
immunohistochemistry. Margin assessment was performed separately for the BLES 
excision and the surrounding surgical specimen by one of two breast pathologists with 
10 and 25 years of experience. The residual tumor burden and histology in the surgical 
specimen was also assessed. In accordance with the Dutch Breast Cancer Guidelines, 
adequate excision was defined as having no more than focal involvement of the resection 
margins, which is defined as foci of invasive tumor and/or adjacent ductal carcinoma in 
situ (DCIS) touching four mm or less of the inked margin22. 
For each lesion, we assessed concordance between the histopathological diagnosis 
obtained at diagnostic biopsy (core needle biopsy (CNB)), BLES, and surgical excision.
5.2.5 | Follow-up
All patients had a post procedure follow-up appointment within two weeks after surgery 
to discuss pathology results and examine the healing process of the incisions and, if 
present, deal with any complications such as hematoma or infection.
5.2.6 | Data analysis
The mean values and the respective standard deviations were used to describe continuous 
measurements, such as the diameter and margins in mm, while frequencies and 
percentages were used for categorical variables such as the lesion types, complications, 
and concordance between BLES and surgery.
All statistical analyses were performed using SPSS software version 25 (SPSS Inc., Chicago, 
IL, USA).
5.3 | Results
From February 2018 to July 2019, a total of 22 patients who had histologically confirmed 
invasive carcinomas with a diameter ≤ 15 mm on US and mammography were enrolled in 
the study. Eleven patients (50%) were subsequently excluded due to MRI findings (n = 10) or 
because the BLES was not available at the time of surgery (n = 1) (Table 5.1). Characteristics 
of patients and lesions are detailed in Table 5.2. 
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Table 5.1 | Reason for subsequent exclusion from BLES procedure
N = 11
BLES not available 1
MRI findings 10 
> 15 mm 3
Multifocal 1
> 15 mm and multifocal 6
Table 5.2 | Baseline characteristics of patients and lesions treated with the BLES
Median (range)
Age 60 years (51 – 73 years)
Lesion diameter
US 8 mm (6 – 11 mm)
MRI 11.8 mm (8 – 13.9 mm)
BLES specimen  (length) 18.9 mm (12 – 25 mm)






Round mass 1 (9.1%)
Oval mass 2 (18.2%)
Irregular mass 8 (72.7%)
ACR density classification
A (Almost entirely fatty) 1 (9.1%)
B (Scattered fibroglandular density) 8 (72.7%)
C (Heterogeneously dense) 2 (18.2%)
D (Extremely dense) 0 (0%)
Histopathological findings
Invasive carcinomas of no special type (NST) 10 (90.9%)
Invasive lobular carcinoma 1 (9.1%)
Radiofrequency-related thermal damage
Mild (<0.5mm) 6 (54.5%)
Moderate (0.6-1 mm) 3 (27.3%)
Extensive (1.1-1.5 mm) 2 (18.2%)
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At histopathological analysis of the surgical resections, the BLES biopsy cavities were 
identified in all cases. None of the BLES biopsies were adequate. Ten excisions (90.1%) had 
more-than-focal involvement of the resection margins and one excision (9.1%) had focal 
involvement with the majority of the tumor situated in the surgical specimen. Margin 
assessment of the BLES specimens was well possible in all cases and thermal damage had 
no influence on the evaluation by the pathologist. Margins were usually compromised on 
both sides of the specimen, indicating that the targeting was accurate, but the excised 
volume was too small (Figure 5.1 and Table 5.3). Residual tumor was present in all surgical 
excision specimens. In all cases this correlated with the positive margin seen on the BLES 
specimen. In the surgical resection the mean depth of the residual tumor was 3.3 mm 
(range: 1 – 9 mm) measured perpendicular to the BLES biopsy cavity.
 
Figure 5.1 | Location indication with respect to the BLES needle
Table 5.3 | Location in BLES resection where tumor is present centrally in the BLES specimen and 
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A technical complication occurred in one case (9.1%), due to the retrieval of an empty BLES 
basket. However, it was possible to retrieve the BLES specimen during subsequent surgery. 
There were no other adverse events or post procedure complications, such as infection, 
hematoma, wound healing problems or unexpected scarring. Histological results were 
identical for CNB, BLES, and surgical specimen in all lesions. 
5.4 | Discussion
Previous studies have shown that the BLES is a safe and accurate diagnostic device, and a 
good alternative to vacuum-assisted biopsy and CNB9,10,15,16. However, our study shows that 
the evaluated BLES needle (diameter of 20 mm) is too small for US guided excision of small 
invasive breast cancers. 
Based on our results, BLES cannot be considered as a therapeutic substitute to 
surgical excision. In this study, we did not observe a single adequate excision of any 
lesion according to the Dutch Breast Cancer Guidelines (no more than focal margin 
involvement22) even though lesions in this study were carefully selected through prior 
imaging. Previous studies have suggested that BLES could enable complete excision of 
small invasive lesions9,11,12,15,23-25, with a success rate of up to 62.5%. However, most of these 
studies had a diagnostic focus, without aiming to excise the entire lesion, and used a 
different definition of an adequate BLES resection. In addition, all these studies included a 
time interval between the BLES procedure and the surgical re-excision, which may explain 
the outcome differences between them and this study. This is because, as reported by 
Nasir et al.26, residual malignant cells may be eliminated during the wound healing process 
that occurs during the time interval between the lumpectomy and the re-excision in case 
of positive margins. In a similar vein, Wiley et al.27 reported that an increased time interval 
between initial lumpectomy and re-excision resulted in a decreased incidence of residual 
disease. 
It might be worth evaluating how important clear margins are for the treatment of breast 
cancer. The minimally accepted resection margin for breast conserving surgery above 
which a re-excision is advised has been already debated for years. The Society for Surgical 
Oncology and the American Society for Radiation Oncology (SSO-ASTRO) and the European 
Society for Medical Oncology (ESMO) recommend no ink on tumor as an adequate margin 
for invasive breast cancer28,29. However, the Dutch Breast Cancer Guidelines considers 
the recurrence risk for focally (≤ 4 mm) positive margins after BCT (resection followed 
by radiation treatment) acceptable22. Vos et al. concluded that this focal involvement is 
usually caused by radial extensions (spicules) of the tumor or residual DCIS30. In another 
study, Vos et al. state that omitting re-excision for focally positive margins does not impair 
the 5-year disease-free and 10-year overall survival rates, provided that adjuvant whole-
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breast irradiation is given, including a boost to the tumor bed31. Accordingly, the treatment 
combination of BLES biopsy to excise the tumor bulk with subsequent adjuvant breast 
irradiation might be a potential option to explore in the upcoming field of minimally 
invasive treatment of breast cancer. Of course, oncological safety, with recurrence rates 
and breast cancer related mortality should be the endpoint of such studies.
All BLES procedures in our study were performed under US guidance. With US guidance 
there is good 3D orientation and positioning with the BLES needle, in addition to real-time 
imaging feedback during the procedure. However, the adequate excision rate was much 
lower in comparison to other studies that reported the performance of the procedure 
under stereotactic guidance. Milos et al.24 and Papapanagiotou et al.25 performed BLES 
resections with stereotactic guidance that resulted in a complete excision rate of 40% 
and 48.8%, respectively, for invasive breast lesions. The compression of the breast, which 
is required for stereotactic guidance, likely provides better tissue immobilization, fixing 
the lesion during the procedure. It can be hypothesized that this relative fixation results in 
fewer positive margins at the distal poles of the ellipsoidal specimen. 
In our study, none of the specimen margins were free of tumor cells. This is not surprising 
given the fact that the specimens had an ellipsoidal shape, measuring approximately 
19 mm in length and 9 mm in thickness. Therefore, it proved impossible to retrieve a 
specimen with a thickness of 20 mm, which we expected from a basket with dimensions 
of 20 mm by 25 mm. This seems to confirm the results of Christou et al.32, who reported 
comparable average specimen dimensions for the 20 mm probe (20 mm in length and 10 
mm in thickness). Killebrew et al.16, did, however, report larger dimensions for the smaller 
15 mm probe (21 mm in length and 15 mm in thickness). To excise even very small lesions 
completely it is thus necessary that this lesion is perfectly centered in the specimen, 
which is quite challenging under US guidance. After starting the deployment of the 
basket, it is not possible to re-adjust the needle location using the available real time 
imaging feedback, even if the deployment itself may cause movement of the lesion due 
to mechanical effect on the tissue, which may push the target aside during the excision. 
In this study, tumor cells were observed in the margins at the poles of the ellipsoid (see 
Figure 5.1 and Table 5.3). In initial procedures it was mainly observed involvement of the 
proximal pole. This implies that the needle tip was positioned too close to the lesion, and 
therefore the basket was not opened wide enough when reaching the lesion. However, 
positioning the needle tip a little further away from the lesion resulted in involvement 
of the distal pole, due to too early closure of the basket. In all patients the margin was 
involved centrally, mainly due to the fact that the lesions were wider than the maximum 
thickness of the specimens. Therefore, it seems unfeasible to excise lesions completely 
with free margins with the currently available probes, even for very carefully selected 
small invasive malignancies. 
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Based on our results and previous studies, we would advise to consider the BLES as a 
therapeutic device only in specific situations and for specific lesions. First, the BLES may 
be a good alternative for surgical excision of small benign lesions11,18,33. However, in recent 
years, vacuum-assisted excision, which is more cost effective compared to the BLES, has 
become the standard of care for this indication34. Second, the BLES procedure is a potential 
alternative for patients that are ineligible for surgical procedure or anesthesia, as it can 
be applied in an outpatient setting without general anesthesia. Nevertheless, complete 
excision of invasive lesions cannot be guaranteed with the BLES and such cancers can 
commonly be controlled with hormonal therapy alone35. 
Only one (9.1%) complication with the device was reported in this study, which is 
comparable with previous literature9,16,23. Another common complication due to the BLES 
system is bleeding (0 - 11.8%) and hematoma (0 - 8.8%)9-18,24,25,33,36, none of which occurred 
during this study. This is probably because the conventional surgery was performed 
immediately after the BLES procedure. 
The small number of patients (n = 22) is the major limitation of our study, especially 
considering that 10 patients (45%) were subsequently excluded due to MRI findings. 
However, it was the purpose of this study to select and evaluate only those patients with 
small lesions that had the best chance of a complete excision with the BLES device. In 
addition, during this study we did not assess the learning curve for our radiologists in the 
use of the BLES. However, the radiologists are experienced with different biopsy techniques 
under ultrasound guidance and all radiologists, surgeons and surgery assistants received 
a training program regarding the use of the BLES device. Furthermore, Michalopoulos 
et al.37 stated that the BLES appears to be an easier-to-learn technique compared to the 
vacuum-assisted biopsy (VAB) procedure, therefore it seems that any bias due to a lack of 
previous experience with this device is minimized. 
In conclusion, based on previous studies and our own experience in selected cases, the 
BLES is a reliable diagnostic method with low underestimation and complication rates. 
However, we discourage its use for excision of malignant lesions as a substitute for 
surgical excision. In the future we hope that the design of the BLES will be modified and 
improved to make it better suitable for complete excision of small malignant lesions. 
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Background: In the Netherlands, ≥7000 women undergo surgery for small breast cancers 
(T1) every year. In the last years there was a shift towards less invasive treatments. The aim 
of the MINIVAB study is to evaluate under which conditions it is possible to excise small 
invasive breast cancers using the vacuum-assisted biopsy (VAB) system under ultrasound 
(US) guidance. 
Methods: The MINIVAB is a Dutch multi-center, translational clinical phase II study. 170 
women with non-lobular invasive carcinomas ≤15 mm in diameter based upon US and MRI 
measurements, and without mammographic or MRI evidence of more extensive disease 
(e.g. microcalcifications , extensive architectural distortion, or non-mass enhancement) 
will be asked for participation. The tumor will be removed under local anesthesia using 
the VAB system (also called a vacuum-assisted excision, VAE) with US guidance, through 
a small skin incision (<0.5 cm). A localization marker will be placed in the biopsy cavity, 
to help determine the cavity location. After 3 weeks, the breast conserving surgery 
is performed, excising the VAE cavity and a ≥1 cm of surrounding tissue, as deemed 
appropriate by the attending breast surgeon. A sentinel node biopsy will be performed 
in the same procedure. The main endpoint of this study is the incidence of successful 
complete or marginally involved tumor excision by VAE based on the surgical specimen. 
Secondary endpoints are patient, tumor, and histopathological related predictive factors 
for complete resection, sentinel node status, quality of life, complications and pain 
experience score. 
Discussion: Our trial tests the feasibility of an innovating approach to remove breast 
cancer, with a thorough evaluation of adverse events or possible complications. The 
burden from this study to the participating patients is the fact that two procedures are 
mandatory. This will result in prolonged time from initial diagnosis to end of surgical 
treatment. Study outcomes may pave the way to minimally invasive treatment in an 
outpatient setting for a selection of women with small invasive breast cancers.
Trial registration: The MINIVAB study is registered in ClinicalTrials.gov since September 27, 
2019, Identifier: NCT04107636, https://clinicaltrials.gov/CT2/show/NCT04107636. 




In case of breast cancer, primary therapy was until the 1980’s a radical mastectomy. 
However, this procedure is highly mutilating, and thanks to progress in screening, 
imaging, surgery, radiation oncology and systemic treatment a clear trend towards less 
invasive therapies emerged in the last decades1,2.
For most cT1-2 tumors breast conserving therapy (BCT), consisting of surgery followed by 
radiation therapy, has largely replaced mastectomy. Moreover, oncoplastic techniques are 
applied to minimize the deformation of the breast in larger resections3.
The survival and local recurrence following BCT has proven to be at least similar and in 
some cohorts possibly superior to mastectomy, despite histologic evidence of multicentric 
disease4,5. In case BCT is performed, careful pathological evaluation of the margins is 
mandatory, because residual (in situ) breast cancer in the resection margins is the most 
important predictive factor for local recurrence6,7. This implies that residual disease in the 
surgical margins is an indication for re-excision, sometimes for mastectomy, or boost 
radiation in low volume residual disease. 
Guidelines of the Society of Surgical Oncology (SSO) and American Society of Radiation 
Oncology (ASTRO) advise re-excision in case of positive margins, defined as “tumor 
on ink”8,9. In the Netherlands the guideline differs and re-excision is indicated when 
there is more than focal involvement of the resection margins, which is defined as 
cancer involvement in an area of more than 4 mm of the resection margins10,11. Focal 
involvement is usually caused by radial extensions (spicules) of the tumor or residual 
ductal carcinoma in situ (DCIS)11. It is also important to recognize that negative margins 
do not guarantee the absence of residual tumor in the breast. Holland et al. described 
that in case of a small breast tumor (≤2 cm) 42% have additional foci of cancer within the 
breast after breast conserving surgery12. For practical purposes, it is assumed that focal 
involvement and remaining foci can be treated with radiotherapy, albeit including a boost 
for focally involved margins. This policy results in local recurrence rates of 2.6% after 5 
years follow-up in BCT, as compared to 3,4% local recurrence rates after mastectomy5. 
Furthermore, omitting re-excision for focally positive margins after BCT followed by 
whole-breast radiotherapy including a boost does not impair the disease-free survival 
and overall survival13. Furthermore, the use of modern imaging techniques, such as MRI 
and tomosynthesis, has led to easier detection of larger additional tumor localizations 
in the breast, thus improving staging of the breast cancer and allowing more careful 
patient selection for BCT14. This implies that with surgery the larger tumor bulk is generally 
removed, whereas microscopic tumor deposits, at the margins as well as anywhere in the 
breast are effectively treated by subsequent radiotherapy and systemic treatments. 
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Due to the national screening program and the increasing diagnostic accuracy of breast 
imaging, the average size of breast cancers has diminished over the past decades. At 
present 53% of detected cancers are below 2 cm (T1). Many breast cancers are detected 
before they become symptomatic, and are often not palpable15. More than 60% of stage I 
and stage II breast cancers are treated with breast conserving surgery16. 
Imaging techniques such as mammography and US have been proven more accurate in 
size assessment than clinical examination, even in symptomatic cases and are part of 
standard work-up in asymptomatic patients17,18. Correlation with pathology is accurate in 
up to 70% of cases, although underestimation of tumor size is common, especially on 
mammography. Breast MRI has been shown to be more accurate than mammography 
and US, and detects additional tumor foci in up to 24% of patients19,20. As described in 
our previous study, MRI provides an accurate estimation of small invasive breast tumors 
albeit the tumor size is underestimated by more than 5 mm in approximately 12% of the 
lesions21. 
Vacuum-assisted biopsy (VAB), introduced in 1995, has been proven as a very reliable 
biopsy tool for the assessment of breast lesions. The VAB system removes multiple larger 
tissue samples of approximately 5 by 15 mm in diameter through a small skin incision 
under mammographic or US guidance. This is done by sucking tissue into the biopsy 
chamber which is subsequently cut loose from the surrounding tissue by an internal 
rotating trocar. As approved by the National Institute for Health and Care Excellence 
(NICE), vacuum-assisted excision (VAE) can be used as an minimally invasive alternative for 
standard surgical excision of benign lesions and lesions of uncertain malignant potential 
(B3 lesions)22, which is commonly performed under US guidance. The advantage of US 
guidance is that there is real-time feedback during positioning of the needle, and during 
the biopsy procedure thus allowing differentiation between hematoma and residual 
tumor, whereas no real-time feedback is possible using mammography. The resulting 
hematoma prevents mammographic assessment of residual disease directly after the 
procedure. Concordance between VAB results and subsequent pathological analysis of a 
surgical specimen is excellent in benign lesions23,24. An overall complete excision rate of 
94.8% for benign lesions ≤3 cm was reported after follow-up with US examination23. 
Only little has been reported on the complete excision rate of malignant breast lesions 
and the use of VAE as a possible treatment modality of malignant lesions25. Margins of 
the VAE are indeterminable and numbers about complete excisions are dependent on 
evaluation of a surgical specimen25. Since these will come from a surgical excision of the 
margins after a visually assessed complete removal of the tumor, the figures reported by 
Holland et al.12 are very important. They reported that in case of small breast cancers (≤2 
cm) 30% of women had additional tumor foci within 2 cm from the lumpectomy cavity 
despite clear margins, but with a clear discontinuity of the reference tumor (the remaining 
12% was found at greater distance). These additional foci would not have led to positive 
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margins in lumpectomy, but might be detected when the cavity-margins after VAE are 
surgically removed. 
This multi-center, translational clinical phase II MINIVAB trial is designed to analyze 
whether it is feasible to remove small breast cancers completely or with a marginally 
involved tumor margin using VAE under US guidance, taking the presence of additional 
tumor foci after lumpectomy into account. Consequently, we expect to be able to remove 
70% of cancers completely or with a marginally involved tumor margin, with successful 
complete tumor and DCIS excision by the VAB system defined as having no residual 
invasive or ductal in situ component in the surgical specimen. Marginally involved means 
no more than 4 mm of residual (ductal in situ) cancer in continuation with the biopsy 
cavity, which is in accordance with the current Dutch breast cancer guideline10. Further, we 
will try to identify, if any, a priori patient and tumor characteristics may be predictive of 
successful complete resection of the tumor. 
6.2 | Study objectives
6.2.1 | Primary objective
Primary objective of this study is to assess whether it is feasible to remove small breast 
cancers completely or with a marginally involved tumor margin, using VAE under US 
guidance (successful is defined as having no residual invasive or ductal in situ component 
in the surgical specimen. Marginally involved means no more than 4 mm of residual 
(ductal in situ) cancer in continuation with the biopsy cavity, which is in accordance with 
the current Dutch breast cancer guideline10).
6.2.2 | Secondary objectives
Secondary objectives include:
1  Predict successful complete resection of the tumor based on preoperative imaging and 
patient related features.
2  Predict successful complete resection of the tumor based upon histopathological 
features from the diagnostic core needle biopsy specimens.
3.  Predict successful complete resection of the tumor based upon histopathologic 
features from the VAE specimens.
4  Analyze the characteristics of eventual residual tumor/DCIS deposits in the surgical 
specimens.
5  Explore sentinel node status following VAB of the primary tumor.




6.3.1 | Study design
The MINIVAB is a multi-center, translational clinical phase II trial and will be performed in 
four Dutch hospitals (Radboudumc, Canisius Wilhelmina hospital, the Netherlands Cancer 
Institute - Antoni van Leeuwenhoek hospital, St. Antonius hospital Nieuwegein). 
All patients will undergo a VAE under US guidance followed by conventional breast 
conserving surgery three weeks later. 
Ethical considerations
This study has been reviewed and approved by the Medical Ethical Committee of the 
Radboudumc (reference no. 2019-5607). The study has also been approved by the local 
ethical committees of each participating hospital. The study will be conducted according 
to the principles of the Declaration of Helsinki and in accordance with national and regional 
legislation, guidelines, regulations and acts. The study is registered in ClinicalTrials.gov 
(reference no. NCT04107636, date registered: September 27, 2019).
Publications will follow the CONSORT statement26. Research findings will be submitted to 
peer-reviewed journals regardless of whether results are statistically significant.
6.3.2 | Study population
Inclusion criteria
Women ≥18 years old with pathologically confirmed non-lobular invasive breast 
carcinomas ≤15 mm based upon US and MRI measurements, without mammographic 
or MRI evidence of extensive disease (e.g. microcalcifications, extensive architectural 
distortion, or non-mass enhancement) and distance from dermis, nipple or pectoral 
muscle >6 mm (or which can be safely extended by injection of saline to 6 mm), are eligible 
for the study. Prior to start of any study related procedure, written informed consent must 
be given according to International Conference on Harmonisation – Good Clinical Practice 
(ICH-GCP) and national legislation.
Exclusion criteria
Women with poor US visibility of the breast cancer, neoadjuvant therapy, patients with 
breast implants, pregnancy or presence of additional malignant lesions at ipsilateral site 
are excluded for the study. 
Recruitment
If it appears that the patient might be eligible after standard US examination and had an 
MRI examination, a breast surgeon together with a researcher or nurse practitioner will 
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inform the patient about the study during the consultation with the preliminary diagnosis. 
A few days later the patient will visit the breast surgeon for the final diagnosis. Any and 
all questions will be answered, and the patient will be given reflection time concerning 
participation. During this consultation the patient will be informed if the patient is indeed 
eligible and will be asked to participate. If the patient agrees, signed informed consent will 
be obtained and participation in the study will be recorded in the electronic patient file.
6.3.3 | Study procedures
Breast cancer risk questionnaire and Quality of life
After informed consent has been obtained patients will be asked to fill out a questionnaire 
to determine the a priori breast cancer risk, using the Tyrer-Cuzick (or IBIS) model27. This 
questionnaire will be used to assess in retrospect whether successful tumor extraction 
can be predicted based upon patient related factors.
In order to analyze the quality-of-life and differences in pain experience after VAE and 
surgery, patients will be asked to indicate a quality-of-life (EORTC QLQ-C30, EORTC 
QLQ-B23)28 and pain experience score (Visual Analogue Scales (VAS)29,30) on the following 
time points:
– 1 week after the VAB procedure (via phone call).
– 1 week following the surgical procedure (via phone call).
Vacuum-assisted excision
All VAE procedures are performed by experienced breast radiologists or breast surgeons. 
The tumor will be removed under local anesthesia using the 7-gauge ENCOR® Breast Biopsy 
System (Bard, Covington, Ga) with US guidance, through a small skin incision (<0.5 cm). The 
biopsied breast will be evaluated with US in two perpendicular directions (anteroposterior 
and left-right). We will score for each patient whether the lesion is completely removed 
based upon US evaluation, immediately following the biopsy. When, according to the 
performing physician, lesion removal was unsuccessful (even after multiple attempts) and 
residual tumor is still visibly present in the breast, subsequent surgery would be indicated 
in any case. Therefore, these patients will be analyzed separately, and will be replaced by 
other patients to achieve the required sample size. The US acquisitions will be stored for 
future retrospective analysis of incompletely excised lesions. 
A localization marker will be placed in the biopsy cavity, to help determine the cavity 
location for eventual resection. The VAE specimens will be weighed and a specimen 





In order to assess the effectiveness of the tumor excision by the VAB device, breast-
conserving surgery is scheduled at 3 weeks following VAE. 
After 3 weeks, the breast conserving surgery is performed, excising the VAE cavity and a 
≥ 1 cm of surrounding tissue, or as wide as deemed appropriate by the attending breast 
surgeon. A sentinel node biopsy will be performed in the same procedure. 
Pathological assessment
After surgery, the specimen will be marked for orientation and weighed, a digital specimen 
X-ray will be made. At the pathology department the specimen will be sliced in 4-5 mm 
thick slices, from the slices a digital specimen X-ray will be made, and the specimen 
will be embedded for pathological evaluation of residual tumor in the cavity margin 
resulting from the VAE. Pathological assessment of the VAE and surgical specimens will be 
performed according to daily clinical practice, with additional reporting for the study (e.g. 
tumor extent around the biopsy cavity). 
The residual tumor burden and histology (DCIS and/or invasive cancer) in the surgical 
specimens will be assessed. We will document whether residual disease is in (dis)continuity 
with the biopsy cavity (and correlates to the tumor found in the VAE specimens), 
documenting involved margins of the surgical specimens and depth of involvement from 
the biopsy cavity in mm. These elements will be correlated to preoperative imaging, tumor 
and patient characteristics. Per institute the first three pathological assessments will also 
be evaluated by pathologists of the other hospitals to tailor and coordinate the assessment. 
6.3.4 | Follow up
Patients will be treated with adjuvant treatment and will be followed up in accordance 
with the standard clinical routine as described in the Dutch breast cancer guideline10. Since 
the tumor size cannot be obtained from the VAE specimen, the cT-stage as obtained from 
imaging (particularly MRI) will be used to guide decisions regarding adjuvant (systemic) 
therapy, as is also standard in the neoadjuvant setting. 
Subjects can leave the study at any time and for any reason if they wish to do so, without 
any consequences. The investigator can decide to withdraw a subject from the study for 
urgent medical reasons.
When subjects leave the study after the VAE and refuse a surgical excision, they will undergo 
standard adjuvant therapy (including radiotherapy and systemic therapy when indicated) 
and be followed-up with regular imaging, according to the Dutch breast cancer guideline10.
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If patients withdraw from the study before the VAE, they will be replaced by other participants. 
All data recorded until withdrawal is used for the study unless the patient objects to this.
6.3.5 | Statistical considerations
Sample size and interim analysis
It is important to keep in mind that margin assessment of the VAE is not possible and 
results are completely dependent of surgical specimen findings. Based upon the above 
described findings by Holland et al. in small breast cancers (≤2 cm), we assume that we will 
encounter additional tumor foci in a surgical excision of the biopsy cavity in at most 30% 
of patients (likely less, due to the fact that these data pre-date the MRI era), while 70% of 
patients have no additional tumor foci within this surgical specimen. Consequently, we 
assume that we can successfully excise the tumor, including surrounding DCIS, using the 
VAB in approximately 70% of patients. 
We intend to prove that the actual success rate is within 7.5% of this figure; i.e., the lower 
border of the interval is 63%, at a confidence level of 95%. 
To calculate the sample size, we used the binomial distribution with the above-mentioned 
assumptions; total width of the expected Confidence Interval (CI) is 0.15 and the expected 
proportion is 0.70. This requires a sample size of 154 patients31. It should be noted that, 
when the actual success rate is higher, less patients need to be included to show this.
To account for technical failures, and patients lost to follow-up, we will include an 
additional 10% of patients. This implies that we will include 170 patients who underwent 
breast tumor resection using VAE under US guidance. 
An interim analysis will be performed after 30 US guided VAB excisions. The trial will 
stop when the successful excision rate in these women is below 40%. The actual 95% 
confidence interval then runs from 23% to 60%, and we believe that a success rate of 
60% is too low to be a viable alternative for surgery. This would equal a situation where 
primary surgery would lead to positive margins in 10% of cases, as the additional 30% is 
to be expected in the surrounding tissue even after lumpectomy with negative or focally 
involved margins. 
Final analysis
The main endpoint of this study is the incidence of successful complete or marginally 
involved tumor excision by VAE. Complete excision is defined as no residual invasive or 
ductal in situ component in the surgical specimen. Marginally involved means no more 
than 4 mm of residual (ductal in situ) cancer in continuation with the biopsy cavity. To 
answer this objective, information will be obtained from the pathological report which 
contains information about residual tumor in the surgical specimen. For the analysis the 
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precision of the VAE will be calculated (number of successful (complete and marginally 
involved) VAE procedure / number of performed VAE procedures). 
An analysis will be performed to identify predicting factors for complete excision of the 
lesion after VAE. Factors included in the analysis are patient related variables, imaging 
features, surgical features, VAE features and histopathological features from the routine 
diagnostic core needle biopsy and VAB. A binary logistic regression model will be used 
to find independent predictors for complete excision of the lesion after VAE. Interaction 
between predictors will be evaluated in the final model by including interaction terms 
along with the main-effect terms.
For the analysis of the quality-of-life and pain experience between VAE and surgery a 
Wilcoxon signed rank test will be performed.
Monitoring
Adverse events will be collected and reported according to predefined regulations of the study 
protocol. Yearly updates of trial progress will be reported to the medical ethical committee. 
Study monitoring will be carried out centrally at the Radboudumc, by an independent 
monitor contracted by the sponsor, according to national guidelines on quality control for 
university medical centers32.
6.4 | Discussion
This study tests the feasibility of the concept of this minimally invasive approach 
to remove carefully selected small breast cancers. In this study only patients with a 
confirmed non-lobular invasive breast cancer can participate. Invasive lobular carcinoma 
(ILC) has a diffuse growth pattern which usually does not form a lump, but is more spread 
out and may have branches or can be multifocal33. For this reason, patients with ILC are 
less suitable for the present feasibility study.
During this study patients will be asked to fill out a questionnaire using the Tyrer-Cuzick 
(or IBIS) model27. This questionnaire will be used to assess in retrospect whether successful 
tumor extraction can be predicted based upon patient related factors. 
In this study a waiting time of three weeks between VAE and breast-conserving surgery will 
be applied. Several studies reported a reduction in the presence of residual disease when 
patients undergo a delayed re-excision of the cavity wall in comparison with the group 
that had immediate re-excision34-36. Furthermore, they state that local repair mechanisms 
in response to the surgical trauma may be responsible for a destruction of up to 50% of 
the residual disease34,35.
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Providing that an acceptable proportion of complete excisions will occur, this treatment 
modality can prove a qualitative step forward in patient comfort. Reduction of the 
impact of local treatment is warranted as the psychosocial and somatic effects of breast 
deformation after breast conserving surgery can be substantial37. According to GLOBOCAN 
only in the Western European approximately 170.000 new breast cancer cases are detected 
per year38. Even if only a small percentage of these women qualify for US guided VAE, it 
might still reduce the impact of therapy for a substantial group of women worldwide. 
The burden from this study to the participating patients is the fact that two procedures 
are mandatory. This will result in prolonged time from initial diagnosis to end of surgical 
treatment. 
While there is neither direct benefit nor detrimental effect from this study to the patients 
participating, the study could have large implications for future selected women with 
small breast cancers. 
Several trials on minimizing treatment (LORD39, COMET40), omitting axillary surgery 
(BOOG 2013-0841, NEONOD 242) or using minimally invasive therapy (FUMOS43, SMALL44) 
have been designed over the past years. The British SMALL trial randomizes patients with 
small low-grade ER positive tumors between surgery and VAE. The complementary value 
of the current study is mainly in the rapid outcome evaluation due to the treat and resect 
design, and the inclusion of a much wider spectrum of small breast cancers, which may 
enable to better define the women that best qualify for VAE. What percentage of residual 
disease in the surgical cavity excision will be deemed acceptable, will depend on patient, 
tumor and center related factors, as well as the progress in systemic therapy. The present 
explorative feasibility study aims at providing a framework to build further research upon 
and it might open the way for more extensive evaluation of minimal invasive therapy of 
breast cancer.
The question how to deal with omitting axillary surgery remains open. Whether there 
is a selection of T1 patients who can forego sentinel node surgery will be elucidated in 
above mentioned ongoing trials41,42. We will monitor the frequency of sentinel lymph 
node involvement in patients participating in this trial. There is still little known about 
neoplastic seeding to the sentinel lymph node following VAE, although less than 2 out 
of 1000 biopsies results in neoplastic seeding along the biopsy tract45-47. Hansen et al.48 
noted that the incidence of lymph node metastasis was significantly greater when fine 
needle aspiration or large core needle biopsy was used for diagnosis of breast lesions 
in comparison with excision. However, Peters-Engl et al.49 were not able to confirm this 
finding and stated that diagnostic breast biopsy did not cause tumor spread to the 
sentinel lymph node. Whether the much larger excisions with VAE might affect lymph 
node status, more specifically stage pN0(ITC) might be elucidated from our study, when 
compared to historical data, albeit the number of treated patients is relatively low. 
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 When safety of VAE can be confirmed and foregoing axillary surgery for selected T1 tumors 
can be established, rapid treatment of selected small breast cancers in an outpatient 
procedure could become within reach. 
6.5 | Ethics approval and consent to participate
The study protocol is approved by the Medical Ethical Committee of the Radboudumc 
(CCMO) in Nijmegen the Netherlands on 11th of February 2020 (reference number 
NL68820.091.19). The study is also approved and registered by the local ethics committees 
of all participating hospitals (Radboudumc in Nijmegen, Canisius Wilhelmina hospital 
in Nijmegen, St. Antonius Hospital in Nieuwegein, Antoni van Leeuwenhoek hospital in 
Amsterdam). The study is published under NCT04107636 on ClinicalTrials.gov and has been 
registered on the 27th of September 2019. Written informed consent will be obtained from 
all participants. 
6.6 | Disclosure and conflicts of interest
The MINIVAB study is funded by BD Medical, Franklin Lakes, New Jersey U.S. BD Medical 
will not be involved in the collection, analysis and interpretation of data, in writing future 
manuscripts or deciding to submit manuscripts for publication.
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Purpose: To compare diffusion-weighted imaging of the breast performed with a 
conventional readout-segmented echo-planar imaging (rs-EPI) sequence to when using a 
prototype simultaneous multi-slice single-shot EPI (SMS-ss-EPI) acquisition.
Method: From September 2017 to December 2018, 26 women with histologically proven 
breast cancer were scanned with the conventional rs-EPI and the SMS-ss-EPI at 3T during 
the same imaging examination. Four breast radiologists (4-13 years of experience) 
independently scored both acquired series of 25 women (one case was used for training) for 
overall image quality (1: extremely poor to 9: excellent) and artifacts (1: very disturbing to 
5: not present). All lesions (n=52; 40 malignant, 12 benign) were also evaluated for visibility 
(1: not visible, 2: visible if location is given, 3: visible). In addition, lesion characteristics 
were rated, and a BI-RADS score was given. Results were analyzed using visual grading 
characteristics and the resulting area under the curve (AUCVGC), weighted kappa, McNemar 
test, and dependent-samples t-test when appropriate.
Results: Overall, radiologists significantly preferred the image quality in rs-EPI over that 
of SMS-ss-EPI (AUCVGC: 0.698, P = 0.002). Infolding and ghosting, and distortion artifacts 
were significantly less apparent in the rs-EPI (AUCVGC: 0.660, P = 0.022 and AUCVGC: 0.700, 
P = 0.002, respectively). Lesions were, however, significantly better visible on the SMS-ss-
EPI images (AUCVGC: 0.427, P = 0.016). Malignant lesions had significantly higher visibility 
with SMS-ss-EPI (P = 0.035). Sensitivity and specificity were comparable between both 
sequences (P = 0.760 and P = 0.549, respectively).
Conclusion: Despite the perceived lower image quality and the increased presence of 
artifacts in the SMS-ss-EPI sequence, malignant lesions are better visualized using this 
sequence. 




The high sensitivity of dynamic contrast-enhanced breast MRI (DCE-MRI) yields many 
lesions that cannot be unequivocally classified as benign on imaging alone, and for which 
biopsy is required. In recent years, studies have shown that the addition of diffusion-
weighted imaging (DWI) to DCE-MRI improves the classification of breast lesions, which 
leads in turn to a decrease of biopsies of benign lesions, and a corresponding increase 
in the positive predictive value of biopsies1-3. Consequently, DWI with evaluation of the 
corresponding apparent diffusion coefficient (ADC) is included in most state-of-the-
art breast MRI protocols, and consensus recommendations for its implementation and 
reporting were recently published by the international European society of breast imaging 
(EUSOBI) DWI working group4,5. 
Still, DWI of the breast is also known for the common presence of imaging artefacts. In a 
recent American college of radiology imaging network (ACRIN) trial, 23 of 107 patients were 
excluded from analysis because of insufficient image quality6. To improve on this, readout-
segmented echo-planar imaging (rs-EPI) has been proposed as an alternative to single-
shot EPI (ss-EPI) due to its reduced sensitivity to motion and improved image quality7-10. 
Nevertheless, in practice, detection of lesions on DWI sequences is often problematic 
due to a relatively low lesion visibility11. Particularly small lesions and lesions presenting 
as non-mass enhancement on DCE-MRI are not always clearly visible on DWI scans. The 
rs-EPI sequence is especially problematic in this aspect due to its lower signal-to-noise 
ratio (SNR) compared to that obtained with ss-EPI8. Furthermore, another disadvantage 
of rs-EPI is the longer acquisition time compared to that of ss-EPI because each readout 
segment in the k-space requires a separate radiofrequency pulse and the subsequent 
time for recovery of the longitudinal magnetization. In order to reduce acquisition time 
and enable higher spatial resolution scans within a clinically acceptable timeframe, the 
simultaneous multi-slice (SMS) acquisition technology was developed. This technique 
allows the simultaneous excitation of multiple slices, providing a scan acceleration that 
is approximately proportional to the number of slices simultaneously obtained. This can 
be used to reduce scan time or increase spatial resolution. The technique can be combined 
with both ss-EPI and rs-EPI. 
In this prospective patient study, we compared a prototype SMS-ss-EPI breast diffusion 
sequence at 3T to our clinical standard rs-EPI sequence. The sequences were evaluated in 
terms of image quality, lesion visibility and diagnosis, and description according to the 
breast imaging reporting and data system (BI-RADS) lexicon.
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7.2 | Material and methods
7.2.1 | Study population
Female patients with histologically proven breast cancer and a clinical indication 
for breast MRI were asked to participate in this prospective study for which ethics 
committee approval and written informed consent was obtained. Exclusion criteria were 
age younger than 18 years or inability to provide informed consent. For lesion specific 
features, we performed a per-lesion analysis. Malignant lesions were included only when 
a histopathological description of that specific lesion was available (either from biopsy 
or from surgical excision). Malignant lesions without any pathological evaluation or 
clinical follow-up were excluded. Additional benign lesions diagnosed on imaging only 
(mammography, ultrasound, and the full MRI scan) were included. 
Table 7.1 |  DWI sequence parameters
 
7.2.2 | Image acquisition
All women were scanned in the prone position on a 3 T MAGNETOM Skyra MRI system 
(Siemens Healthcare, Erlangen, Germany), with a 16-channel bilateral breast coil (Siemens 
Healthcare). Women were scanned with the conventional clinically used rs-EPI sequence 
and the prototype SMS-ss-EPI during the same clinical examination, prior to contrast agent 
administration. The sequence parameters for the rs-EPI were those used as standard of care 
(Table 7.1). The parameters for SMS-ss-EPI were chosen for optimal performance in a clinical 
setting (Table 7.1). Therefore, compared to the rs-EPI sequence, the scan time was reduced, 
rs-EPI SMS-ss-EPI
TR (ms) 5450 4000
TE (ms) 57 70
Slices 28 42 
Distance factor 20% 0%
Voxel size (mm3) 1.2 x 1.2 x 5.0 0.9 x 0.9 x 4.0
Fat suppression SPAIR SPAIR
Readout segments 5 -
Readout partial Fourier acquisition 5/8 -
Field of view (mm2) 340x340 340x340
Bandwidth (Hz/Px) 829 1644





GRAPPA acceleration factor 2 2
Slice acceleration factor - 2
Acquisition time (min:s) 4:23 2:45
GRAPPA, generalized autocalibrating partially parallel acquisitions; TE, echo time; TR, repetition time
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while the spatial resolution was increased. The rest of the DCE-MRI acquisition protocol 
was performed as the standard-of-care, as previously described12: one pre- and five post-
contrast administration standard T1-weighted Dixon acquisitions, ultrafast T1-weighted 
TWIST acquisitions during the inflow of contrast, and a T2-weighted Dixon acquisition. 
7.2.3 | Image analysis
A reader study was performed to assess several aspects of image quality and lesion 
appearance in both sequences. Prior to the study, the ground truth location of the lesions 
was annotated based on clinical information (pathology and radiology reports) and under 
the supervision of an experienced radiologist (13 years of experience with MRI). The reader 
study was carried out by four breast radiologists with 4, 6, 10, and 13 years of experience. 
For each reader, two reading sessions, separated by at least 2 weeks, were performed in 
order to avoid possible bias in the results due to a direct comparison between images of 
the same patient. The two sequences of each patient were alternatively and randomly split 
between the two reading sessions. Both original DWI images and maximum-intensity 
projection (MIP) reconstructions of high-b-value DWI images, were used for image 
interpretation. 
For the assessment of image quality and artifacts, the entire images were used. For image 
quality, a nine-point scale (1: Extremely poor; 3: Moderately poor; 5: Average; 7: Moderately 
good; 9: Excellent) and for artifacts a five-point scale (1: Very disturbing; 2: Moderately 
disturbing; 3: Mildly disturbing; 4: Not disturbing but present; 5: Not present) were used. 
Each lesion was shown to the readers, who were asked to describe it according to the 
BI-RADS MRI lexicon13,14. In addition, a lesion visibility score on a three-point scale (1: Not 
visible; 2: Only visible if location is given; 3: Visible) and a BI-RADS score (1 - 5) was provided 
for each lesion based upon the interpretation of the DWI images alone. Evaluation of all 
examinations was performed on an in-house-developed workstation, using a standardized 
layout.
One author blinded to histopathological results determined the site of ADC measurement 
using DCE-images for reference. On the ADC map, the ADC values were determined by 
measuring signal intensity over manually-defined regions of interest (ROIs) in the lesions. 
An ROI smaller than the actual solid portion of the breast lesion was carefully placed in the 
enhancing (part of the) lesion to avoid the necrotic portion4.
7.2.4 | Statistical analysis
Visual grading characteristics (VGC) analysis was used to determine the difference in 
image quality, lesion visibility and artifacts scores between the two techniques, using 
open source software (VGC analyzer, version 1.0.2)15-18. VGC is a non-parametric, rank-
invariant statistical method derived from receiver operating characteristics (ROC) 
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analysis. The area under the VGC curve (AUCVGC) measures the separation between the two 
rating distributions, with AUC>0.5 indicating in our case that rs-EPI was preferred over 
SMS-ss-EPI.
To assess whether lesion characteristics were comparable for the two sequences, we 
calculated the inter-method agreement using weighted kappa statistics. When lesion 
visibility was classified as ‘not visible’, lesions were excluded for assessment of lesion 
characteristics. In all statistical tests the level of agreement was defined as poor for less 
than 0.0, slight for 0.0 to 0.2, fair for between 0.2 and 0.4, moderate for between 0.4 and 
0.6, substantial for between 0.6 and 0.8, and almost perfect for above 0.8. 
Sensitivity and specificity of both sequences was calculated using the BI-RADS scores. For 
a clinical diagnostic setting, BI-RADS 3, 4 and 5 were considered positive, whereas for a 
screening setting BI-RADS 4 and 5 were considered positive. Sensitivity and specificity for 
both scenarios are reported, which were calculated using the pooled scores for all readers 
and compared using McNemar tests19. 
For each sequence and by lesion type, mean values of ADCs were calculated in manually 
chosen ROIs. The differences were evaluated with the independent-samples t-test. 
Comparison between rs-EPI and SMS-ss-EPI regarding ADC was performed using the 
dependent-samples t-test. 
All statistical analyses were performed using SPSS (version 22, IBM, Chicago, IL). Results 
with 2-sided P-values of 0.05 or less were considered statistically significant.
7.3 | Results
7.3.1 | Patient and lesion characteristics
Twenty-six patients were included from September 2017 to December 2018. Six lesions 
were diagnosed as benign based on radiological evaluation only. All other lesions were 
pathologically evaluated or underwent clinical follow-up. Two patients (with three 
malignant lesions in total) received neo-adjuvant treatment with a pathologically 
proven complete response. After visual inspection, one lesion (lesion size: 92 mm) was 
excluded for further analysis due to fat saturation issues in the SMS-ss-EPI sequence. 
A study flowchart can be found in Figure 7.1. For a detailed description of the patient 
characteristics, histopathological diagnosis, and lesion size, see Table 7.2.
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Figure 7.1 | Study flow chart 
Table 7.2 | Patient and lesion characteristics
N (%)
Mean age in years ± SD [range] 58.6 ± 9.6 [42-74]
Indication for breast MRI
Preoperative staging 18 (72)
Pre-neoadjuvant staging 4 (16)
Post-neoadjuvant analysis 3 (12)
Mean lesion size on DCE-MRI in mm ± SD [range] 14.4 ± 9.6 [3-40]
Malignant 17.1 ± 9.4 [3-40]
Benign and high-risk lesions 5.8 ± 3.9 [3-15]
Lesion type
Malignant 40 (76.9)
Invasive carcinoma of no special type (NST) 32 (61.5)
ILC 4 (7.7)
Mixed carcinoma 2 (3.8)
DCIS 1 (1.9)
Micropapilar carcinoma 1 (1.9)
Benign and high-risk lesions 12 (23.1)
Fibroadenoma 1 (1.9)
Lymph node 3 (5.8)




7.3.2 | Image quality and artifacts
Three out of four radiologists significantly preferred the image quality in rs-EPI over SMS-
ss-EPI (Figure 7.2). Only the AUCVGC resulting from the assessment of reader 4 was found to 
be non-significantly different than 0.5 (P = 0.065). Overall, the AUCVGC was 0.698 (95% CI = 
0.583-0.804, P = 0.002). 
Overall, artifacts that disturbed image interpretation were relatively common. Infolding 
and ghosting artifacts, and distortion artifacts were significantly less visible in the rs-EPI 
with an AUCVGC of 0.660 (95% CI = 0.514-0.797, P = 0.022) and 0.700 (95% CI = 0.571-0.822, 
P = 0.002), respectively (Figure 7.3). Table 7.3 shows the proportion of acceptable artifact 
ratings for rs-EPI and SMS-ss-EPI. Figure 7.4 shows an example of a typical infolding and 
ghosting artifact. 
 
Figure 7.2 | The VGC curves of the image quality ratings above a certain threshold for the rs-EPI 
against the same proportion for SMS-ss-EPI at various threshold settings. The figure shows the 
separation between rs-EPI and SMS-ss-EPI per reader. The AUCVGC of 0.698 (P = 0.002) shows a higher 
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Figure 7.3 | The VGC curve of the artifacts ratings above a certain threshold for the rs-EPI against 
the same proportion for SMS-ss-EPI at various threshold settings. The AUCVGC of 0.660 (P = 0.022) 
and 0.700 (P = 0.002) shows fewer artifacts in the rs-EPI. The grey line is the reference line were both 
sequences show the same artifact appearance.
Table 7.3 | Average number and percentage of mildly, moderately or very disturbing artifact ratings 
for rs-EPI and SMS-ss-EPI
Mildly, moderately or very disturbing artifacts, average number  
[range] (%)a
rs-EPI SMS-ss-EPI
Infolding and ghosting 
artifacts
14.5 [11-23] (58%) 18.5 [15-22] (74%)
Distortion artifacts 4.5 [0-13] (18%) 10.3 [1-20] (41%)
aArtifact assessments are cumulative number and percentages of images that were scored as not 
acceptable in terms of categorized artifact data (not present or not disturbing but present vs. mildly, 

















Figure 7.4 | Example of a typical ghosting (or Nyquist) artifact in SMS-ss-EPI.
7.3.3 | Lesion appearance
Overall, lesions were significantly more visible on the SMS-ss-EPI images (AUCVGC was 
0.427, 95% CI = 0.358-0.498, P = 0.016) (Figure 7.5). Malignant lesions had significantly 
higher visibility with SMS-ss-EPI (P = 0.035). Benign and high-risk lesions were not analyzed 
separately with VGC due to the lack of enough data to draw appropriate conclusions. 
Figure 7.5 | The VGC curves of the lesion visibility ratings above a certain threshold for the rs-EPI 
against the same proportion for SMS-ss-EPI at various threshold settings. The figure shows the 
separation between rs-EPI and SMS-ss-EPI for all lesions and malignant lesions only. The AUCVGC 
of 0.427 (P = 0.016) shows a higher lesion visibility in preference of SMS-ss-EPI. The grey line is the 
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In Figure 7.6, an example is given of a lesion that is visible on SMS-ss-EPI and not visible 
on rs-EPI. Lesions scored as not visible or only visible if location is given by the majority 
of the readers, had a mean size at DCE-MRI of 12.6 mm ± SD 9.5 mm and 10.4 mm ± 
SD 10.1 mm for rs-EPI and SMS-ss-EPI, respectively. Lesions that were only visible in the 
rs-EPI sequence and remained occult on the SMS-ss-EPI ranged from 3 mm to 6 mm. 
Conversely, lesions that were only visible in the SMS-ss-EPI sequence and remained occult 
on the rs-EPI ranged from 3 mm to 26 mm. 
 
Figure 7.6 | MR images of a 67-year-old woman with a 26 mm invasive carcinoma NST in her right 
breast (see arrow) with an average image quality score of 5.6 and 4.0 for rs-EPI and SMS-ss-EPI, 
respectively. The lesion was scored as not visible (n=3) and only visible if location is given (n=1) in the 
rs-EPI sequence, whereas it was scored as visible by all readers in the SMS-ss-EPI sequence. Contrast-
enhanced T1-weighted MR images (A), diffusion-weighted images (DWI) (B; b=850 and C; b=800), the 
































































































































































































































































































































































































































































































































































































































































































































































































































Comparison of SMS-ss-EPI to rs-EPI for evaluation of breast lesions at 3T MRI
149
7
In a clinical diagnostic setting, using BI-RADS 3 or higher as the cut-off point, sensitivity 
and specificity based on BI-RADS assessment did not differ significantly (P = 0.280 and 
P = 0.824, respectively), with a pooled sensitivity and specificity of 67.5% and 72.9% for 
rs-EPI and 72.5% and 68.8% for SMS-ss-EPI, respectively.
In a screening setting, using BI-RADS 4 or higher as the cut-off point, sensitivity and 
specificity based on BI-RADS assessment did also not differ significantly (P = 0.760 and 
P = 0.549, respectively), with a pooled sensitivity and specificity of 51.2% and 91.7% for 
rs-EPI and 53.1% and 85.4% for SMS-ss-EPI, respectively. 
The inter-method agreement between the two sequences is shown in Table 7.4. Overall 
lesion shape has a moderate agreement (K= 0.464, p < 0.001); however, non-mass lesions 
had an overall poor agreement.
7.3.4 | ADC value
One malignant lesion with DCIS was excluded from ADC value measurements, due to the 
presence of a hematoma caused by a stereotactic biopsy performed several days before the 
MR scan. The distribution of ADC values obtained by rs-EPI and SMS-ss-EPI is shown in Table 
7.5 and in the boxplot in Figure 7.7. Overall, the mean ADC of malignant lesions was lower 
than that of benign and high-risk lesions. However, this was only significant in the rs-EPI 
(P = 0.042). Within all lesions, the mean ADC measurements were lower for SMS-ss-EPI. 
Especially in the malignant lesions, there was a significant difference between the two 
sequences (P = 0.013). Average ROI area was well matched between rs-EPI and SMS-ss-EPI 
sequences for benign and high-risk lesions (mean ± SD: 13.0 ± 5.1 mm2 and 12.5 ± 5.4 mm2, 
respectively) and malignant lesions (mean ± SD: 18.0 ± 10.3 mm2 and 17.6 ± 10.4 mm2, 
respectively).



























Our study indicates that rs-EPI is superior to SMS-ss-EPI in terms of image quality and 
lesion visibility, which is consistent with previously published studies8-10. Nevertheless, 
the SMS-ss-EPI results in better visibility of lesions, especially in cases of malignant 
lesions. These findings are clinically relevant, because geometric distortion hamper the 
visual interpretation of DWI sequences and should thus be minimized. However, while 
improved general image quality is desirable, it is not relevant if it does not result in an 
improvement in the visualization of lesions.
The cause of the better lesion visibility on the SMS-ss-EPI is not entirely clear. Partly 
this may be due to the higher resolution of the SMS-ss-EPI sequence. However, we 
encountered lesions of up to 26 mm that were only visible in this sequence and remained 
occult on the rs-EPI. Consequently, the lower visibility cannot only be explained by 
spatial resolution but it is likely also caused by the inherently lower SNR of the rs-EPI 
sequence. Unfortunately, it is difficult to pinpoint the exact cause of the lower visibility 
of the lesions in the rs-EPI sequence, as several settings differed between the two 
sequences. This might be overcome by phantom studies in which it is feasible to adapt 
one parameter at a time to evaluate the effect on image quality, an approach that is 
simply not feasible in patients. However, lesions in such phantoms need to be realistic 
and variable in order to represent the high variability of lesions observed in humans. 
Future clinical studies should focus on the use of SMS on both sequences and the interplay 
among different spatial resolutions, fat saturation, and b-values, to investigate which 
combination gives the best DWI setting in clinical use. Despite the lower visibility of 
the malignant lesions on the rs-EPI sequence, the sensitivity of both sequences, using 
BI-RADS 4 or higher as cut-off is similar. In other words, most malignant lesions that 
were visible only at the SMS-ss-EPI sequence were scored BI-RADS 3 by the evaluating 
Table 7.5 | ADC values for rs-EPI and SMS-ss-EPI
ADC (x10-3 mm2/sec) rs-EPI SMS-ss-EPI Pb
(Mean ± SD)
All lesions 1.06 ± 0.41 0.94 ± 0.41 0.003
Benign and high-risk 1.33 ±0.52 1.20 ± 0.60 0.145
Malignant 0.97 ± 0.33 0.85 ± 0.30 0.013
Pa 0.042 0.069
Pa: p-value based on the independent-samples t-test comparing measurements between benign and 
high-risk, and malignant lesions. 
Pb: p-value based on the dependent-samples t-test of paired rs-EPI and SMS-ss-EPI measurements 
within each MRI exam.
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radiologists, which underlines that mainly subtle lesions are missed on the rs-EPI 
sequence. 
Overall, SMS-ss-EPI obtained lower mean ADC values in comparison to rs-EPI. Also, the 
mean ADC value in malignant lesions was lower in comparison to that in benign and high-
risk lesions. This is not completely attributable to the acquisition parameters and can also 
not be directly attributed to increased image noise, as the SNR is lower in rs-EPI. Although 
there were significant differences in mean ADC values between the two sequences and 
the benign and high-risk, and malignant lesions, in practice these differences were small, 
and the values overlapped. Clinically, this may result in the need to adopt different ADC 
thresholds for different sequences4,20. 
Comparing the present results with those reported in other studies analyzing breast 
lesion characteristics in DWI images, the present sensitivities of both sequences fall 
below values reported previously (51.2% and 53.1% vs. up to 91% for rs-EPI, SMS-ss-EPI, 
and sensitivity described in literature11,21, respectively). However, the majority of studies 
are based on mass lesions only, because the diagnostic accuracy in non-mass enhanced 
lesions is limited22. This lesion characteristic was not considered for patient selection in 
this study. 
The present specificity of both sequences is comparable with the values in literature (91.7% 
and 85.4% vs. up to 87% for rs-EPI, SMS-ss-EPI and specificity described in literature, 
respectively11,21,23). Further, our results are in the given range reported in meta-analysis23. It 
should be noted that different DWI sequences were pooled in the meta-analysis, causing 
mixing of rs-EPI and ss-EPI data. In this study the sensitivity and specificity of both 
sequences were similar. 
Ohlmeyer et al. and Frost et al. both describe that SMS acquisitions do not introduce serious 
artifacts24,25. However, Filli et al. describe an increase of shading in the prepectoral region 
and ghosting26. Shading was not commonly encountered in our study, but ghosting was 
significantly visible in this study. In fact, one of the most common artifacts encountered 
in this study was Nyquist ghosting in the image phase-encoding direction (see Figure 
7.4). This is a well-known and common artifact caused by the alternating nature of EPI 
readout, which leads to inconsistencies between k-space lines of opposite polarity27. In 
breast imaging, this is exacerbated by unsuccessful or insufficient fat saturation. Like in 
conventional ss-EPI sequences, these artifacts were more commonly found in the SMS-ss-
EPI acquisitions than in the rs-EPI acquisitions, which would currently be a major drawback 
for the use of SMS-ss-EPI in practice. However, recent studies proposed alternative 
navigator approaches to reduce these artefacts in breast imaging28, which might increase 
the usefulness of the SMS-ss-EPI approach, also exploiting the documented higher 
sensitivity in our study.
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A commonly postulated hypothesis is that DWI may be used as a fully non-invasive 
screening technique for breast cancer. DWI sequences represent a fast and non-invasive 
approach compared to the current standard full diagnostic protocol and therefore might 
play an important role in screening and detection of suspicious breast lesions without 
exposing the patient to additional ionizing radiation or intravenous contrast agents. With 
the addition of MIP, a short examination and reading time can be obtained. However, it may 
be clear from our analysis that neither the SMS-ss-EPI sequence nor the rs-EPI sequence is, 
according to our experience, good enough for unenhanced screening purposes yet. These 
findings are in line with prior research that, although obtaining encouraging results, 
shows a definite inferiority of DWI-only approaches compared to contrast-enhanced MRI 
of the breast11,21. 
Overall image quality and spatial resolution need to be improved substantially in order 
to make DWI feasible as a standalone screening sequence. In recent studies, DWI at much 
higher spatial resolutions, either by image manipulation or acquisition, was evaluated29-31. 
However, acquisition times were in the order of 15 minutes, and therefore such an 
approach is currently not yet clinically feasible. Another approach to DWI screening is 
the use of strong background suppression and high b-values, which already have been 
shown to improve lesion visibility32,33. Nevertheless, in case the image quality and spatial 
resolution will be improved in the future and the DWI sequence is used as a first screening 
modality, further diagnostic examination can be performed in case a suspicious breast 
lesion is detected by DWI screening.
Our study has some limitations. First, we performed a lesion-based analysis, rather than a 
patient-based analysis. This implies that distinct foci from single multifocal lesions were 
actually regarded as separate lesions, whereas in many studies these would be regarded as 
parts of the same tumor and hence would be regarded as positive in a sensitivity analysis. 
However, this finding adds to the statement that DWI is currently not very good for the 
detection of small and non-mass lesions. Second, our readers were aware of the fact that 
all scans contained lesions. By having readers score multiple tumor foci in order to also 
include smaller lesions, and by explicitly asking whether lesions were clearly visible, or 
only visible when indicated, we intended to overcome these biases. Third, three patients 
who received neo-adjuvant treatment were included for analysis which may introduce 
bias. However the ground truth location of these lesions were annotated based on clinical 
information and visibility on DCE-MRI. Fourth, in this study we used the SMS only on the 
ss-EPI. As stated above in future clinical studies it is important to compare the use of SMS 
on both sequences. 




Our results suggest increased visibility of malignant lesions using the SMS-ss-EPI 
compared to the conventional clinically used rs-EPI. Although the overall image quality 
is much better in rs-EPI, other factors including patient-related issues and the choice of 
acquisition parameters affect the image quality and should be further investigated. Still, 
further development of the SMS-ss-EPI sequence is needed for improved image quality, 
decreased presence of artifacts, and even better lesion visibility.
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Background: Diffusion-weighted imaging (DWI) is of particular interest in breast cancer 
imaging due to its potential for lesion detection with no need for contrast enhancement.
Purpose: To compare image quality, lesion visibility, and evaluation time of a prototype 
single-shot echo-planar-imaging (ss-EPI) with modified Inversion Recovery Background 
Suppression (ss-EPI-mIRBS) sequence using a b-value of 2000 s/mm2 to the clinical 
standard readout-segmented (rs)-EPI at 3T.
Study type: Prospective.
Subjects: In all, 23 women (one case used for training) with known breast cancer. 
Field strength/Sequence: 3T, rs-EPI sequence and ss-EPI-mIRBS.
Assessment: Four breast radiologists independently scored both series for overall image 
quality. All lesions were evaluated for visibility and probability of malignancy. Apparent 
diffusion coefficient (ADC) values were determined by measuring signal intensity in the 
lesions using dynamic contrast-enhanced (DCE) images for reference. Evaluation times for 
all assessments were automatically recorded.
Statistical Tests: Results were analyzed using visual grading characteristics (VGC) and the 
resulting area under the curve (AUCVGC). Statistical analysis was performed in SPSS, with 
McNemar tests, and paired t-tests used for comparison.
Results: No significant differences were detected between the two sequences, both 
in terms of image quality (AUCVGC: 0.398, P = 0.087) and lesion visibility (AUCVGC: 0.534, 
P = 0.336). Differences were also not detected in terms of sensitivity (ss-EPI-mIRBS: 78.5% 
vs. rs-EPI: 72.2%, P = 0.108) or specificity (70.5% vs. 56.8%, P = 0.210, respectively). In 
both sequences the mean ADC value was higher for benign and high-risk lesions than for 
malignant lesions (ss-EPI-mIRBS: P = 0.022 and rs-EPI: P = 0.055). On average, ss-EPI-mIRBS 
resulted in a non-significant decrease in overall reading time of 7.7 s/case (17%, P = 0.067).
Conclusion: The ss-EPI sequence using a b-value of 2000 s/mm2 allows for an mIRBS 
acquisition with quality and lesion conspicuity that is comparable to conventional rs-EPI, 
but with a decreased reading time.
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Diffusion-weighted imaging (DWI) detects changes in the Brownian motion of water 
molecules, which is restricted in areas of increased tissue density and/or cellularity. The 
addition of DWI to contrast-enhanced breast MRI improves the classification of eventual 
breast lesions, as malignant lesions tend to present with higher restriction than benign 
abnormalities, which leads in turn to an increase in the positive predictive value of 
biopsies1,2. Consequently, DWI with corresponding apparent diffusion coefficient (ADC) 
values is included in most state-of-the-art breast MRI protocols3-5. Recently, readout-
segmented echo-planar-imaging (rs-EPI) based DWI sequences have been introduced 
to reduce distortion and improve image quality by shortening of the echo train of this 
sequence. However, these sequences have a relatively low signal-to-noise ratio (SNR)6. 
In practice, detection of lesions on DWI is often problematic, due to the resulting relatively 
low lesion conspicuity7. To improve the value of DWI for lesion detection, Takahara et 
al. developed a diffusion-weighted whole body imaging with background body signal 
suppression (DWIBS) sequence in 20048. Bickelhaupt et al.9 suggested the use of an 
optimized single-shot echo-planar-imaging with DWIBS (ss-EPI-DWIBS) and a high b-value 
of 1500 s/mm2 to further improve the detectability of lesions at 1.5T. This is explained by 
the fact that higher b-value images depict structures with a high water signal and a high 
diffusion restriction only, such as most malignant breast lesions. 
Based on this, in this prospective study, we evaluated a prototype ss-EPI with modified 
Inversion Recovery Background Suppression (ss-EPI-mIRBS) sequence at 3T using a b-value 
of 2000 s/mm2 in terms of image quality, artifacts, lesion conspicuity, sensitivity and 
specificity. For comparison, we used the current clinical rs-EPI sequence. In addition, ADC 
values and reading time were measured and compared between the two sequences. 
8.2 | Materials and method
8.2.1 | Study population
This prospective study was conducted at a single site, and was approved by the regional 
ethical review board, with written informed consent obtained from all participants. 
Between September 2017 and December 2018, 23 female patients with histologically proven 
breast cancer who underwent a breast MRI for standard of care were asked to participate 




8.2.2 | MRI protocol
The MRI examinations were performed with a clinical 3T MAGNETOM Skyra MRI system 
(Siemens Healthcare, Erlangen, Germany), with a 16-channel bilateral breast coil (Siemens 
Healthcare, Erlangen, Germany). The patients were placed in headfirst prone position. The 
acquisition protocol, as previously described10, included DWI (rs-EPI and ss-EPI-mIRBS), 
one pre- and five post-contrast administration standard T1-weighted Dixon acquisitions, 
ultrafast T1-weighted TWIST acquisitions during the inflow of contrast, and a T2-weighted 
Dixon acquisition. The conventional rs-EPI sequence and the ss-EPI-mIRBS sequence 
were obtained during the same clinical examination before contrast administration. 
Parameters were used as in the clinical setting and are listed in Table 8.1.
Table 8.1 | DWI sequence parameters
rs-EPI ss-EPI-mIRBS
TR (ms) 5450 10740
TE (ms) 57 82
Slices 28 30 
Distance factor 20% 20%
Voxel size (mm3) 1.2 x 1.2 x 5.0 0.9 x 0.9 x 4.0†
Fat suppression SPAIR STIR
Readout segments 5 -
Readout partial Fourier acquisition 5/8 -
Field of view (mm2) 340x340 360x360
Acquisition matrix 274x110 190x112
Bandwidth (Hz/Px) 829 1644




GRAPPA acceleration factor 2 2
Acquisition time (min:s) 4:23 4:39
†Interpolated
GRAPPA, generalized autocalibrating partially parallel acquisitions; rs-EPI, readout-segmented echo-
planar-imaging; SPAIR, Spectral Attenuated Inversion Recovery; ss-EPI-mIRBS, single-shot echo-planar-
imaging with modified Inversion Recovery BackgroundSuppression; STIR, Short-TI Inversion Recovery; TE, 
echo time; TR, repetition time.
8.2.3 | Image preparation
Each lesion was annotated based on clinical information (pathology and radiology reports) 
by an imaging scientist (4 years of experience in breast imaging) and under the supervision 
of an experienced radiologist (13 years of experience with MRI). Malignant lesions were 
only included when a histopathological description of that specific lesion was available 
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(either from biopsy or from surgical excision). Malignant lesions without any pathological 
evaluation or clinical follow-up were excluded from the reader study (i.e., in case of 
multifocal or multicentric cancer, only independent lesions detailed in the pathology 
report were included). Lesions diagnosed as benign or high-risk based on imaging only 
(mammography, ultrasound, and the full MRI scan) were included in the reader study.
8.2.4 | Image analysis
Four radiologists (with 4, 6, 10, and 13 years of experience with MRI), who were blinded 
to the histopathological diagnosis and types of MR sequences, participated in a reader 
study. Each reader evaluated all cases twice in two reading sessions in an independent 
crossover multi-reader-multi-case study. The reading sessions were at least 2 weeks 
apart to minimize memory bias. To reduce the reading time for radiologists, maximum-
intensity projection (MIP) images of the high b-value images were also available for 
reading. Each case was evaluated according to a two-step reading protocol. In the first 
step, readers evaluated the acquisitions of the DWI sequence with the corresponding ADC 
map and MIP image in terms of image quality and artifacts. For image quality a nine-point 
scale (1: Extremely poor; 3: Moderately poor; 5: Average; 7: Moderately good; 9: Excellent) 
and for artifacts a five-point scale (1: Very disturbing; 2: Moderately disturbing; 3: Mildly 
disturbing; 4: Not disturbing but present; 5: Not present) was used. 
In a second step, the lesion location was highlighted in the images included in the first 
step and shown to the reader for a per lesion analysis. The readers assessed each lesion 
according to the BI-RADS MRI lexicon11,12. In addition, a lesion conspicuity score on a three-
point scale (1: Not visible; 2: Only visible if location is given; 3: Visible) and a BI-RADS score 
(1 to 5) was provided for each lesion. Evaluation of all examinations was performed on 
an in-house developed workstation. The readers performed a training session with one 
patient case with three suspicious lesions, to become familiar with the workstation and 
reading protocol.
One author, blinded to histopathological results, determined the site of ADC measurement 
using dynamic contrast-enhanced (DCE) images for reference. On the ADC map, the 
ADC values were determined by measuring signal intensity in regions of interest (ROIs) 
manually defined within the lesions. An ROI smaller than the actual solid portion of the 
breast lesion was carefully placed to avoid necrotic parts of the lesion3.
8.2.5 | Statistical analysis
Visual grading characteristics (VGC) analysis was used to determine the difference in image 
quality, lesion visibility, and artifacts scores between the two techniques, implemented in 
open-access software (VGC analyzer, version 1.0.2)13-16. VGC is a non-parametric, rank-invariant 
statistical method derived from receiver operating characteristics (ROC) analysis. The area 
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under the VGC curve (AUCVGC) measures the separation between the two rating distributions, 
with AUCVGC >0.5 indicating in our case that ss-EPI-mIRBS was preferred over rs-EPI.
The sensitivity and specificity of both sequences was calculated using the BI-RADS scores. 
For a clinical diagnostic setting, BI-RADS 3, 4 and 5 were considered positive, whereas for 
a simulated screening setting, only BI-RADS 4 and 5 were considered positive. Sensitivity 
and specificity for both settings were calculated using the pooled scores for all readers and 
compared using McNemar tests17. 
For each sequence and by lesion type, mean values of ADCs were calculated. The 
differences were evaluated with the Independent-Samples T-test. Comparison between rs-
EPI and ss-EPI-mIRBS regarding ADC was performed using the Dependent-Samples T-test. 
Reading time was compared for each reader individually by using Dependent-Samples 
T-test. Only the readings recorded within the 95th percentile were included in the analysis 
to correct for inactivity of the reader during the reading sessions.
Statistical analyses were performed using SPSS (version 22, IBM, Chicago, IL). Results with 
2-sided P-values of 0.05 or less were considered statistically significant.
8.3 | Results
8.3.1 | Patient and lesion characteristics
Figure 8.1 shows the study flow chart, including the number of study participants and 
number of lesions identified on DCE-imaging. Six benign lesions were included based on 
radiological evaluation only (as assessed on the full multiparametric protocol and other 
imaging modalities). All other lesions were pathologically evaluated. Table 8.2 summarizes 
the patient and lesion characteristics.
 
Figure 8.1 | Study flow chart
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Table 8.2 | Patient and lesion characteristics
N (%)
Mean age in years ± SD [range] 60.1 ± 9.0 [44-74]
Indication for breast MRI
Preoperative staging 18 (81.8)
Pre-neoadjuvant treatment staging 4 (18.2)
Mean lesion size on DCE-MRI in mm ± SD [range] 15.9 ± 14.9 [3-92]
Malignant 19.1 ± 15.5 [3-92]
Benign and high-risk lesions 5.4 ± 3.7 [3-15]
DCE, dynamic contrast-enhanced; MRI, magnetic resonance imaging; SD, standard deviation
 
8.3.2 | Reader study
Overall the image quality was deemed comparable between both sequences; the AUCVGC 
was 0.398 (95% CI = 0.260-0.524, P = 0.087). Only one of four readers had a significant 
preference for rs-EPI over ss-EPI-mIRBS (P = 0.023). 
Overall, artifacts that disturbed image interpretation were relatively common. However, 
there was no significant difference between the two sequences (AUCVGC: 0.462, 95% CI 
= 0.365-0.567, P = 0.421). Neither were there differences between the sequences when 
artifacts were divided into infolding and ghosting artifacts (P = 0.507) and distortion 
artifacts (P = 0.570).
Lesion visibility scores were comparable in both sequences when all reader scores were 
pooled; AUCVGC was 0.534 (95% CI = 0.467-0.602, P = 0.336) (Figure 8.2). Dichotomizing 
lesions into benign and high-risk, and malignant lesions yielded the same results (P = 0.183 
and P = 0.714, respectively), as well as for small (≤10 mm) and larger (>10 mm) lesions 
(P = 0.347 and P = 0.566, respectively). Table 8.3 shows the percentage of lesions that were 
scored as visible (after dichotomization: visible vs. only visible if location is given or not 
visible). In Figure 8.3 an example of both sequences is given. Lesions, scored as not visible 
or only visible if location is given by the majority of the readers, had a mean size at DCE-
MRI of 12.75 mm ± SD 10.0 mm and 13.8 mm ± SD 11.3 mm for rs-EPI and ss-EPI-mIRBS, 
respectively. Lesions that were only visible in the rs-EPI sequence and remained occult 
on the ss-EPI-mIRBS ranged from 4 mm to 40 mm. Conversely, only visible in the ss-EPI-
mIRBS and remained occult on the rs-EPI, the lesions measured 3 mm to 26 mm. 
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Figure 8.2 | The VGC curve of a plot of the proportion of ratings above a certain threshold for the 
rs-EPI against the same proportion for ss-EPI-mIRBS, at various threshold settings. The figure shows 
the separation between rs-EPI and ss-EPI-mIRBS for image quality, lesion visibility and artifacts. An 
AUCVGC >0.500 shows that readers prefer ss-EPI-mIRBS. The grey line is the identity line where both 
sequences show the same preference. 
Table 8.3 | Average number and percentage of visible lesions by reader for rs-EPI and ss-EPI-mIRBS
Visible lesions, average number [range] (%)a
rs-EPI ss-EPI-mIRBS
Overall 28 [22-33] (59.6%) 30.8 [25-36] (65.4%)
Malignant 23.8 [19-27] (66.0%) 25 [21-29] (69.4%)
Benign and high-risk 4.3 [2-8] (38.6%) 5.8 [4-7] (52.3%)
≤ 10 mm 10.8 [8-15] (53.8%) 12.5 [10-16] (62.5%)
> 10 mm 17.3 [14-19] (63.9%) 18.3 [15-20] (67.6%)
aVisible lesions are cumulative number and percentages of lesions that were scored as visible in terms of 
dichotomized conspicuity data (visible vs. only visible if location is given or not visible), averaged across 
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Figure 8.3 | MR images of a 49-year-old woman with a 13 mm invasive carcinoma of no special 
type (NST)  in her left breast (see arrow) with average image quality scores of 7 and 6.3 for rs-EPI 
and ss-EPI-mIRBS, respectively. Diffusion-weighted images (DWI) (A; b=850 and B; b=2000), the 
corresponding ADC map (C and D), and maximum intensity projections (MIP) (E and F) for rs-EPI and 
ss-EPI-mIRBS, respectively. 
In a clinical diagnostic setting, using BI-RADS 3 or higher as cut-off point, both the pooled 
sensitivity (rs-EPI: 72.2%, ss-EPI-mIRBS: 78.5%, P = 0.108) and the pooled specificity (rs-EPI: 
70.5%, ss-EPI-mIRBS: 56.8%, P = 0.210) did not differ significantly.
In a screening setting, using BI-RADS 4 or higher as cut-off point, the pooled sensitivity 
(rs-EPI: 55.6%, ss-EPI-mIRBS: 66.7%, P = 0.008) was significantly different. The pooled 
specificity (rs-EPI: 90.9%, ss-EPI-mIRBS: 75.0%, P = 0.065) did not differ significantly. 
The distribution of ADC values obtained by rs-EPI and ss-EPI-mIRBS is shown in Table 8.4. 
Overall, the mean ADC value was higher for benign and high-risk lesions in comparison to 
malignant lesions, but only significantly different within ss-EPI-mIRBS. 
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Table 8.4 | ADC values for rs-EPI and ss-EPI-mIRBS
ADC (x10-3 mm2/s) Mean ± SD Pb
rs-EPI ss-EPI-mIRBS
All lesions 1.02 ± 0.37 0.68 ± 0.28 <0.001
Malignant 0.93 ± 0.27 0.62 ± 0.27 0.014
Benign and high-risk 1.28 ±0.51 0.93 ± 0.40 <0.001
Pa 0.055 0.022
Pa: P-value based on the Independent-Samples T-Test comparing measurements between benign and 
high-risk, and malignant lesions.
Pb: P-value based on the Dependent-Samples T-Test of paired rs-EPI and ss-EPI-mIRBS measurements 
within each MRI exam.
 
On average, reading ss-EPI-mIRBS decreases the overall reading time by 7.7 s/case 
(P = 0.067), which is a reduction of 17% (Table 8.5). For malignant lesions average reading 
time was significantly shorter using ss-EPI-mIRBS (64.0 s/lesion) compared with rs-EPI 
(75.9 s/lesion, P = 0.039). 
Table 8.5 | Average reading time for rs-EPI and ss-EPI-mIRBS
Average reading time ± SD Percentage decrease P-value
rs-EPI ss-EPI-mIRBS
Reader 1 63.3 ± 33.4 54.0 ± 22.5 14.7 0.051
Reader 2 63.5 ± 22.5 69.0 ± 51.1 +8.6‡ 0.585
Reader 3 42.2 ± 23.2 36.1 ± 23.3 14.5 0.129
Reader 4 105.6 ± 70.8 84.9 ± 68.3 19.6 0.097
Pooled Average 68.1 ± 53.4 60.4 ± 48.3 16.9 0.067
Overall image interpretation 63.5 ± 57.0 52.8 ± 50.5 15.7 0.174
Malignant 75.9 ± 55.5 64.0 ± 47.6 15.7 0.039
Benign and high-risk 49.8 ± 30.2 62.3 ± 46.6 +25.1‡ 0.141
‡Time increasement for ss-EPI-mIRBS
8.4 | Discussion
ss-EPI-mIRBS demonstrated at least equivalent image quality and breast lesion visibility 
and classification. The use of the ss-EPI-mIRBS prototype sequence, however, resulted in 
a shorter reading time. This may eventually improve the clinical value of DWI for lesion 
detection. 
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Stadlbauer et al. demonstrated that the use of DWIBS is superior to a conventional DWI 
sequence in the visualization of lesions in the breast18. While in this study the sensitivity 
of the ss-EPI-mIRBS was also higher, this didn’t reach statistical significance. In our study, 
overall sensitivity was only 78.5% at the BI-RADS 3 cut-off and 66.7% using BI-RADS 4. 
A potential explanation for this limited effect on sensitivity is the much lower spatial 
resolution used by Stadlbauer et al. in comparison with the spatial resolution used in this 
study (interpolated: 3.1x3.1x3.0 mm3 and 0.9x0.9x4.0 mm3, respectively)18. This was done to 
improve the morphological lesions evaluation, but it might have led to a too low SNR in 
some of the voxels, thus leading to non-visualization of some lesions. 
While the mean ADC value in malignant lesions was lower in comparison to benign and 
high-risk lesions for both sequences, overall the ss-EPI-mIRBS resulted in lower mean 
ADC values in comparison to rs-EPI. The ADC values of the rs-EPI are comparable to those 
in previously reported studies and, therefore, the ADC values obtained with the ss-EPI-
mIRBS were relatively low19,20. In fact, they were even low when compared to studies 
that used ss-EPI in combination with extremely high b-values19-22. There are several 
explanations that might cause this difference. First of all, this could be a consequence of 
a low SNR, which can cause an underestimation of the ADC values when high b-values or 
higher resolution are used3. While the SNR is typically lower with high b-values, we tried 
to compensate for that by acquiring many more averages in the high b-value acquisition. 
However, this may still have been insufficient. Water diffusion in tissues follows a 
non-Gaussian nature, accordingly the choice of b-values has influence on obtained 
ADC values3. Also, the different methods for suppressing the fat signal may have had 
an important influence on the measured ADC values. In literature the use of SPAIR is 
recommended over STIR3,22 for typical clinically-used high b-values of around 800 s/mm2, 
however STIR is often more robust and therefore better suited for the creation of 
images with strong background suppression. Furthermore, involuntary inclusion of 
areas of necrosis within the ROI could have influenced the ADC values. To make very 
high b-value images suitable as a standalone technique for lesion detection, dedicated 
phantom studies are needed to optimize the balance between resolution and SNR and to 
determine the ideal parameters for optimal image quality and ADC values.
In our study, reading time for ss-EPI-mIRBS decreased by 17% to 60.4 s/case. This is 
still much higher than in other studies that reported reading times of 30 s/case and 
48 s/case23,24. This is likely mainly due to the study design, and the relative reduction is 
therefore more important than the absolute values. The reading sessions were performed 
in a laboratory setting instead of a clinical setting and the readers, consequently, had to 
answer multiple questions during the evaluation. It is therefore likely that although in 
clinical practice reading and interpretation times for all sequences are shorter, that the 
relative reading time differences are more likely to remain stable. Typically, we noticed 
an increase in reading time for benign and high-risk lesions. This may be related to the 
lower diffusion restriction in these lesions which made them harder to evaluate. However, 
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the number of benign lesions in this study was also relatively limited, hence it was not 
possible to reach reliable conclusions regarding different types of lesions. Future research 
should focus on larger datasets with differing lesion types.
Apart from the presence of artifacts, we did not quantify other image quality aspects such 
as sharpness of contours or image homogeneity, but rather focused on the subjective 
reader assessment of image quality for diagnosis. This is due to the fact that physical 
parameters often do not match with clinical or diagnostic values. Hence, we focused 
more on general acceptability of the sequences for radiologists. However, when using 
automated algorithms for lesion classification, standardization of physical parameters 
might become more essential as such algorithms are often not capable of dealing with 
even subtle artefacts.
The present study has limitations. First, we included a limited number of patients with a 
limited number of benign lesions, which could bias the reported sensitivity and specificity. 
Second, our study evaluated women with histologically proven breast cancer and a clinical 
indication for breast MR. Therefore, additional studies to determine the feasibility of using 
DWI for a target screening population with increased risk are necessary. 
In conclusion, the results of this study suggest that the ss-EPI sequence using a b-value 
of 2000 s/mm2 enables mIRBS acquisition with good image quality and lesion conspicuity 
that is comparable with the conventional rs-EPI. Furthermore, it shows that the ss-EPI-
mIRBS has the potential to improve the efficiency of reading DWI images by improving the 
reading speed.
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In this thesis, various aspects of early diagnosis and minimally invasive treatment were 
evaluated in order to improve the outcomes of patients with breast cancer. This general 
discussion will further elaborate on the implications of the results of this thesis for current 
practice and future directions.
9.1 | De-escalation of therapy
In the last few decades there has been a substantial shift from mastectomy towards breast 
conserving surgery (BCS) in combination with radiotherapy, also called breast conserving 
treatment (BCT)1. Currently, BCT is generally accepted, and even considered preferable, as 
a treatment modality because it results in similar overall survival rates to mastectomy 
while being less invasive and stressful for the patient1-3. However, overdiagnosis and 
overtreatment of breast cancer now occur more often due to the introduction of breast 
cancer screening. As a result, research is now focusing on even further treatment de-
escalation, by, for example, developing minimally invasive treatment options, to reduce 
aggressiveness of treatment, overdiagnosis, and overtreatment. Admittedly, to make 
minimally invasive treatment also generally accepted, it must offer, at least, the same 
local control and survival as BCT, as well as optimal patient-reported outcomes, and an 
acceptable complication profile, at reasonable costs.
9.1.1 | Limitations in specimen assessment
Current research mainly focuses on minimally and non-invasive treatment options, 
such as high intensity focused ultrasound (HIFU) and cryoablation, which involve in situ 
treatment of the cancer, rather than excising it. A substantial disadvantage of these 
techniques is the fact that there is no resulting specimen for evaluation of therapy 
success. Knuttel et al.4 described that, overall, BCT was preferable over minimally invasive 
or non-invasive treatment by breast cancer patients because after BCT margin evaluation 
is possible, providing a ‘feeling of security’ for the patient and physician alike. However, 
healthy volunteers show no significant difference in preference between BCT and 
minimally invasive treatment, which reveals that this is also due to how therapy results 
are communicated. 
Not only margin evaluation is inaccessible after minimally invasive or non-invasive 
treatment, but also tumor characteristics, which are required for assessment of adjuvant 
treatment decisions, are often challenging to determine, albeit this is currently already a 
common issue due to the widespread use of neoadjuvant systemic therapy. Consequently, 
tumor characteristics increasingly need to be assessed in advance on diagnostic biopsy 
specimens. Therefore, it is important to know how accurate these diagnostic biopsy 
evaluations are. One measure of accuracy for a test that partially samples a lesion 
and provides a histologic diagnosis is to quantify the extent of underestimation of 
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malignancy of the test. This reflects histologic under-staging by the diagnostic biopsy 
relative to the reference standard, in this case surgical excision. In Chapter 2 tumor 
grading on core needle biopsy (CNB) and vacuum-assisted biopsy (VAB) in comparison to 
that of the surgical excision specimen was underestimated in 27.7% and 11.2% of cases, 
respectively5,6. Incorrect grade assessment on biopsy specimens is probably also caused 
by under-sampling and variability in the histopathological assessment7,8. Tumors are 
heterogeneous and tumor grade may differ within the tumor. When a limited amount 
of tissue is obtained, this heterogeneity might be missed9. When no surgical specimen 
is available for evaluation, for example after cryoablation or HIFU, this might hamper 
the subsequent treatment decisions. As described in Chapter 2, only minimally invasive 
excision techniques, such as vacuum-assisted excision (VAE) and the breast lesion excision 
system (BLES), can remove lesions through a minimally invasive approach. With the BLES, 
it is possible to evaluate the specimen margins, which makes it a promising minimally 
invasive treatment method. Conversely, with VAE, the lesion is fragmented by the device 
and margin assessment is impossible with conventional pathological evaluation. During 
the MINIVAB study the VAE will be performed under ultrasound (US) guidance. This allows 
real-time imaging feedback during positioning of the needle and during the biopsy 
procedure. Hence, the question arises whether it is feasible to use peri-treatment image 
evaluation to differentiate between hematoma and residual tumor, and if it can be used 
as substitute for histopathological margin evaluation. Alternatively, this could be solved if 
post-treatment imaging could be used to determine if any lesion rim has remained in situ. 
However, currently, proof of complete tumor resection with imaging techniques only is 
impossible to obtain. In the future, improved imaging techniques may play an important 
role in judging complete tumor resection. 
9.1.2 | The role of imaging in treatment planning
Accurate imaging is of the utmost importance when de-escalation of treatment is 
considered; to define the extent of the disease, to guide minimally invasive instruments, 
to monitor treatment during the procedure, and to confirm complete tumor resection or 
ablation. 
The extent of breast cancer
Lesions eligible for minimally invasive treatment must be selected carefully. Ideal 
candidates are well-defined, molecular low risk (ER+ HER2-) and small lesions (up to 
2 cm). Therefore, tumors with undefined borders, invasive lobular carcinomas, scattered 
microcalcifications, and extensive ductal carcinoma in situ (DCIS) are not suitable 
candidates. In terms of size determination, imaging techniques such as mammography 
and US have been proven accurate for size assessment in up to 70% of the cases, and 
are part of standard work-up10,11. Nevertheless, underestimation of tumor size is common, 
especially on mammography. Breast magnetic resonance imaging (MRI) has been shown 




foci detection in up to 24% of patients12,13. As described in Chapter 4, MRI provides 
an accurate estimation of small invasive breast tumors even though the tumor size 
is underestimated by more than 5 mm in approximately 12% of the lesions. Not only 
underestimation of tumor size has influence on de-escalation of treatment, but also 
overestimation must not be underrated. In Chapter 4 we found that MRI overestimated the 
tumor size by more than 5 mm in approximately 11% of the small invasive breast tumors. 
Previous studies reported an MRI tumor size overestimation rate of 27% to 38%14,15. As 
Grimsby et al. describes, 65% of the patients with overestimation of the tumor size had 
additional pathology findings, such as DCIS or satellite lesions. For these patients MRI 
still had an added value, due to resulting in the correct widening of the surgical excision 
around the main tumor. Nevertheless, due to tumor size overestimation, it is more likely 
that women will unnecessarily opt for mastectomy15, while gaining no actual benefit in 
overall survival, local failure, or contralateral breast cancer16. One possible explanation for 
the equivalent outcomes between patients with and without pre-operative breast MRI is 
the effect of radiation therapy. As stated before, BCS in combination with radiotherapy 
reduces the risk of local recurrence, and possibly improves overall survival17,18. It is known 
that radiotherapy successfully treats microscopic foci of residual tumor after surgery and 
without treatment with either radiotherapy or mastectomy these microscopic foci may 
lead to local recurrence19,20. 
Guidance and monitoring during treatment
As described in Chapter 2, different image-guidance techniques are available in the 
diagnostic and therapeutic setting. MRI would be a logical therapeutic guidance 
technique, since it has the highest sensitivity, but interventional devices would need to 
be adapted for it. Furthermore, in MRI, lesions are often only visible with contrast agent, 
making it a greater burden for the patient, and causing a limited time span during which 
the lesion is clearly visible on the screen. Finally, it is currently not possible to see in real-
time what is happening with the lesion and surrounding tissue. 
US is the first-choice modality for image guided breast biopsy. Compared to other guidance 
techniques, US is well accepted, quick, widely available, and affordable. For therapeutic 
guidance purposes, US guidance allows for good 3D orientation and positioning of the 
device with real-time imaging feedback, whereas no real-time feedback is possible using 
mammography. Furthermore, it has been shown that the re-excision rates in BCT are 
reduced when US-guidance is used during surgery21.
In Chapter 3, we describe that the use of BLES in a diagnostic setting resulted in a variable 
rate of complete excisions across studies for both benign and malignant lesions. Up to 
63% of invasive ductal carcinomas were completely excised using the BLES, while most 
of these studies did not aim to excise the entire lesion22-29. However, in our BLES study 
(Chapter 5), where we selected patients and lesions very carefully, we did not observe a 
single adequate excision of any lesion. One possible explanation for this difference in 
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complete excision compared to literature is that we used US guidance in our study, while 
other studies mainly performed diagnostic biopsies under stereotactic guidance. The 
compression of the breast, which is required for stereotactic guidance, likely provides 
better tissue immobilization, fixing the lesion during the procedure, which is not 
possible during US guidance, and allowing for the extraction of a larger amount of tissue. 
Furthermore, the difference in complete excision might be caused by the difference in 
stiffness of small breast lesions in comparison to normal breast tissue. Even a perfectly 
targeted biopsy needle may push stiffer lesions away, resulting in incomplete tumor 
removal. The fact that the BLES needle only allows one excision, unfortunately, prohibits 
the removal of residual parts of the lesion that are left in situ.
Despite the results in Chapter 5, in Chapter 6 we proposed to continue our research on 
minimally invasive breast lesion excision by performing vacuum-assisted excision (VAE) 
in the MINIVAB study, under US guidance. We expect that the suction of the VAE might 
compensate for this ‘moving lesions’ problem, and very different from the BLES needles, it 
is possible to take multiple samples with the same needle; a process that can be continued 
until the entire lesion, as macroscopically seen under real time ultrasound guidance, is 
removed. 
Treatment outcome
In most minimally invasive approaches, there is no possibility for pathological 
examination of the surgical specimen after treatment, which makes it challenging to 
evaluate complete necrosis or removal of the lesion. For this evaluation, not only the 
histology of tissue, but especially the viability of tissue, is important. Also, due to the 
fact that even after radical surgery the presence of residual cancer around the resection 
cavity is common. Direct assessment of the margins after tumor resection may provide 
a more negative idea about the curative nature of the therapeutic procedure than is 
strictly necessary. Nevertheless, the question remains how much of eventual residual 
cancer will still be vital in the longer term. Several groups reported a reduction in the 
presence of residual disease when patients undergo a delayed re-excision of the cavity 
wall in comparison to the group that had immediate re-excision30-32. Therefore, it might 
be useful for treat and resect studies to introduce a waiting time of at least several weeks 
between the treatment of the primary tumor and the resection of the residual margin. 
Due to the findings in Chapter 5 we decided to implement a time interval between the 
MINIVAB procedure and the surgical lumpectomy as described in Chapter 6. However, it 
is important to keep in mind that a reduction of the amount of vital cancer in the tumor 
margin was only confirmed for invasive carcinomas while the same effect was not found 
for DCIS lesions32. This makes patient selection essential in future research. Potentially, 
follow-up imaging techniques with high sensitivity can overcome the limitation of the 
lack of pathological assessment of the tumor margin, and be used to just detect eventual 
recurrences in a timely fashion. Contrast-enhanced imaging techniques appear to be the 




techniques are not good enough to accurately indicate whether clinically significant 
tumor deposits are left behind or if the entire lesion has been excised, and this approach 
remains therefore to be tested. 
9.1.3 | Sentinel lymph node biopsy
Alongside the research described in this thesis, other ongoing clinical trials may influence 
the role of minimally invasive treatment in breast cancer patients. For example, how 
should we deal with sentinel lymph node biopsy (SLNB) if patients are treated in an 
outpatient setting with only local anesthesia? Nowadays, SLNB is performed as a surgical 
biopsy and is still standard procedure in clinically node negative breast cancer patients. In 
the future, if patients opt for minimally invasive treatment, SLNB will remain a burden due 
to the need for surgery, with potential for complications and reduction of quality of life as 
a result33,34. This is especially troubling considering that approximately 74% of clinically 
negative lymph nodes were also negative after sentinel lymph node resection35,36. There 
are several trials that investigate whether SLNB can be omitted for clinically node negative 
breast cancer patients (BOOG 2013-0837, Sound38). Results from these trials will have a 
major influence on the use of, and patient selection for, minimally invasive treatment. 
9.1.4 | Eligible patients for minimally invasive treatment
Several patient categories may benefit more from minimally invasive treatment than 
others. Elderly patients or patients that are ineligible for surgery are often undertreated 
and have a worse outcome than younger patients39. Minimally invasive treatment with 
local anesthesia may allow these patients with severe comorbidity to be eligible for local 
treatments with curative intention. Patients with neoadjuvant treatment and clinical 
complete response based upon imaging might also be an eligible group. The lack of 
residual disease can potentially be shown without the need for surgery and can increase 
the quality of life of these patients. However, results from ongoing or recently finished 
trials on omitting surgery after neoadjuvant treatment are necessary before it can be used 
in clinical practice40-42. 
9.2 | Early detection
The evolution toward minimally invasive treatment is possible due to widely implemented 
breast cancer screening programs. These programs make it possible to detect breast 
cancers at an earlier and smaller stage. This likely improves the possibility that these 
cancers can be treated with minimally invasive therapy approaches. Dynamic contrast-
enhanced (DCE)-MRI is an excellent technique that can be used for early detection and 
provides valuable information about morphology of the breast. However, a contrast 
agent is necessary to assess morphological and kinetic patterns in lesions43. A commonly 
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postulated hypothesis is that diffusion-weighted imaging (DWI) may be used as a fully 
non-invasive screening technique for breast cancer. DWI in combination with apparent 
diffusion coefficient (ADC) mapping makes it possible to distinguish between benign 
and malignant lesions44. Several studies found that DWI provides a high specificity and 
is useful for lesion characterization45. The sensitivity of DWI alone may be equal or even 
higher than that of screening mammography and US46-48. Nevertheless, until now DCE-MRI 
still exceeds the sensitivity of breast DWI, and it is clear from the results of Chapters 7 and 
8, along with other studies, that DWI still has several limitations for unenhanced screening 
purposes. DWI is known for the presence of artifacts, especially echo-planar imaging 
(EPI) related artifacts, such as ghosting and chemical shift49. Adequate fat suppression is 
critical to minimize artifacts and increase lesion conspicuity50. Inadequate fat suppression 
also results in inaccurate ADC measurements due to intravoxel fat signal50. Another 
approach to improve image quality in DWI screening is the use of strong background 
suppression and high b-values48,51. Nevertheless, in Chapter 8 we did not find a significant 
improvement when high b-values were used compared to a conventional DWI sequence. 
Furthermore, a limited spatial resolution in DWI images is concerning when considering 
its use for screening. This is because the goal of screening is early detection, i.e., when 
lesions are still small and not yet metastasized, and therefore high spatial resolution is 
especially important52. However, research to improve spatial resolution in DWI is ongoing, 
and significant improvements are expected in the near future53-55. 
9.3 | Future perspectives
Whether minimally invasive treatment will be successful in the future depends on many 
aspects. The most important is that it must offer advantages over BCT, that it proves 
comparable in regard to disease free and overall survival, and that is generally acceptable 
for patients and clinicians. 
Due to the incidence of unexpected foci of invasive carcinoma or DCIS outside the index 
lesion, adjuvant radiation treatment might be required for local control in patients treated 
minimally invasive just like with conventional BCT56. As it has become clear over the years 
that BCT is at least as safe as mastectomy for women with smaller breast cancers, even 
when surgery is only used to excise the bulky part of the lesion, subsequent cure can be 
expected from adjuvant radiotherapy and systemic therapies57. So far, very few studies left 
the tumor in situ after application of minimally invasive treatment and even fewer studies 
applied subsequent radiotherapy to the treated breast. Consequently, it is currently 
unclear whether radiotherapy after initial minimally invasive treatment is capable of 
providing sufficient supplemental therapy, as it does after surgical excision. Therefore, 
large randomized prospective trials with local recurrence and cancer-related survival to 




Although the results of the BLES study as presented in Chapter 5 were not as expected, 
that study was the first step towards the therapeutic use of minimally invasive excision 
for treatment of small invasive carcinomas. The next step is the assessment of VAE as a 
therapeutic device for these cancers. For this, the new MINIVAB study has been developed, 
which was approved by the medical ethical committee of the Radboudumc in February 
2020. If the results of this study are favorable, the technique is ready for a prospective 
randomized phase III trial, where the effectiveness of VAE can be compared to that of 
BCT. Eventually, the 10 year overall survival, local recurrence free survival, and salvage-
mastectomy-free survival rates need to be assessed. 
Independently of what minimally invasive treatment method is most common in future, 
a cost-effectiveness study is needed. It is expected that the costs of the procedure 
and hospital costs are lower for minimally invasive treatment, due to lower costs for 
surgical instruments, procedure time, shorter hospital stay, and fewer postoperative 
complications than for traditional open surgery. However, it is unclear what the long-term 
costs are for patients treated with minimally invasive techniques, and the used probes and 
needles are relatively expensive compared to simple surgical knives. Moreover, additional 
or extended adjuvant treatment might be necessary. Consequently, even when shown to 
be effective, the true cost-effectiveness of minimally invasive treatment of small breast 
cancers is still unknown. Another important factor that needs to be evaluated in this 
setting is patient preference. When therapies are equally effective short-term and long-
term patient preference also with regard to eventual body image should be investigated. 
It may well be that this varies strongly from patient to patient, hence it should also lead 
to the description of important items to discuss with patients to enable informed shared 
decision making. 
9.4 | Conclusions
The main conclusions of the research described in this thesis are:
Part I | Minimally invasive treatment of breast cancer
•  In the past decades, a variety of methods for minimal- or non-invasive diagnosis and 
treatment of breast cancer have been introduced (Chapter 2).
•  The breast lesion excision system is an efficient and safe breast biopsy method with 
acceptable complication rates. In a diagnostic setting it may be used as an alternative 
to vacuum-assisted biopsy. The variable rate of complete excision raises questions 




•  The size measurements of small breast cancers on MRI are within 5 mm of pathological 
size in 88% of patients. 12% of MRI-based measurements underestimate the pathological 
size, which may hinder patient selection for minimal invasive therapy (Chapter 4).
•  The breast lesion excision system allows accurate diagnosis of small invasive breast 
carcinomas, however it cannot be considered as a therapeutic device due to not 
achieving complete excisions (Chapter 5).
•  A multicenter, translational clinical phase II study is underway, evaluating under which 
conditions it is possible to excise small invasive breast cancers using the vacuum-
assisted biopsy system under ultrasound guidance (MINIVAB study, Chapter 6).
Part II |  Innovative MRI sequences for early detection of breast cancer
•  The simultaneous multi-slice single-shot DWI (SMS-ss-EPI) sequence has a lower overall 
image quality, but seems to result in increased visibility of malignant lesions compared to 
the conventional, clinically used readout-segmented DWI (rs-EPI) sequence (Chapter 7).
•  The single-shot DWI (ss-EPI) sequence with modified Inversion Recovery Background 
Suppression (mIRBS) using a b-value of 2000 s/mm2 enables acquisitions with good 
image quality and lesion conspicuity that is comparable to the conventional readout-
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Breast cancer is the most common cancer diagnosed and leading cause of cancer death 
in women worldwide. Early detection of breast cancer in women is key as it allows for less 
aggressive treatment and reduces the risks of death from breast cancer. It is estimated 
that about one in eight women in Europe who lives to be 80 years old will develop invasive 
breast cancer over the course of their lifetime.
Part I | Minimally invasive treatment of breast cancer
Over the past decades several devices and treatment options have been developed and 
adopted to improve breast cancer treatment. One of the future aims is to increase the 
use of minimally invasive or even non-invasive treatment options. In Chapter 2 the 
strengths and weaknesses of the different diagnostic and therapeutic minimally invasive 
techniques was described in detail. So far, many diagnostic biopsy techniques have been 
developed and are in use. However, the development and application of minimally invasive 
treatment techniques lags behind, due to one huge limitation when ablation techniques 
are used: the lack of reliable margin evaluation or verification of therapeutic success. 
To date, most prospective studies performed for the assessment of minimally invasive 
treatment with ablation techniques are treat and resect studies, because there are no 
reliable imaging tools for real-time treatment planning and assessment of response to 
treatment. This is one advantage that minimally invasive excision techniques have over 
ablation techniques; theoretically, with the former, it is possible to evaluate the tumor 
margin and evaluate the success of therapy. 
The breast lesion excision system (BLES) is an automated, image-guided, single-pass biopsy 
system, developed to overcome this issue. As opposed to other breast biopsy devices, the 
aim of BLES is to excise and retrieve an intact breast tissue specimen, which may not only 
facilitate easier diagnosis but also might allow for minimally invasive resections. In Chapter 3 
the diagnostic and therapeutic potential of the device was determined in a systematic 
review. Overall, the BLES is an efficient and safe breast biopsy system with acceptable 
complication rates. Underestimation rates of biopsies are commonly used to determine the 
accuracy of percutaneous biopsy techniques. As described in Chapter 2 and 3, according 
to literature, the atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) 
underestimation rates for BLES are in the range of 0% to 14% and 0% to 22%, respectively. 
This is a similar performance as that reported for vacuum-assisted biopsy (VAB) (21% 
and 11%, respectively). Even though most studies did not aim to remove lesions entirely, 
complete excision occurs regularly, depending on the type of lesion. Different studies 
reported a median complete excision of 60%, 50%, and 43% for ADH, DCIS, and invasive 
ductal carcinoma (IDC), respectively. Overall, these results point to the need for a trial to test 
the suitability of the BLES as a therapeutic device for the excision of small breast lesions. 
Due to the shift towards minimally invasive treatment, accurate tumor size estimation is 
essential for the appropriate selection of small breast cancers that are eligible for limited 
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resection. In Chapter 4 the reliability of magnetic resonance imaging (MRI) based tumor 
size measurements was determined. Furthermore clinical, histological, and radiomics 
characteristics were examined to determine which are predictive for underestimation. 
In this Chapter we saw that the overall correlation of MRI measurements with pathology 
was moderately strong in small (<20 mm) breast cancers. Nevertheless, in 12.2% of the 
cases MRI underestimated the size of the lesion by more than 5 mm. Especially in higher-
grade tumors and DCIS lesions, this underestimation occurred more often, but none of the 
patient, imaging, or biopsy characteristics were predictive. Therefore, patients with high 
grade tumors or DCIS in the tumor should be selected with caution for minimally invasive 
treatment.
In Chapter 5 we investigated whether it is feasible to excise small breast cancers completely 
using the BLES under ultrasound (US) guidance. Specifically, 22 patients diagnosed with an 
invasive carcinoma ≤ 15 mm on US and mammography were enrolled in this prospective, 
multi-center study. To verify that the exact lesion size met the inclusion criteria, all patients 
underwent breast MRI. Eleven patients were eligible for BLES-based excision and surgical 
excision during the same procedure. Histopathological results were identical for the 
needle biopsy, BLES, and surgical specimens for all lesions. Unfortunately, none of the BLES 
excisions were adequate. Nevertheless, margin assessment was good for all BLES specimens 
and only one complication occurred during the procedure (no retrieval of a specimen). 
Overall, we could conclude based on Chapter 3 and 5 that the BLES allows accurate diagnosis 
of small invasive carcinomas but that it cannot be considered a therapeutic device. 
As described in Chapter 2, the VAB has been proven as a reliable biopsy tool for diagnostic 
assessment of breast lesions, which removes multiple larger tissue samples. Also, as a 
therapeutic device vacuum-assisted excision (VAE) is approved as a minimally invasive 
alternative for surgical excision of benign lesions and lesions of uncertain malignant 
potential. Nevertheless, little evidence exists on the complete excision rate of malignant 
breast lesions and the use of VAE as a possible treatment modality for malignant lesions. 
Therefore, we designed a multi-center, translational clinical phase II trial to analyze 
whether it is feasible to remove small breast cancers completely using VAE under US 
guidance. The outline and methods of this study were discussed in Chapter 6. 
Part II | Innovative MRI sequences for early detection of breast cancer
For the implementation of minimally invasive treatment methods, it is important that 
breast cancer lesions are small and are found at an early stage. Breast cancer screening 
programs play a major role in this. Nevertheless, current screening methods use radiation 
and/or contrast agents, which may harm the patient. Therefore, a new fast screening 
method without radiation and/or contrast agent would be an improvement. This 
improved screening method should approximate the same specificity as mammography 




small stage. The current evidence regarding such MRI screening sequences is extensively 
reviewed in Chapters 7 and 8. 
In Chapter 7, we investigated the performance of a new diffusion-weighted imaging (DWI) 
sequence for breast MRI (simultaneous multi-slice single-shot echo-planar imaging (SMS-
ss-EPI)). This sequence is intended to reduce acquisition time and enable higher spatial 
resolution scans within a clinically acceptable timeframe. Using this new sequence, we 
were able to obtain a DWI scan in less than 3 minutes at a spatial resolution of 0.9x0.9x4.0 
mm. In this prospective patient study, we compared this sequence at 3T to our clinical 
standard readout-segmented (rs)-EPI-DWI sequence, in terms of image quality, lesion 
visibility and diagnosis, and description according to the breast imaging reporting and 
data system (BI-RADS) lexicon. Our results suggest an increased visibility of malignant 
lesions using the SMS-ss-EPI compared to rs-EPI, although the overall image quality 
is much better in the conventional sequence. Further development of the SMS-ss-EPI 
sequence is needed to improve image quality, decrease the presence of artifacts, and 
further increase lesion visibility. 
In Chapter 8 we compared a prototype ss-EPI with modified Inversion Recovery Background 
Suppression (ss-EPI-mIRBS) sequence using a high b-value to the clinical standard rs-EPI 
sequence. The sequences were evaluated and compared in terms of image quality, lesion 
visibility, apparent diffusion coefficient (ADC) values, and reading time. The ss-EPI-
mIRBS has a higher signal-to-noise ratio (SNR) in comparison to the rs-EPI, which allows 
the use of higher b-values without severe signal loss with a comparable scan time. Our 
results demonstrated that ss-EPI-mIRBS has at least equivalent image quality and lesion 
visibility. However, this prototype sequence resulted in a shorter reading time, which 
might eventually improve the clinical value of DWI for screening either as standalone 
technique or in addition to dynamic contrast-enhanced (DCE) MRI.
Conclusion
In summary, this thesis shows the current status of and explores possible future directions 
for minimally invasive treatment of small breast cancers and the mechanisms to identify 
these small breast cancers, which may be candidates for minimally invasive treatment. 
Several weaknesses have been identified and potential points for improvements have 
been discussed. Moreover, potential characteristics for MRI tumor size estimation is 
investigated and criticized. Lastly, this thesis takes a quick glance at improving the 
screening program with new MRI sequences.
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Borstkanker is de meest gediagnostiseerde vorm van kanker en wereldwijd de belangrijkste 
doodsoorzaak door kanker bij vrouwen. Ongeveer één op de acht vrouwen die 80 jaar oud 
worden in Europa ontwikkelt invasieve borstkanker in de loop van haar leven. Vroegtijdige 
opsporing van borstkanker is essentieel, omdat daardoor een minder agressieve 
behandeling mogelijk is en het risico op overlijden door borstkanker vermindert. In dit 
proefschrift hebben we ons enerzijds gericht op het optimaliseren van vroegdiagnostiek 
en anderzijds op de kansen en uitdagingen van minder invasieve methoden om een kleine 
tumor patiëntvriendelijk te verwijderen. 
Deel I | Minimaal invasieve behandeling van borstkanker
In de afgelopen decennia is er een veelheid aan apparatuur en behandelingsopties 
ontwikkeld en toegepast met wisselend succes, waardoor de behandeling van borstkanker 
geleidelijk werd verbeterd. Een potentiele verdere verbetering waar we ons in dit 
proefschrift met name op richten is het gebruik van minimaal-invasieve of niet-invasieve 
behandelingen. 
In hoofdstuk 2 worden de sterke en voor verbetering vatbare punten van de verschillende 
diagnostische en therapeutische minimaal invasieve technieken in detail beschreven. Tot 
nu toe zijn veel verschillende diagnostische biopsietechnieken ontwikkeld en klinisch 
in gebruik. Hoewel er technische ontwikkelingen zijn op therapeutisch gebied, blijft het 
gebruik van minimaal invasieve innovaties bij therapeutische behandelingen achter. Het 
ontbreken van een pathologisch preparaat voor marge-evaluatie ter verificatie van het 
therapeutisch succes is een van de belangrijkste beperkingen van ablatietechnieken. Tot 
op heden zijn bijna alle prospectieve onderzoeken naar minimaal invasieve behandeling 
met ablatietechnieken uitgevoerd in ‘behandel en resectie’ studies. Dit komt omdat 
er geen betrouwbare beeldvormende technieken zijn die in staat zijn de behandeling 
realtime te volgen en direct te beoordelen of de behandeling is gelukt. Minimaal 
invasieve excisietechnieken staan in tegenstelling tot ablatietechnieken evaluatie van 
therapeutisch succes wel toe. Theoretisch is het mogelijk om na een minimaal invasieve 
excisie de tumormarge te evalueren en het succes van de behandeling te bepalen.
Het breast lesion excision system (BLES) is ontwikkeld als een geautomatiseerd 
biopsiesysteem wat onder geleide van stereotaxie of echografie werkt. In tegenstelling 
tot andere biopsiesystemen, is het doel van de BLES om een intact weefselfragment 
te verkrijgen. Dit kan niet alleen de diagnose verbeteren, maar maakt ook minimaal 
invasieve resecties mogelijk waarvan de marge geëvalueerd kan worden. In hoofdstuk 3 
werden de diagnostische en therapeutische mogelijkheden van dit apparaat samengevat 
in een systematische review. Over het algemeen is de BLES een efficiënt en veilig 
biopsiesysteem met een beperkt percentage aan complicaties. Om de nauwkeurigheid 
van biopsietechnieken te bepalen worden vaak de onderschattingspercentages 
gebruikt. Het gaat dan om de fractie afwijkingen waar bij biopsie een minder agressieve 
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afwijking wordt gevonden dan bij de daaropvolgende resectie. Zoals beschreven in de 
hoofdstukken 2 en 3 ligt, volgens de beschikbare literatuur, de onderschatting van de BLES 
voor atypische ductale hyperplasie (ADH) tussen de 0% en 14% en voor ductaal carcinoom 
in situ (DCIS) tussen de 0% en 22%. Dit komt overeen met de gerapporteerde waarden voor 
het vacuüm geassisteerde biopsie (VAB) systeem (21% en 11%, respectievelijk). Hoewel de 
meeste studies naar de BLES niet het doel hadden laesies volledig te verwijderen, vond er 
regelmatig volledige excisie plaats, weliswaar afhankelijk van het type laesie. Verschillende 
onderzoeken rapporteerden een volledige excisie van respectievelijk 60%, 50% en 43% 
voor ADH, DCIS en invasief ductaal carcinoom (IDC). Deze resultaten suggereren dat een 
klinische test met de BLES gericht op therapeutische excisie van kleine borsttumoren zou 
kunnen worden uitgevoerd. 
Vanwege de verschuiving naar minimaal invasieve behandeling is een nauwkeurige 
schatting van de tumorgrootte essentieel voor kleine borsttumoren. In hoofdstuk 4 werd 
bepaald wat de betrouwbaarheid van tumorgrootte bepaling met behulp van magnetic 
resonance imaging (MRI) is. Daarnaast werden klinische, histologische en radiologische 
kenmerken onderzocht om te bepalen welke voorspellend zijn voor tumorgrootte 
onderschatting. In dit hoofdstuk vonden we een matig sterke correlatie tussen MRI-
afmetingen en pathologische afmetingen bij kleine (<20 mm) borstkankers. Toch 
onderschatte MRI in 12,2% van de gevallen de grootte van de laesie met meer dan 5 mm. 
Vooral bij hooggradige tumoren en DCIS kwam deze onderschatting vaker voor. Geen van 
de patiënt, radiologische of pathologische karakteristieken was echter voorspellend voor 
deze onderschatting. Daarom moeten patiënten met hooggradige tumoren of DCIS met 
voorzichtigheid worden geselecteerd voor minimaal invasieve behandeling.
In hoofdstuk 5 hebben we onderzocht of het haalbaar is om kleine borstkankers volledig 
te verwijderen met behulp van de BLES onder echogeleiding. In totaal werden 22 patiënten 
met een invasief carcinoom ≤ 15 mm op zowel echografie als mammografie geïncludeerd 
in deze prospectieve, multicenter studie. Om te controleren of de exacte grootte van de 
laesie aan de inclusiecriteria voldeed, ondergingen al deze patiënten een borst-MRI. Naar 
aanleiding van deze MRI kwamen elf patiënten in aanmerking voor de BLES-excisie en de 
daaropvolgende chirurgische excisie. De histopathologische resultaten waren identiek 
voor de naaldbiopsie, BLES en chirurgische excisie voor alle laesies. Helaas was geen 
van de laesies volledig verwijderd met behulp van de BLES en waren er in alle preparaten 
positieve snijranden aanwezig. Desalniettemin was de kwaliteit van de margebeoordeling 
goed voor alle BLES-specimens en trad er slechts één complicatie op tijdens de procedure. 
Al met al konden we op basis van de hoofdstukken 3 en 5 concluderen dat de BLES een 
nauwkeurige diagnose van kleine invasieve carcinomen mogelijk maakt, maar dat het niet 
als een therapeutisch apparaat kan worden beschouwd.
Zoals beschreven in hoofdstuk 2, is VAB een betrouwbaar biopsieapparaat voor diag-
nostische beoordeling van borstlaesies, waarbij meerdere grotere weefselmonsters 
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kunnen worden verkregen. Als therapeutisch apparaat, ook wel vacuüm geassisteerde 
excisie (VAE), is het goedgekeurd voor het minimaal invasief verwijderen van goedaardige 
en potentieel kwaadaardige laesies. Desalniettemin is er tot op heden weinig bewijs voor 
het therapeutische gebruik voor het verwijderen van kwaadaardige laesies met behulp van 
VAE. Daarom hebben we een multicenter, translationele klinische fase II-studie ontworpen 
om te analyseren of het haalbaar is om kleine borstkankers volledig te verwijderen met VAE 
onder echogeleiding. De opzet en methode van deze studie zijn besproken in hoofdstuk 6.
Deel II | Innovatieve MRI sequenties voor vroege opsporing van borst kanker
Voor de implementatie van minimaal invasieve behandelmethoden is het belangrijk dat 
de borstkankers klein zijn en in een vroeg stadium worden ontdekt. Hierbij speelt het 
bevolkingsonderzoek naar borstkanker een grote rol. De huidige screeningsmethoden 
gebruiken straling (mammografie) en/of contrastmiddelen (bij MRI) die de patiënt 
kunnen schaden. Daarom zou een nieuwe snelle screeningmethode zonder straling en/of 
contrastmiddel een verbetering zijn. Hierbij is het wel belangrijk in acht te nemen dat deze 
verbeterde screeningsmethode dezelfde sensitiviteit en specificiteit bereikt als de huidige 
methodes. Twee nieuwe MRI-screeningssequenties die hierin een rol zouden kunnen 
spelen worden uitgebreid besproken in de hoofdstukken 7 en 8.
In hoofdstuk 7 hebben we de prestatie van een nieuwe MR diffusion-weighted imaging 
(DWI)-sequentie, ook wel simultaneous multi-slice single-shot echo-planar imaging 
(SMS-ss-EPI) sequentie, onderzocht. Deze sequentie is bedoeld om de acquisitietijd (tijd 
die de patiënt in het toestel doorbrengt) te verkorten, maar een hoge spatiële resolutie 
mogelijk te maken binnen een klinisch aanvaardbaar tijdsbestek. Met behulp van deze 
nieuwe sequentie konden we een DWI-scan verkrijgen in minder dan 3 minuten met een 
spatiele resolutie van 0.9x0.9x4.0 mm. In deze prospectieve studie vergeleken we een 
nieuwe SMS-ss-EPI sequentie met de in het Radboudumc standaard klinische readout-
segmented (rs)-EPI-sequentie op een 3T scanner. De sequenties werden geëvalueerd op 
basis van beeldkwaliteit, zichtbaarheid en diagnose van laesies, en beschrijving volgens 
het BI-RADS lexicon. Onze resultaten suggereren een verhoogde zichtbaarheid van 
maligne laesies met behulp van de nieuwe sequentie ten opzichte van de standaard 
sequentie, hoewel de algehele beeldkwaliteit veel beter is in de standaard sequentie. 
Verdere ontwikkeling van de SMS-ss-EPI sequentie is nodig om de beeldkwaliteit te 
verbeteren, de aanwezigheid van artefacten te verminderen en de zichtbaarheid van de 
laesies te vergroten.
In hoofdstuk 8 hebben we een prototype ss-EPI sequentie met ‘modified Inversion 
Recovery Background Suppression’ (ss-EPI-mIRBS) met een hoge b-waarde vergeleken met 
de klinische standaard rs-EPI sequentie. De sequenties werden geëvalueerd en vergeleken 
op basis van beeldkwaliteit, zichtbaarheid van laesies, ‘apparent diffusion coefficient’ 
(ADC) waarden en leestijd. De ss-EPI-mIRBS heeft een hogere signaal-ruis verhouding 
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(SNR) in vergelijking met de rs-EPI waardoor hogere b-waarden kunnen worden gebruikt 
zonder ernstig signaalverlies in vergelijkbare scantijd. Onze resultaten toonden aan dat de 
prototype sequentie een gelijkwaardige beeldkwaliteit en laesiezichtbaarheid heeft. Deze 
prototypesequentie resulteerde echter in een kortere leestijd, wat uiteindelijk de klinische 
waarde van DWI voor screening naast de contrast MRI zou kunnen verbeteren. 
Conclusie
Samenvattend toont dit proefschrift de huidige status en een mogelijk toekomst-
perspectief van minimaal invasieve behandeling van kleine borstkankers en de 
mechanismen om deze kleine borstkankers te identificeren die in aanmerking komen 
voor minimaal invasieve behandeling. Er zijn verschillende zwakke punten vastgesteld 
en mogelijke verbeterpunten zijn besproken. Bovendien werden mogelijke kenmerken 
voor het schatten van MRI-tumorgrootte aan een kritisch onderzoek onderworpen. 
Ten slotte geeft dit proefschrift een vooruitblik op opties ter optimalisering van het 
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This thesis is based on the results of human studies, which were conducted in accordance 
with the principles of the Declaration of Helsinki. The medical and ethical review board 
Committee on Research Involving Human Subjects Region Arnhem Nijmegen, Nijmegen, 
the Netherlands has given approval to conduct these studies.
The paper trial master files and case report forms for Chapter 5 is stored in the department 
archive (Radboudumc, Long-term storage M330.02.219). The digital trial masters files are 
stored at the Radiology department network drive (\\umcfs097\radngdata$\Research\
Trialbureau\_Archief\Trialbureau_digitaal).
All paper data were entered into the computer by use of Castor EDC. The privacy of the 
participants in this study is warranted by use of encrypted and unique individual subject 
codes. The codes were stored separately from the study data. Data where converged from 
Castor EDC to SPSS (SPSS Inc., Chicago, Illinois, USA).
The raw data (MR images) for Chapter 4, 7 and 8 were pseudonymized and stored on the 
network drive of the department of Radiology and Nuclear Medicine (\\umcsanfsclp01\
radng_axti\datasets). The final outcomes values are stored in SPSS format: IKNL_
Wendelien\SPSS (Chapter 4), BLES_Wendelien (Chapter 5), MRDWI_Wendelien\SPSS_SMS 
(Chapter 7) and MRDWI_Wendelien\SPSS_High_bValue (Chapter 8).
The data will be saved for 15 years after termination of the study. Using these participants 
data in future research is only possible if explicit permission by the participant is given 
in the informed consent or after a renewed permission by the participant. The datasets 






Met veel plezier heb ik de afgelopen 5 jaar aan dit proefschrift gewerkt, maar nu is het 
dan toch echt af! Dit had ik natuurlijk niet alleen gekund. Daarom wil ik graag iedereen 
bedanken die een bijdrage heeft geleverd.
Dr. Mann, beste Ritse, zonder jou was dit nooit gelukt. Ondanks alle tegenslagen die 
we hebben gehad met de BLES studie bleef je vertrouwen in mij houden en wist je mij 
weer enthousiast te maken met nieuwe ideeën en uitdagingen. Je was altijd beschikbaar 
voor een snel praatje of feedback (als ik je wist te vinden), ook al was dit buiten de 
wetenschapstijd om. Bedankt dat ik mijn interesses in het wetenschappelijk onderzoek 
verder mag uitbreiden binnen de BIG groep en de MINIVAB studie verder kan uitvoeren en 
afronden. 
Dr. Sechopoulos, dear Ioannis, thank you for ‘adopting’ me in the AXTI group, despite 
the fact that I didn’t do anything with x-rays, it never felt as not fitting into the group. I 
appreciated that you always made time for me or were flexible to re-schedule the meeting 
if I had a ‘standard PhDer-excuse’. Furthermore, thank you for all your comments and 
corrections on my papers, I learned a lot from it.   
Dr. Strobbe, beste Luc, met je kritische blik was je een belangrijke factor binnen mijn 
promotieteam. Je zorgde ervoor dat zowel de onderzoeken als de artikelen evenwichtiger 
waren. Daarnaast heb ik veel geleerd van je kennis omtrent de borstkankerchirurgie en 
tijdens het meelopen op de poli en de OK. Ik heb genoten van onze kritische gesprekken, 
maar ook van je onophoudelijke enthousiasme voor wetenschappelijk onderzoek. 
Bedankt dat je me altijd met open armen hebt ontvangen in het CWZ.
Dr. Bult, beste Peter, bedankt voor alle hulp en inzichten die je me hebt gegeven op het 
gebied van mammapathologie. Ook al had je het erg druk, je was altijd beschikbaar (en 
met name ‘s morgens voor 8 uur) voor een snelle meeting of een kort persoonlijk praatje. 
Ik heb veel geleerd van je commentaren, feedback, en advies. Daarnaast heb ik genoten 
van onze trip naar Barcelona en zal ik je enthousiasme en blijdschap in de FC Barcelona 
shop nooit vergeten. 
Prof. dr. ir. Karssemeijer, beste Nico, bedankt dat ik in eerste instantie kon promoveren 
binnen jouw Breast imaging groep. Ondanks dat je mij volledig vrij liet in de onderzoeken 
die ik deed was je altijd erg benieuwd en betrokken bij mijn promotietraject. 
Willem Vreuls, bedankt voor al je hulp bij het beoordelen en her(her)beoordelen van de 
BLES preparaten. Het was altijd een feest om langs te lopen voor een praatje of een eigen 
gezette kop koffie. Hoewel er in dit proefschrift geen stellingen zijn opgenomen wil ik er 
toch nog graag één voor jou benoemen: ’DCIS is te herkennen aan het eyeliner effect’. Als 
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je op een zondag nog weer naar het Arboretum Poort Bulten komt, kom dan ook bij mij 
langs voor een kop koffie. 
Alle mamma radiologen in het Radboudumc en het CWZ, bedankt voor alle hulp bij het 
opzetten en uitvoeren van de verschillende studies. Linda, bedankt voor alle uren die je 
hebt gestoken in mijn reader studies. Susanne, bedankt dat je elke keer weer voor mij 
naar het CWZ wilde komen. Zonder jouw toewijding en flexibiliteit was de logistiek rond 
de BLES studie nooit gelukt. Ik kijk uit naar onze volgende samenwerking in de MINIVAB 
studie. 
Alle mamma chirurgen in het Radboudumc en het CWZ, bedankt voor het includeren van 
patiënten voor de BLES studie. Zonder jullie extra inzet was dit nooit gelukt. Margrethe, 
dank voor je extra tijd die je beschikbaar maakte tijdens de OK’s en het invullen van de 
vragenlijsten. Annelies, bij Costa Coffee denk ik even terug aan jou.   
De leden van de manuscriptcommissie, professor Bloemendal, professor Ruers, en 
professor van Diest, dank voor het lezen en beoordelen van mijn manuscript. Ik verheug 
mij op jullie kritische vragen tijdens mijn verdediging.
Alle patiënten die hebben deelgenomen aan de studies beschreven in dit proefschrift. 
Borstkanker en de behandeling daaromheen is een zwaar traject. Ik heb dan ook veel 
respect voor iedereen die dit heeft moeten meemaken, en dan ook nog mee willen doen 
aan een wetenschappelijk onderzoek… Hartelijk bedankt!
I would like to thank all co-authors who have contributed to obtaining the results in the 
chapters of this thesis. I have always regarded all your tips and comments as extremely 
valuable.
Wieteke Jacobs, bedankt voor de fijne samenwerking en voor alle telefoontjes om te 
informeren hoe het was gegaan tijdens de procedures. 
Ook veel dank aan de mammalaboranten, mammacareverpleegkundigen en verpleeg-
kundig specialisten in zowel het Radboudumc als het CWZ. Jullie waren altijd beschikbaar 
voor vragen en hulp bij het includeren van patiënten. Jullie hebben de tijd waarbij ik moest 
wachten op patiënten of artsen een stuk gezelliger gemaakt. 
Het Trialbureau, Gerrita, Michel, Karlijn en Marijke, bedankt voor al jullie hulp bij het 
meedenken, opstarten en uitvoeren van mijn klinische studies. 
Dear AXTI colleagues, thank you for the wonderful time together. Ioannis, Alejandro, 
Dagmar, Christian, Marco, Joana, Koen, Marjolein, Gerrita, Christiana, Luuk, Marta, Olga, 
Sjoerd, Suzanne, Alma, Juan, Mikhail, Jessie, Sarah, Franziska and Noelia, thank you for the 
214
Dankwoord
great discussions and many coffee/tea moments at the coffee corner. I enjoyed being in 
the office and out on AXTI activities. Hopefully a lot more great AXTI activities may happen 
after the covid time. Marjolein, dank voor al je snelle antwoorden en hulp op mijn vragen. 
Gerrita, bedankt dat je mij zoveel hebt geleerd over het indienen van wetenschappelijk 
onderzoek bij de medisch ethische toetsingscommissie en hoe je onderzoek uitvoert 
volgens de richtlijnen. Christiana, you are my starting buddy at the AXTI, thank you for 
the time we spent together, and to quote yourself: ‘You are so much fun’. Joana, sorry that 
I let you ‘run’ through Budapest, but I really enjoyed our trip. Good luck with finishing 
your thesis and hopefully you can defend it very soon! Koen, bedankt voor alle hulp bij 
technische en computer gerelateerde problemen. Daarnaast kwam je kennis over speciaal 
bieren altijd goed van pas. Christian, you were a great colleague. The song ‘Berend botje’ 
will never be the same for me. Marco, thank you for all the great coffee breaks (before 
and after 9-o’clock, online and in real life). I am excited about all the new projects in 
which we are collaborating. When I can eat sushi again, I will introduce you to the best 
sushi restaurant in the Netherlands! Dagmar, wat heb ik genoten van de tijd naast jou. 
Ik kon aan je voetstappen al horen dat je er aan kwam, en elke dag was het weer vanaf 
de eerste minuut gezellig. Dankje, dat je altijd naar mij luisterde, ook al was het niet 
altijd begrijpelijk Nederlands, en al je advies. Ik heb aan jou niet alleen een goede collega, 
maar ook een geweldige vriendin over gehouden. Ik ben daarom ook super blij dat je mijn 
paranimf wil zijn!
Dear BIG colleagues, although the group is still very young, it feels already as a real team. 
Suzanne, Alma, Lejla, Linda, Nikita, Riccardo, Carmen, Jonas, Xin, Yuan, Tianyu, Kay, Luyi 
and Shannon, I learned a lot from all the regular meetings and discussions going on about 
the different research topics. Hopefully we will have great group activities in the future. 
Suzanne, Alma en Lejla, bedankt voor alle gezellige koffie momenten en persoonlijke 
discussies. Ik kijk er naar uit elkaar weer vaker in real life te kunnen zien.
Collega’s van DIAG, erg bedankt voor jullie gezelligheid. Midas, Ajay, Thomas, Freerk, Sil, 
Bart, Christina en Kevin, dank voor de gezelligheid op kantoor en de geweldige DIAG-AXTI 
weekendjes, uitstapjes en etentjes. Suzan, bedankt voor al je hulp en aandacht tijdens het 
begin van mijn PhD. Ik heb erg veel gehad aan je lessen ‘hoe om te gaan met begeleiders’ 
of ‘waar kan ik mijn begeleider vinden’ (sorry Ritse). Oscar, door jou is mijn belangstelling 
voor het wetenschappelijk onderzoek ontstaan en gegroeid. Het was dan ook super dat 
we weer collega’s werden op het Radboudumc. Bedankt voor alle levendige gesprekken en 
discussies. We moeten snel weer een kop thee met elkaar drinken.
Dank aan mijn collega’s van de BioMR groep. Marnix en Marinette, bedankt voor alle hulp 
bij mijn MRI vragen. Linda, Carlijn en Andor, ik heb genoten van ons Canada tripje.
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Jan en Marianne, Inge en Gery, bedankt voor alle interesse in mijn onderzoek en alle 
gastvrijheid die ik van jullie heb mogen ontvangen. 
Henrieke en Rick, Dindy en Bart, Francis en Ruud, Tay, Ziva, Felize, Alyna, Elze, Lenne en 
Foss, bedankt voor jullie interesse en vertrouwen in mij. Ik kon altijd op jullie rekenen. Nu 
ben ik dan echt de doctor (of boktor) van de familie. 
Lieve Pap en Mam, bedankt voor de kansen die jullie mij gegeven hebben. Vanaf het begin 
hebben jullie geloofd in mij en geholpen waar mogelijk was. Jullie wisten mij altijd te 
motiveren om door te leren en studeren. Zonder jullie onvoorwaardelijke steun zou ik hier 
nu niet zijn geweest. Ik hou van jullie!  
Lieve Ruud, bedankt voor al je steun en liefde. Je probeerde mijn onderzoeken en 
onderwerpen altijd te begrijpen, hoewel dit niet altijd makkelijk was. Als ik het niet meer 
zag zitten, omdat het onderzoek niet liep zoals ik had gehoopt, wist je mij altijd weer op 
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